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Abstract 
 
The work presented in this thesis aimed to establish the metabolomic profile of urine and breast 
cancer (BC) tissue from BC patients (samples cordially provided by Funchal Hospital), in addition to 
BC cell lines (MCF-7, MDA-MB-231, T-47D) as a powerful strategy to identify metabolites as 
potential BC biomarkers, helping on the development of non-invasive approaches for BC diagnosis 
and management. To achieve the main goal and obtain a deeper and comprehensive knowledge on 
BC metabolome, different analytical platforms, namely headspace solid-phase microextraction (HS-
SPME) combined with gas chromatography-quadrupole mass spectrometry (GC-qMS) and nuclear 
magnetic ressonance (1H NMR) spectroscopy were used. 
The application of multivariate statistical methods - principal component analysis (PCA) and 
orthogonal partial least square – discriminant analysis (OPLS-DA), to data matrix obtained from the 
different target samples allowed to find a set of highly sensitive and specific metabolites metabolites, 
namely, 4-heptanone, acetic acid and glutamine, able to be used as potential biomarkers in BC 
diagnosis. Significant group separation was observed in OPLS-DA score plot between BC and CTL 
indicating intrinsic metabolic alterations in each group. To attest the robustness of the model, a 
random permutation test with 1000 permutations was performed with OPLS-DA. The permutation 
test yielded R2 (represents goodness of fit) and Q2 values (represents predictive ability) with values 
higher than 0.717 and 0.691, respectively. Several metabolic pathways were dysregulated in BC 
considering the analytical approaches used. The main pathways included pyruvate, glutamine and 
sulfur metabolisms, indicating that there might be an association between the metabolites arising from 
the type of biological sample of the same donor used to perform the investigation. 
The integration of data obtained from different analytical platforms (GC-qMS and 1H NMR) for 
urinary and tissue samples revealed that five metabolites (e.g., acetone, 3-hexanone, 4-heptanone, 2-
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Resumo 
 
O trabalho apresentado nesta tese teve como objetivo estabelecer o perfil metabolómico da urina 
e do tecido da mama de doentes com cancro de mama (BC) (amostras cordialmente fornecidas pelo 
Hospital do Funchal), além das linhas celulares de BC (MCF-7, MDA-MB-231, T -47D) como uma 
poderosa estratégia para identificar metabolitos como potenciais biomarcadores de BC, auxiliando no 
desenvolvimento de abordagens não invasivas para o diagnóstico e a gestão da patologia. Para obter 
um conhecimento mais profundo e abrangente do metaboloma de BC, diferentes plataformas 
analíticas, nomeadamente a microextração em fase sólida em modo headspace (HS-SPME) 
combinada com a cromatografia em fase gasosa acoplada à espectrometria de massa (GC-qMS) e 
espectroscopia de ressonância magnética nuclear (1H RMN), foram usadas para atingir o objetivo 
principal. 
A aplicação de métodos estatísticos multivariados - análise de componentes principais (PCA) e 
análise discriminante de mínimos quadrados parciais ortogonais (OPLS-DA) à matriz de dados obtida 
a partir das diferentes amostras alvo, permitiu estabelecer um grupo de metabolitos sensíveis e 
específicos, nomeadamente a 4-heptanona, o ácido acético e a glutamina, possíveis de serem 
utilizados como potenciais biomarcadores no diagnóstico de BC. Uma separação significativa entre 
os grupos BC e CTL foi observada pelo OPLS-DA, indicando alterações metabólicas em cada grupo. 
Para verificar a robustez do modelo, foi realizado um teste de permutação aleatória com 1000 
permutações com o sistema OPLS-DA. Valores de R2 (representa o ajuste) e Q2 (representa a 
capacidade preditiva) superiores a 0,717 e 0,691, foram obtidos utilizando o teste da permutação. 
Diversas vias metabólicas estavam desreguladas no BC considerando as abordagens analíticas 
utilizadas. As principais vias incluíram os metabolismos do piruvato e glutamina, indicando que 
poderá haver uma associação entre os metabolitos derivados do tipo de amostra biológica do mesmo 
doador utilizado para realizar a investigação. 
A integração de dados obtidos pelas diferentes plataformas analíticas (GC-qMS e 1H RMN) para 
amostras urinárias e de tecido revelou cinco metabolitos significativos usando a dupla abordagem 
analítica. (i.e., acetona, 3-hexanona, 4-heptanona, 2-metil-5- (metiltio) - furano e acetato). 
 
 
Palavras-chave: Cancro da Mama; Linhas celulares, urina e tecido; Metabolómica; NMR; GC-
qMS; Ferramentas estatísticas. 
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Regarding to the structure of this thesis, the publications of original research that resulted from the 
experimental data were used to organize the results obtained presented in section 3. In order to 
organize the information and present the developed research, a general introduction, integrated 
discussion and conclusions were made. In summary, this thesis is divided in the following sections: 
 
1. Introduction 
In this section, a brief introduction will be presented about breast cancer (BC) comprising a review 
with the most current analytical thecniques used in BC metabolomic studies and their applications to 
identify metabolites as potential BC biomarkers based on the main advantages and advances in 
metabolomics research. In addition, chemometric methods used in metabolomics will be also focused. 
 
2. Aims and Scope 
The main objectives of this thesis will be presented according to the proposed research. 
 
3. Metabolomic Pattern in Breast Cancer 
In this section, the results obtained as well as their discussion will be presented by manuscripts. 
 
4. Integrated Discussion 
This section provides na integrated discussion of the results obtained through this thesis and 
compared with the results obtained by other authors. 
 
5. Conclusions and Future Perspectives 
A general conclusion is presented regarding to the ability of the analytical techniques to establish 
potential BC biomakers. Also, the improvements that should be taken into account to validate the 
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SECTION 1| Breast cancer metabolomics: from 
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Introduction 
Cancer is a public health problem and causes a tremendous burden on patients, families and society 
creating a significant problem on global economy. Although has been extensively investigated, cancer 
still remains one of the leading causes of death in the world after coronary diseases [1]. Globally, 
breast cancer (BC) remains at the top of women´s cancers worldwide followed by colorectal, lung, 
cervix, and stomach cancers according to GLOBOCAN series of the International Agency for 
Research on Cancer (IARC), contributing with more than 11.6 % of all cancer types. (Figure 1. 1 A).  
 
Figure 1. 1 - Estimated cancer incidence rates (A) and (B) number of deaths worldwide for 2018. 
Adapted from GLOBOCAN [1]. 
In addition, around 2.1 million BC new cases were diagnosed in 2018 and occured 630 thousands 
deaths (6.6 % of all cancers) (Figure 1. 1 B). 
The incidence rates are highest in North America, Australia and Europe and lowest in Asia. These 
differences might be related to societal changes, as result of industrialization, such as, unhealthy 
lifestyle, expressed by overweight and other symptoms, alcohol consumption, tobacco smoking, 
physical inactivity, early menarche, among others [2,3]. Although its incidence is high in some 
developed countries, mortality is higher in low and middle income countries [4]. The incidence of 
breast cancer increases with age and is generally in the 50–60 age group. Moreover, mortality rates 
affect the group below 35 years and above 75 years, due to the younger group have the most 
aggressive type of the disease and in the older group the treatment cannot be so aggressive [5]. 
Concerning the incidence rates and mortality for breast cancer in Europe, it was observed that in 
2012, the incidence of breast cancer was around 361,608 cases with 91,585 deaths. For 2020, around 
400 thousand new cases will be diagnosed resulting in 100 thousand deaths according to International 
Agency for Research on Cancer (IARC). For Portugal and USA, the expected number of breast cancer 
cases in 2020 will be nearly 6000 and 270 thousand resulting in around 1700 and 51,000 deaths, 
respectively as shown in Figure 1. 2. 
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Figure 1. 2 - BC incidence and mortality rates in Portugal, Europe and USA from 2012, 2015 and 
expected rates for 2020. Data available at IARC. Legend: INC: incidence; MORT: mortality. 
This trend might be as consequence by the availability of better screening procedures resulting in 
an early detection and also in the development of new treatments [2,6,7], which lead to an improved 
survival. Several risk factors associated with BC have been already recognized, namely 
epidemiological factors (e.g., age, reproductive factors, socioeconomic status, ethnicity), often using 
standard analysis approaches (e.g., logistic regression) with adjustment for multiple comparisons. 
Other factors as lifestyle (e.g., alcohol, tobacco, obesity, physical activity), and exposure to radiation 
[8] are also associated. The risk of developing BC increases with age being rare in women younger 
than 25 years, but tending to be more aggressive in younger people. The most common BC that occurs 
is the invasive type independently of age [9]. The highest risk of family history is associated with 
increasing number of first-degree relatives diagnosed with BC (age under 50 years). The risk is further 
increased when the affected relative is diagnosed in both breasts [10]. Particularly, the mutations in 
genes BRCA1, BRCA2 and TP53 are strongly associated with the development of BC [9], even if 
these mutations are low, accounting for a small portion of the total BC incidence [3]. Consistent 
physical activity has many benefits and greater activity has been related to lower BC risk by 
decreasing the circulating estrogen levels in postmenopausal women [11,12]. Extensive literature has 
linked alcohol consumption to BC risk and reveal the role of ethanol in carcinogenesis altering 
estrogen levels through acetaldehyde. Briefly ethanol is converted to acetaldehyde (AA) through 
alcohol dehydrogenase (ADH), that then binds to DNA interfering with the DNA synthesis and repair 
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hyperinsulinemia [14]. Insulin has anabolic effects on cellular metabolism and an overexpression of 
insulin receptor has been demonstrated in human cancer cells [9,15]. The involvement of insulin-like 
growth factor (IGFs) in carcinogenesis is attributed to their role in linking high energy intake, 
increased cell proliferation, and suppression of apoptosis to cancer risks [15,16]. With regard to 
obesity and BC risk, some studies indicate that is strongly associated with increased invasive BC risk 
in postmenopausal women particularly for estrogen receptor–positive cancers (ER+) [17–19]. In 
clinical practice, there are nowadays several biomarkers routinely used for prognosis and 
identification of tumors, including the estrogen receptor (ER), progesterone receptor (PR) and the 
human epidermal growth factor receptor-2 (HER2) [20,21]. Another promising prognostic and 
predictive biomarker of BC is Ki-67 (present in dividing cells) as indicator of cell proliferation and 
also as an endpoint for neoadjuvant systemic therapy [20]. However there are other proposed markers 
of proliferation measured by immunohistochemistry (IHC), such as, cyclin D, cyclin E, p27, p21, 
among others that are used to determine the predictive and prognostic levels [22]. 
In the last years, metabolomics emerged as a powerful approach in the advanced disease biomarker 
discovery which includes the comprehensive study of metabolites that are present in biological 
samples [23]. The study of metabolome to search biomarkers for any disease involves the 
identification of endogenous metabolites that have the potential to discriminate between samples 
obtained from healthy subjects and diseased patients. Plasma, serum, urine, tissue and cerebrospinal 
fluid (CSF), are the most commonly used biological samples in metabolomic studies. These biological 
samples contain hundreds of metabolites that vary in chemical and physical properties and 
concentration levels. Metabolomic studies includes two main approaches – targeted and untargeted. 
The targeted analysis is focused in specific groups of chemical characterized and annotated 
metabolites and their related pathways, whereas in the untargeted analysis the study includes a 
comprehensive measurement of all metabolites present in samples [24,25]. 
The type of approach chosen will determine the experimental design, sample preparation, and 
which analytical techniques can be used to obtain the results. Both targeted and untargeted follow the 
similar pipeline. Briefly, the study design includes the population that will be part in the study and 
also the determination of the conditions that are relevant for the hypothesis in investigation, namely 
the sample size, randomization (as a study design consideration), storage (as a sample handling issue), 
freeze/thaw cycles and timing during sample preparation are the most common factors that should be 
taken into account to guarantee reproducible and successful experiments minimizing variability. 
There are three main analytical platforms frequently used in metabolomic studies, which include mass 
spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy [26]. Moreover, after data 
acquisition, the obtained dataset, normally is subjected to statistical analysis (univariate and 
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multivariate methods) to find significant variations that allow the discrimination of patients with a 
specific disease (in this case, BC) from a control group [27]. The most common approaches for the 
identification of important metabolites comprise the application of unsupervised methods, such as, 
principal component analysis (PCA), hierarchical cluster analysis (HCA), as well as supervised 
methods, like partial least squares discriminant analysis (PLS-DA), random forest (RF) and support 
vector machines (SVM) [26,28]. A training set is used to construct the multivariate analysis models 
(e.g., PCA or PLS-DA), followed by an external validation set to predict the new cohort of samples 
using the model constructed with the training model. Finally, the putative biomarkers can be placed 




The OMICs is a neologism broadly adopted in biomedical research, that comprises the dataset of 
genomics (DNA), transcriptomics (RNA), proteomics (proteins) and metabolomics (metabolites) 
based on the central dogma of molecular biology [29]. The purpose of OMICs science in cancer 
research is to discover cancer-specific biomarkers (diagnostic, prognostic and/or putative). The Food 
and Drug Administration (FDA) defined biomarkers as a “characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or biological 
responses to a therapeutic intervention” [30]. Biomarkers are powerful tools, when used for the early 
cancer detection and selection of therapeutic strategy, thus improving the outcome of cancer treatment 
and reduce cancer-related mortalities. 
One of the newest promising OMICs sciences is metabolomics being a suitable tool that provides 
state of the art of analytical instrumentation tandem with pattern recognition procedures and 
chemometric tools to discover new disease- biomarkers providing novel insights into disease etiology, 
and more robust assessment of etiological pathways [30,31]. Metabolomics studies the complex 
interaction in biological systems providing a comprehensive and detailed information of the 
phenotype and molecular physiology as result of environmental factors, genetic as well as exogenous 
and endogenous factors (e.g. age, gender, race, diet, drugs, exercise, gut microbiota) [31]. In addition, 
metabolomics can be used in early detection and diagnosis of cancer, in the assessment of therapies 
and medical interventions, since cancer is a disease that promotes changes in cellular metabolism 
[32–35] . This OMICs tool has been extensively applied in clinical health practice due to its ability 
to quickly analyze biological samples (e.g. blood, tissue, saliva and urine) with relatively simple 
sample preparation (10 – 30 min), cost-effective and high-throughput [30,36,37]. Nevertheless, 
metabolomics present several drawbacks resulting from biological and experimental features, such as 
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sampling variability, inter- and intra-individual differences and a lack of validated protocols for 
biological samples handling which have a significant impact on the OMICs data approach [38,39]. 
It will be further discussed the the metabolic profile of several biological samples, including 
lipidomics (lipids), labeled substrates (e.g., 13C labeled glucose), volatomic (volatile organic 
metabolites), and metabolites resulting from Krebs cycle [30,39] with the purpose of an early 
diagnosis, metabolic reprogramming, cancer typing, staging and therapeutic intervention response 
[29,37]. Regarding the Krebs/TCA cycle, there is evidence that the role of TCA for energy production 
and macromolecule synthesis by cancer cells, especially those with dysregulated oncogene and tumor 
suppressor expression [40–42]. Over the last years, there has been a rapidly growing number of 
metabolomic studies intended to discover new biomarkers or make disease diagnosis using different 
biological matrices , such as cell lines [43–46], blood [47], exhaled breath [48], plasma [33,49,50], 
saliva [51–54], tissues [55–57], serum [58] and urine [59]. In Table 1 are resumed the most 
common analytical approaches used in metabolomic studies grouped by type of biological sample 
and objective of the study. Interestingly, the main studies involve a diagnostic purpose using BC cell 
lines with the aim of search biomarkers, inspect the metabolome (endo- and exo-). Moreover, lipids 
as building blocks of cell membranes have their levels changed during the malignant transformation. 
Lipid metabolism plays a vital role in oxidative stress and is correlated with other parameters linked 
to BC risk (e.g. hormonal balance, body mass index, breast density, drug metabolism and growth of 
insulin levels) [43,60] (Table 1.1).
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Table 1. 1 - Summary of metabolomics studies performed in breast cancer biomarker discovery in different biological matrices. 
Biological sample Sample groups Aim 
Analytical 
approaches 
Main conclusions References 
Human cell lines      
     
Diagnostic 
biomarkers  





Control (MCF10A)  
To compare the differences in the lipidomic 
compositions of human cell lines derived from 
normal and BC tissues, and tumor vs. normal tissues 
obtained after the surgery of BC patients. 
LC-MS/MS,  
GC-MS 






453, BT-474), Control 
(MCF-10A) 
To determine endo- and exo-metabolite analysis of 
the BC cell lines 
UPLC-MS/MS, 
LC-MS/MS 
* Statistical analysis allowed a discrimination of the breast epithelial cells 
from the BC cell lines  
* MDA-MB-231 showed an increase in nicotinamide levels, namely in 1-







To establish the BC cell lines volatile metabolomic 
signature 
GC–MS 
* 60 VOMs were identified and six of them were detected only in the 






To quantify specific metabolites in BC cell extracts NMR 
* Significantly differences were observed between cell lines, namely in the 
concentrations of 15 metabolites* The current method represented a useful 




BC (Cal 51, SKBR3, 
MCF-7) 
To measure the absolute metabolite concentrations in 
complex mixtures with a high precision in a 
reasonable time 
NMR 
* The proposed approach represented a powerful tool to quantify 14 
metabolites (alanine, lactate, leucine, threonine, taurine, glutathione, 
glutamate, glutamine, choline, valine, isoleucine, myo-inositol, proline, and 
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Diagnostic 
biomarkers 




patients (n= 35) 
To investigate the metabolic profiles of human BC 
cell lines carrying BRCA1 pathogenic mutations 
LC-MS/MS 
* It was possible to collect differential metabolic signature for BC cells 
based on the BRCA1 functionality  
[50] 
Therapy response BC cell line (MCF-7) 
To develop a robust and highly sensitive platform to 
identify endogenous estrones in clinical specimens 
MALDI-MS, LC-
MS/MS 
* The results suggested that MALDI-MS-based quantitative approach can 
be a broad method for the ketone-containing metabolites target analysis thus 
replicating the clinical stage.  
[62] 
Therapy response 
BC tissue (n = 40), 
Blood (n = 27), BC cell 
lines (n = 3) 
To detect alterations in metabolites and their linkage 
to metabolic processes in several pathological 
conditions including BC 
NMR 
* Functional of IP3Rs in causing metabolic disruption was observed in 
MCF-7 and MDA MB-231 cells 
* The results offered new insights regarding the relationship of BC 






To study toxic effects of bisphenol and the underlying 
mechanisms on 
tumor metastasis-related tissues 
LC-MS/MS, 
MALDI-MS 
* Metabolites-based studies might be suitable for BC diagnosis 




     
Diagnostic 
biomarkers 
BC patients (n = 258), 
Benign mammary 
gland (n = 159), 
Control (n = 78) 
To screen metabolite markers with BC diagnosis 
potentials 
MS 
* The method developed allowed the discrimination of BC from non-BC 





14 Catarina Silva (2019) 
Diagnostic 
biomarkers 
Metastatic BC patients 
(n = 95), Early-stage 
BC patients (n = 80) 
To explore whether serum metabolomic spectra could 
distinguish between early and metastatic BC patients 
and predict disease relapse 
NMR 





BC patients (n= 132), 
Control (n= 76) 
To develop a new computational method using 




* The method allowed to determine important metabolic pathways 
signature for BC diagnosis, representing a suitable tool for diagnostic and 





BC patients (n = 45), 
Control (n = 45) 




* 661 metabolites were detected, but only 338 metabolites were found in all 





BC patients (n = 29), 
Control (n = 29) 
To establish a plasma metabolic fingerprint of 
Colombian Hispanic women with BC 
LC-MS, GC-MS, 
NMR 
* The current report showed the effectiveness of multiplatform strategies in 




BC patients (n = 91), 
Control (n = 20) 
To explore whether serum metabolomic profile can 
discriminate the presence of human BC irrespective 
of the cancer subtype  
LC-MS/MS 
* From the 1269 metabolites identified in plasma from controls and 





BC patients (n = 27), 
control (n = 30) 
To apply 1H NMR and DART-MS for the 
metabolomics analysis of serum samples from BC 
patients and healthy controls. 
NMR, DART-MS 
* The approach allowed the disease classification and  





Metastatic BC patients 
(n = 39 + 51 for 
validation), Early-stage 
BC patients (n = 85 + 
112 for validation) 
To distinguish between early and metastatic BC NMR 
* Metabolic phenotyping by NMR showed a robust potential for the 




BC patients (n = 40) BE 
patients (n = 40) and 
healthy controls (n = 
34). BE patients with 
To investigate the free fatty acid (FFA) metabolic 
profiles to identify biomarkers that can be used to 
distinguish patients with BC (BC) from benign (BE) 
patients or healthy controls. 
GC-MS 
The FFA biomarkers proved to be helpful for the prevention and 
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fibroma (n = 25) and 
chronic fibroadenosis 
of breast (n = 15) 
Therapy response BC patients (n = 19) 
To compare metabolite concentrations and Pearson’s 
correlation coefficients to examine concomitant 
changes in metabolite concentrations and 
psychoneurologic symptoms before and after 
chemotherapy. 
UPLC-MS/MS 
* The post-chemotherapy global metabolites were characterized by higher 
and lower amounts of acetyl-L-alanine and indoxyl sulfate and 5-oxo-L-
proline, respectively. 
* Metabolomics was useful for further understanding of biological 
mechanisms associated with psychoneurologic symptoms. 
[70] 
Therapy response BC patients (n = 28) 
To identify potential biomarker candidates that can 
predict response to neoadjuvant chemotherapy for BC 
LC-MS, NMR 
* The concentrations of threonine, isoleucine, glutamine, linolenic acid had 
significantly different responses to chemotherapy  
* The purposed approach clearly discriminates patients regarding the 
response to drugs providing a valuable tool for a non-invasive prognosis of 
the treatment strategy. 
[71] 
Endogenous factors 
BC patients (n = 206), 
Control (n = 396) 
To investigate whether plasma untargeted 
metabolomic profiles could contribute to predict the 
risk of developing BC 
NMR 
* The study contributed to the development of screening approaches for the 
identification of BC at-risk women. 
[31] 
Endogenous factors 
BC patients (n = 621), 
Control (n= 621) 
To evaluate associations 
 of diet-related metabolites with the risk of BC in the 




* The data obtained showed how nutritional metabolomics might identify 
diet-related exposures associated to cancer risk. 
[72] 
Human urine      
Diagnostic 
biomarkers 
BC patients (n= 30), 
CC (n = 30), Control (n 
= 30) 
To discriminate different types of cancer based on 
urinary volatomic biosignature 
GC-MS 
* The butanoate metabolism was highly activated in studied cancers, as well 
as tyrosine metabolism, but in a reduced proportion 
* Different clusters allowed to establish sets of VOMs fingerprints resulted 
in the discrimination of the studied cancers 
[59] 
Therapy response 
BC patients (n = 31), 
Control (n = 29) 
To identify metabolites which can be helpful in the 
understanding of metabolic alterations driven by BC 
as well as their potential usage as biomarkers 
LC-MS, GC-MS 
* The analytical multiplatform approach enabled a wide coverage of urine 
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Human Saliva      
Diagnostic 
biomarkers 
BC patients (primary, n 
= 8; relapse, n = 22), 
Control (n = 14) 
To determine polyamines including N-acetylated 
forms in human saliva and the diagnostic approach to 
BC Patients 
UPLC−MS/MS 
* The increase on polyamines level in BC patients 
 Ac-SPM, DAc-SPD, and DAc-SPM levels were significantly higher only 





BC patients (n = 30), 
Control (n = 25) 
To screen the potential salivary biomarkers for BC 
diagnosis, staging, and biomarker discovery. 
UPLC-MS 
* Saliva metabonomics approach may provide new insights into the 




BC patients (n = 111), 
Control (n = 61) 
To determine of polyamines including their 
acetylated structures for the diagnosis of BC patients. 
UPLC-MS/MS 
* The ratio of N8-Ac-SPD/ (N1-Ac-SPD + N8-Ac-SPD) can be used as a 




BC patients (n = 66), 
Control (n = 40) 
To explore the potential of the volatile composition of 
saliva samples as biosignatures for BC non-invasive 
diagnosis 
GC-MS 
* This study defined an experimental layout appropriate for the 
characterization of volatile fingerprints from saliva as potential 




     
Diagnostic tool 
BC patients (n = 14), 
Control (n = 11) 
To detect and identify human exhaled BC–related 
volatile profile 
MS 
* Eight metabolites enabled a clear discrimination of exhaled breath of BC 
patients from controls.  
* The analytical technique provided a non-invasive strategy to detect VOMs 
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Human Tissues      
Diagnostic 
biomarkers 
BC patients (n = 10) 
To establish a detailed lipidomic characterization 
with the goal to find the statistically differences 
between BC and normal tissues. 
HPLC-MS 
* Total concentrations for phosphatidylinositols, phosphatidylcholines, 
phosphatidylethanolamines and lysophosphatidylcholines were increased 





Paired tumor and non-
tumor liver (n = 60), 
breast (n = 130) and 
pancreatic (n = 76) 
To assess the metabolomic profiling as a novel tool 
for multiclass cancer characterization 
GC-MS, LC-MS 
* The findings provided a framework to validate cancer-type specific 




BC patients (n = 37), 
Control (n = 35) 
To identify potential biomarkers that differs TNBC 
from ER+ BC 
GC-MS, LC-
MS/MS 
* 133 metabolites presented significant differences between ER+ and 
TNBC tumors  




BC patients (n = 47), 
Control (n = 35) 
To identify how TNBC differs from LABC subtypes 
within the African-American and Caucasian BC 
patients 
HR-MAS-NMR 
* Increased pyrimidine synthesis was related to TNBC in Caucasian 
women* Novel treatment targets for TNBC could be explored through the 




BC patients (n = 228) 
To distinguish between tumor and non-involved 
adjacent tissue 
HR-MAS-NMR 
* Metabolic profiling of tumor tissues by NMR can be a suitable method 




BC patients (n = 25), 
Control (n = 5) 
To establish metabolic profiles of ER+ vs. ER– and 
of ER– subtypes linked to genetics 
GC-MS, LC-MS 
* Changes in the metabolic profile of ER- vs. ER + breast tumors were 
observed 





BC patients (n = 270), 
Control (n = 97) 
To quantify the dysregulation of the glutamate-
glutamine equilibrium in BC 
GC-TOFMS 
* A positive correlation between glutamate and glutamine in normal breast 
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Diagnostic 
biomarkers 
95 OC (84 peritoneal, 
11 pleural), 10 BC (7 
pleural, 2 peritoneal, 1 
pericardial), and 10 
malignant 
mesotheliomas (6 
peritoneal, 4 pleural) 
To identify the metabolic differences between 
ovarian serous carcinoma effusions obtained pre- and 
post-chemotherapy and compare ovarian carcinoma 
(OC) effusions with breast carcinoma and malignant 
mesothelioma specimens. 
1H-NMR 
* Differences in metabolic profiles of different malignant effusions were 
detected  
* Metabolic characterization by NMR can be a technique to additional 
knowledge the mechanisms of effusion development  
[78] 
Therapy response BC patients (n = 122) 
To explore the effect of neoadjuvant therapy on 
metabolic profiles of BC tissues 
HR-MAS-NMR 
* Non-metastatic breast tumor tissue reflected different alterations in all 
patient groups after treatment. 
* Metabolic profiles discriminated pNRs from pMRD patients thus 
complementing other molecular assays allowing the knowledge of the 
underlying mechanisms affecting the response. 
[79] 
Therapy response BC patients (n = 18) 
To study metabolite levels in human BC tissue, 
assessing, for 
instance, correlations with prognostic factors, 
survival outcome or therapeutic response 
HR-MAS-NMR 
* Significant changes between the tumors were identified, indicating that 
the intertumoral changes for numerous metabolites were greater than the 
intratumoral changes for these three tumors. 
 
[80] 
Therapy response BC patients (n = 37) 
To determine whether metabolic profiling of core 
needle biopsy (CNB) samples using HR-MAS-NMR 
could be used for predicting pathologic response to 
neoadjuvant chemotherapy (NAC) in patients with 
locally advanced BC 
HR-MAS-NMR 
* The purposed method can be applied to predict the pathologic response 
before neoadjuvant chemotherapy  
[81] 
Therapy response BC patients (n = 271) To establish metabolic signatures for ER+ vs. ER– BC GC-TOFMS 
Some metabolites levels were increased in ER- subtype, such as, beta-
alanine, glutamate and xanthine 
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To identify global metabolic profiles of breast tumors 
isolated from multiple transgenic mouse models and 




* C3-TAg was the only cohort with a tumor metabolic signature composed 
of ten metabolites with significance prognostic value in BC patients 
[83] 
ANOVA – Analysis of variance; AUC – Area under the curve; BC – BC; BFS– Bootstrap feature selection; CE-MS – Capillary electrophorese-mass spectrometer; DART-MS – Direct analysis in real time mass 
spectrometry; GC-MS – gas chromatography – mass spectrometry; GC-TOF-MS – Gas chromatography time-of-flight mass spectrometry; GGM –  Gaussian graphical modelling; HCA – Hierarchical cluster 
analysis; HR-MAS-NMR - High resolution magic angle spinning nuclear magnetic resonance spectroscopy; LC-MS/MS – Liquid chromatography tandem with mass spectrometer; LC-TOF-MS – Liquid 
chromatography time-of-flight mass spectrometry; LDA – Linear discriminant analysis; MALDI-MS – Matrix-assisted laser desorption/ionization mass spectrometry; MCCV – Monte Carlo cross validation; MS – 
Mass spectrometry; MWT – Mann Whitney U test; NMR – Nuclear resonance magnetic; NRI – Net reclassification improvement; OPLS-DA – Orthogonal projections to latent structures discriminant analysis; 
OSC-PLS – Orthogonal signal correction partial least squares; PC – Pearson correlation; PCA – Principal component analysis; PEA – Pathway enrichment analysis; PLS-DA – Partial least squares discriminant 
analysis; RF – Random Florest classifier; ROC – Receiver operating characteristic; SCC – Spearman correlation coefficient; SVM – Support vector machine ; TNBC – Triple negative BC; UPLC-MS/MS – Ultra 
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In literature, the reports performed involving human cell lines focus mainly in diagnostic purpose. 
As for example in the volatile composition (VOMs) as described by Silva et al. [44] where the 
volatomic signature of BC cell lines was established, and based on the results, 2-pentanone, 2-
heptanone, 3-methyl-3-buten-1-ol, ethyl acetate, ethyl propanoate and 2-methyl butanoate were 
detected only in cultured BC cell lines. These VOMs are formed endogenously or obtained from 
exogenous sources (e.g., environmental, lifestyle, biological agents) [51], and can be recognised as a 
useful tool to BC non-invasive diagnosis [44,51]. Other study by Willmann et al. [46] observed the 
changes of the exo- and endometabolite profiles in BC cell lines by LC-MS/MS and observed a clear 
discrimination of the breast epithelial from the BC cell lines through statistical tools. Moreover, a 
decrease on ratio of glutathione (GSH) and glutathione disulfide (GSSG) was observed in BC cell 
lines as a result of oxidative stress. The lipidomic profile of several BC cell lines was compared with 
normal cells obtained from non-cancerous tissues by LC-MS/MS and GC-MS that changes observed 
in breast tumor tissues were caused mainly by difference in lipidomic profiles of tumor cells and these 
alterations can be correlated with the lipidomic composition of the nine breast cancer cell lines. 
Furthermore, Martineau et al. [61], determined the absolute concentration of several metabolites (e.g., 
alanine, lactate, threonine, taurine, glutathione, glutamate, glutamine, choline, valine, isoleucine, myo 
inositol, serine, proline, aspartate and histidine), revealing the usefulness for the establishment of 
potential biomarkers. Also, BC cell lines with BRCA1 pathogenic mutations were investigated by 
LC-MS/MS in order to obtain their metabolic signature as possible diagnostic approach. 
Regarding plasma, serum or blood, many studies have been conducted as observed in Table 1, 
with multiple aims as Cala et al. [49] that developed a pilot control case-study, where a metabolomic 
and lipidomic approach was performed in order to establish a plasma metabolic fingerprint of 
Colombian Hispanic women with BC. According to these authors, the plasma metabolites could 
contribute to an enhanced knowledge of the underlying metabolic shifts driven by BC in women of 
Colombian Hispanic origin. Moreover, despite racial differences, the mapped metabolic signatures in 
BC were comparable but not identical to those described for non-Hispanic women. Wang et al. [47] 
used a dried blood spot approach for rapid BC detection. In the first study, the target analytes were 
23 amino acids and 26 acylcarnitines, and based on the results piperamide, asparagine, proline, 
tetradecenoylcarnitine/palmitoylcarnitine, phenylalanine/tyrosine, and glycine/alanine could be used 
as potential biomarkers to diagnose BC. Lyon et al. [70] established a serum metabolome analysis 
from the tryptophan pathway of 19 women with early-stage BC. The targeted analysis indicated 
higher kynurenine levels and kynurenine/tryptophan ratios post-chemotherapy. Also, the symptoms 
of pain and fatigue had association with several targeted metabolites. An improved metabolic profile 
of human serum samples was obtained using complementary thecniques, namely MS and NMR and 
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this approach may be useful to achieve more accurate disease detection and gain more insights 
regarding disease mechanisms and biology [67]. 
Another study conducted by Lécuyer et al. [31] combined metabolomic and epidemiological 
approaches by NMR to investigate whether plasma untargeted metabolomic profiles could contribute 
to the identification of BC at-risk women, whereas Playdon et al. [72] focused on the evaluation of 
the associations of diet-related metabolites with the risk of breast cancer. It was possible to verify that 
the prediagnostic serum concentrations of metabolites related to alcohol, vitamin E, and animal fats 
were associated with ER+ breast cancer risk. 
Urine became a very interesting biological sample to investigate as diagnostic tool or as result 
of a treatment, as it is easy to collect, and also as ending point of all reactions that occur in the 
body. Furthermore, Porto-Figueira [59] established the urinary volatomic biosignature from breast 
(BC), and colon (CC) cancer patients as well as healthy individuals. This last work observed that 
several pathways are over activated in cancer patients, being phenylalanine pathway in BC and 
limonene and pinene degradation pathway in CC the most relevant. Yu et al. [84] explored the 
relationship between urinary metabolites and clinical chemotherapy response in BC. As results, 
chemotherapy-sensitive patients exhibited 30 % of change in metabolite levels when compared to 
healthy individuals, while chemotherapy-insensitive patients showed only 9 % of change in 
metabolite levels when compared to healthy people that presented recurrence. 
Another explored biological fluid is saliva as described by Zhong et al. [53] that screened the 
putative salivary biomarkers for BC diagnosis, staging, and biomarker discovery. As a result, 18 
biomarkers were identified, but only three up-regulated metabolites, displayed the area under the 
curve (AUC) values higher than 0.920, indicating the high accuracy to predict BC. Also, Cavaco et 
al. [51] screened salivary volatiles for a putative BC discrimination, and from metabolites 
identified, only 3-methyl-pentanoic acid, 4-methyl-pentanoic acid, phenol, p-tert-butyl-phenol, 
acetic, propanoic, benzoic acids, 1,2-decanediol, 2-decanone, and decanal were statistically 
relevant for the discrimination of BC patients in the populations analyzed. Another type of 
molecules, the polyamines were associated with tumor growth due to their biosynthesis and 
accumulation [54]. In this context, Tsutsui et al. [52] and Takayama et al. [54] determined polyamines 
including N-acetylated forms in saliva to diagnose BC. According to Tsutsui et al. [52], the level of 
polyamines increased in BC patients, and the levels of N1-acetyl-spermine, N1N8-diacetyl-spermidine 
and N,N-diacetyl-spermine were significantly higher only in the relapsed patients. Takayama et al. 
[54] demonstrated that eight polyamines are strongly correlated with the BC patients. Furthermore, 
the ratio of N8-acetyl-spermidine/ (N1-acetylspermidine + N8-acetyl-spermidine) may be adopted as 
an index of the health status after the surgical treatment. 
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In-vitro analysis of BC tissues can be a valuable tool to inspect the metabolic differences between 
tissue classes, either using the hydrophilic or the lipophilic part. As a result, one might use the 
metabolomic profile as a novel tool for cancer characterization. Breast tissue is also an interesting 
biological sample used for diagnostic purposes and /or response to a treatment as demonstrated by 
Euceda et al. [79] that explored the effect of the antiangiogenic drug bevacizumab on metabolic 
profile from BC tissue. On the other hand, Budczies et al. [77] studied the glutamate enrichment as a 
new diagnostic opportunity in BC, and a positive correlation between glutamate and glutamine in 
normal breast tissues switched to negative correlation between glutamate and glutamine in BC tissues. 
Euceda et al. [79] observed a metabolic alteration indicating a decline in glucose consumption as an 
effect of chemotherapy. In addition, a lower glucose and higher lactate level was observed in patients 
(≥ 90% of tumor reduction) when compared to those with no response (≤ 10% of tumor reduction). 
In turn, Choi et al. [81] determined the metabolic profiling of core needle biopsy samples in order to 
predict pathologic response to neoadjuvant chemotherapy in patients with locally advanced BC. 
These authors observed that there was a trend of lower levels of phosphocholine/creatine ratio and 
choline-containing metabolite concentrations in the pathologic complete response group when 
compared to the non-pathologic complete response group. Most of the BC patients undergo a cycle 
or more of chemo being the general treatment that uses cancer-killing drugs before (neoadjuvant or 
preoperative therapy) and after (adjuvant therapy) surgery [31,36], Then, the therapeutic chemo effect 
may shift significantly between patients, as a result of BC phenotypes [37] of and intra- and inter- 
individual differences. For this reason, it is necessary to punctually and accurately evaluate the 
therapeutic effects of chemotherapy, which could help to adjust the chemotherapy regimen [71,84]. 
whereas the advances in treatment increased significantly the survival rates for women with BC, as 
women often report psychoneurologic symptoms (e.g. pain, fatigue, depression) during and after 
chemotherapy cycles. 
Regarding exhaled breath a less explored biological sample in terms of BC diagnostic purpose. In 
a study performed by Martinez-Lozano Sinues et al. [48] who developed a pilot study to identify 
cancer–related volatile profile in exhaled breath of BC patients. Concerning exhaled breath and the 
possible mechanisms involved in the production of endogenous VOMs, in Figure 1. 3 is represented 
a schematic illustration about the possible pathways. 
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Figure 1. 3 - Scheme to illustrate the possible origin of some VOMs. 
The principle behind this is based on the fact that cancer growth is promoted by the progressive 
accumulation of genetic and epigenetic changes leading to cellular oxidative stress, which in turn 
increases the liver's production of cytochrome P-450 (CYP450) oxidase enzymes to take into account 
with stress. Both processes affect the abundance of VOMs in breath once oxidative stress causes lipid 
peroxidation of polyunsaturated fatty acids (PUFA) in membranes, producing alkanes and 
methylalkanes which are catabolized by CYP450 [85]. 
 
Analytical approaches 
Metabolomics encompasses targeted and non-targeted analysis of endogenous and exogenous 
metabolites (<1500 Da), such as lipids, amino acids, hormonal steroids, peptides, nucleic acids, 
organic acids, vitamins, thiols and carbohydrates, which represent a promising tool for biomarker 
discovery [86,87]. The complexity of the metabolome, the metabolites properties and their 
concentration levels in biological samples complicates the separation and detection on a single 
analytical platform. For this fact, the integration of high resolution analytical frameworks, mass 
spectrometry (MS) and nuclear magnetic resonance (NMR), appear as an outcome in metabolomics 
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biological sample and related metabolic pathways within a few minutes [27,86,87] as shown in Figure 
1.4. 
 
Figure 1. 4 - General flowchart in targeted/untargatet metabolomic approaches. 
MS - based metabolomics 
MS is an analytical tool extensively used in metabolomics applications, ranging from 
understanding the structural characterization of important metabolites to biomarker discovery [86]. 
Metabolic fingerprinting is general obtained by MS direct-injection, but this approach presents 
several drawbacks namely co-suppression and low ionization efficiencies. Thus, generally MS based 
metabolomics includes a separation step, based on gas chromatography (GC–MS) 
[43,44,51,59,65,66,77,82], liquid chromatography (LC–MS) [33,43,46,50,52–55,70] or capillary 
electrophoresis (CE-MS) [83,84], to solve co-suppression and to decrease the complexity of the 
biological sample. The integration of MS with a chromatographic technique (GC, LC) and capillary 
electrophoresis showed high sensitivity, speed, selectivity and improves the accuracy of compound 
identification, detection and quantification. In addition, GC-, LC- and CE-MS are destructive 
methods, requires sample preparation and are expensive, being these facts the main drawbacks of 
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Gas Chromatography-Mass Spectrometry (GC-MS) - based metabolomics 
In the last decades, MS and chromatography have been broadly developed, and GC-MS becomes 
a core and reliable separation, detection and identification analytical framework on metabolomics 
analysis [43,44,51,59,65,66,77,82]. After sample collection and metabolites extraction, a small 
volume of sample is common injected in splitess mode, once the metabolites are in trace levels, to 
improve the sensitivity and carrier gas propels the sample through the high resolution capillary 
columns (30 or 60 m columns with 5–50% phenyl stationary phases). The separation in GC occurs in 
an oven at high temperatures, and the metabolites need be thermally stable and volatile (e.g., 
aldehydes, ketones, alkanes, organic acids) or non-volatile metabolites requiring derivatization (e.g., 
amino acids, sugars, phosphorylated metabolites, amines, lipids) [86,88,89]. The samples are ionized 
by electron-impact (EI) or chemical ionization (CI) for MS detection, being EI the most used since it 
provides molecular ion fragmentation to obtain a mass spectrum revealing of the metabolite’s 
structure [88]. The MS employed influences the sensitivity of detection, being the quadrupole (q), 
time-of-flight (TOF) and ion trap the most usually applied in metabolomics. GC-qMS was used to 
screen salivary volatiles for putative BC as an exploratory study involving geographically distant 
populations [51], also to establish the metabolomic signature of human BC cell lines [44] and to 
discriminate different types of cancer based on urinary volatomic biosignature [59], among other 
examples reported in Table 1. In the first study, up to 120 volatiles from distinct chemical classes, 
with significant variations among the groups, were identified [51], whereas Silva et al. [44] and Porto-
Figueira et al. [59] identified 60 and 130 volatiles in BC cell lines and urine, respectively. On the 
other hand, Budczies et al. [77,82] used GC × GC-TOFMS framework to evaluate the glutamate 
enrichment as new diagnostic opportunity in BC and to accomplish a comparative metabolomics of 
estrogen receptor positive (ER+) and estrogen receptor negative (ER-) in BC. Budczies et al. [82] 
identified 19 metabolites and the GC–TOFMS based analysis of metabolites present in BC tissues 
revealed significantly differences in central metabolism in the more aggressive ER− compared to the 
ER+ type. The detected changes included the metabolism of glutamine with a decrease in 
concentration of glutamine and an increase in concentration of glutamate and 2-hydroxyglutaric [82]. 
In turn, Dougan et al. [66] used GC-MS to evaluate the detectability, reliability, and distribution of 
metabolites measured in pre-diagnostic plasma samples in a pilot study of women listed in the 
Northern California site of the BC Family Registry. In this study. 661 metabolites were detected, 338 
(51 %) of them were found in all samples, and 490 (74 %) in more than 80 % of samples. 
The main advantages of GC-MS-based metabolomics are sensitivity, specificity, high-throughput 
technology to handle a large volume of samples and reproducible. Nevertheless, this hyphenated 
technique has limited in mass range (m/z 30 – 550), the molecular ion is often not detected owing to 
 
 
26 Catarina Silva (2019) 
fragmentation, which makes more difficult the identification of unknown metabolites and the 
metabolites need be volatile and thermally stable [89,90]. 
 
Liquid Chromatography-Mass Sectrometry (LC-MS) - based metabolomics 
Currently, liquid chromatography (LC) in particular high performance liquid chromatography-
mass spectrometry (HPLC-MS, LC-MS) represents an easy-going tool on separation and 
characterization of a metabolites pool, namely salts, acids, bases, hydrophilic and hydrophobic 
metabolites. The versatility of LC-MS is due to the several separation procedures and wide-ranging 
mass analyzers [90]. Contrarily to GC-MS, HPLC-MS is not limited to volatile and thermo stable 
metabolites and it is a promising tool for global metabolomics and the establishment of disease 
biomarkers. 
Basically, the metabolites are eluted through a column based on their selective partition between 
a stationary phase (column material) and a mobile liquid phase. The metabolites according to the type 
of stationary phase can be eluted based on their charge, size, hydrophobicity and molecular weight 
[91]. Nowadays, the evolution of the HPLC is focused in miniaturization, smaller columns and low 
solvent volumes to attain a faster separation of metabolites. Ultra-high performance chromatography 
(UHPLC) appears as solution, since compared to HPLC promotes the resolution within a low analysis 
time and requires low volumes of solvent [92,93]. UHPLC columns are packed with 2 µm particles 
and the system operates at higher pressures (1000 bar) and tandem with MS, results in higher peak 
capacity, resolution, specificity and high-throughput abilities (reduced run time per sample) 
compared with HPLC [86,90,92–94]. 
Furthermore, Willmann et al. [46] analyzed the endo- and exometabolite of the BC cell lines MDA-
MB-231, -453 and BT-474 as well as the breast epithelial cell line MCF-10A through two different 
analytical platforms: UHPLC-ESI-QTOF and HPLC-ESI-QqQ, which resulted in the identification 
of 92 annotated exometabolites and 58 endometabolites. In turn, Jové [33] used LC-ESI-
qTOFMS/MS to establish the metabolomic profile of BC, whereas HPCL-ESI-MS was used to 
determine the determine the lipidomic differences between human BC and the surrounding normal 
tissues [55]. UHPLC tandem with MS was applied to explore novel blood plasma biomarkers 
associated to the BRCA1-mutated phenotype of BC [50], to determine polyamines including 
N‑acetylated forms in saliva [52,54], and to screen the potential salivary biomarkers for BC diagnosis, 
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NMR – based metabolomics 
NMR spectroscopy has been announced as a promising tool of metabolomics, providing a 
comprehensive view of metabolite fingerprinting, profiling and metabolic flux analysis under specific 
conditions, despite its inherent lower sensitivity compared to MS, limiting its skill with trace level 
metabolites. The main advantages of NMR are automation, requires low or no sample preparation, 
high reproducibility, non-destructive, non-selectivity in metabolite detection and the ability to 
simultaneously quantify multiple classes of metabolites [29,87]. 
The principle of NMR spectroscopy is based on the fact that the nucleic of many isotopes (e.g., 
1H, 13C, 14N, 15N, 17O), when placed in a magnetic field, absorb radiation at a specific frequency [90]. 
The result is a NMR spectrum which corresponds to a unique metabolite pattern and provides 
structural information that can simplify the identification of unknown metabolites [86,89]. A fast 
identification of metabolite results from a combination of chemical shifts, spin–spin coupling, and 
relaxation or diffusion information [86,89]. Jobard et al. [68] reported a 1H NMR-based metabolic 
phenotyping study aiming the identification of metabolic serum changes associated with advanced 
metastatic BC (MBC) in comparison to the localized early disease (EBC). Histidine, acetoacetate, 
glycerol, pyruvate, glycoproteins (N-acetyl), mannose, glutamate and phenylalanine were the 
metabolites that allowed the discrimination between MBC and EBC groups. NMR was also used by 
Tenori et al. [58] to explore whether serum metabolomic spectra could distinguish between early and 
metastatic BC patients and predict disease relapse, whereas Singh et al. [63] used NMR to detect 
alterations in metabolites and their linkage to metabolic processes in a number of pathological 
conditions including BC. In the last study, the authors observed an increase in lipoprotein, lactate, 
lysine and alanine level and a decrease in the levels of pyruvate and glucose in serum of inositol 1, 4, 
5-trisphosphate (IP3R) receptor group patients when compared to control. In addition, NMR offers 
the possibility to study tissue through high-resolution magic angle spinning (HR-MAS) to reduce line 
widths in NMR spectra of tissue samples [74,75,79–81]. Tayyari et al. [74] performed the 
metabolomic analysis of triple-negative and luminal A BC subtypes in African-American using HR-
MAS-NMR. A total of 27 metabolites were assigned and the metabolic profiles of these subtypes 
were also distinct from those revealed in Caucasian women. In turn, the feasibility of HR-MAS-NMR 
of small tissue biopsies to distinguish between tumor and non-involved adjacent tissue was 
investigated by Bathen et al. [75]. The results showed that the samples with a low tumor content have 
higher levels of glucose, while samples with a high tumor content have higher levels of ascorbate, 
lactate, creatine, glycine, taurine and the choline-containing metabolites (glycerophosphocholine 
(GPC), phosphocholine (PCho), and free choline). Euceda et al. [79] evaluate the metabolomic 
changes during neoadjuvant chemotherapy combined with bevacizumab in BC using HR-MAS-
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NMR. According to these authors, despite metabolic profiles not being able to predict the pathological 
complete response (pCR) prior to treatment, a significant metabolic difference in pCR+ patients 
compared to pCR- was detected after neoadjuvant chemotherapy. 
 
Comprehensive analytical frameworks on metabolomics approach 
Comprehensive analytical frameworks are gained popularity on metabolomics fields [86], being 
hundreds of metabolites detected simultaneously through analytical frameworks such as GC×GC-
TOFMS, HPLC-CE-MS, LC×LC-MS, LC-MS-NMR, MALDI-FT-ICR-MS, LC-FT-ICR-MS, 
among others. 
On the last decade, two dimension (2D) liquid-liquid chromatography (LC×LC) as well as gas-gas 
chromatography (GC×GC) have been gained increasing attention since overcome overlapping of 
metabolites by diverting each peak from a GC or LC column to a second GC or LC column, improve 
sensitivity and complementary selectivity being a promising tool in metabolomics field [95]. 
Nevertheless, other comprehensive analytical framework has been purposed in metabolomic field, in 
this context LC-MS-NMR platform is used in the identification of unknown metabolites in biological 
samples at trace levels, providing sample efficiency higher than the conventional flow injection 
methods [86]. In this sense, Reichenbach and co-workers [96] developed a suitable approach based 
on GC×GC-HRMS to analyze a cohort of 18 samples from BC tumors. This approach avoided the 
intractable problem of comprehensive peak matching, through a few reliable peaks for alignment and 
peak-based retention-plane windows to define comprehensive features that can be consistently 
matched for cross-sample analysis. In addition, a clear discrimination was achieved between sample 
of different grades and establish potential BC biomarkers. On the other hand, Yu et al. [97] optimized 
GC×GC-MS for robust BC cells, tissue, serum and urine metabolite profiling. GC×GC-MS analysis 
revealed detection around 600 molecular features from which 165 were characterized representing 
different chemical groups, such as amino acids, fatty acids, lipids, carbohydrates, nucleosides and 
small polar components of glycolysis and the Krebs cycle using EI spectrum matching. NanoLC-FT-
ICR MS was used to analyze protein digests of ~3000 laser capture microdissection (LCM)-derived 
tumor cells from breast carcinoma tissue, corresponding to ~300 ng of total protein [98]. 
 
Data analysis 
Data analysis is crucial in the metabolomics, being indispensable in every step of research, namely 
in sampling and experiment designs, data pre-processing and metabolite identification, as well in 
variables selection, classification modeling and validation procedures. The great challenge of data 
analysis in metabolomics is high dimensionality and complexity of datasets under analysis. Several 
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chemometric tools and statistical software’s are used in order to attribute value for high-dimensional 
metabolomic information obtained previously by the analytical tools [99,100]. Normally, a complete 
data analysis procedure in metabolomics is based on the following steps: dataset pre-treatment 
(centering, scaling, normalization), pre-processing (exploratory projection, variables selection), 
processing (predictive models), validation (model verification) and post-processing (pathway 
analysis) [101]. However, data analysis is adaptable and dependent on the objective of the study, and 
may be simple exploratory research or complex discovery of biomarkers and metabolic pathways, for 
this reason not all steps are always present or are not followed in this order. The data analysis 
procedures of recent metabolomics studies in BC are described in Table 2. 
 
Dataset pre-treatment 
Dataset pre-treatment is the initial step in data analysis, being extensively used in metabolomics 
to resolve the heteroscedasticity of high-dimensional datasets. Commonly, pre-treatment in BC 
metabolomics is done through normalization of dataset based on the centering, scaling, 
transformation and/or experimental corrections of variables values [102–104]. Centering is 
performed when the data analysis is focused on the differences between variables, where all 
measurements (e.g., concentrations, areas) are converted to values around zero based on variation 
measures. Mean [46,67,68,79] is the measure normally used in centering. Scaling is used to adjust 
the variables measurements based on a scaling factor, converting the measurements of all variables 
into values relative to the scaling factor. The scaling factor selected can be a dispersive measure (e.g., 
standard deviation) or size measure (e.g., mean). The main scaling approaches based on dispersive 
measures are autoscaling (standard deviation) [46,51,59] and pareto scaling (square root of the 
standard deviation) [43,53,55]. On the other hand, the most of size measure approaches uses scaling 
factors based on the mean [80], median [51,57,59,66,75,78,83] or total intensity value 
[53,58,67,68,71,73,74,81]. Transformations are mathematical approaches used to decrease the 
heteroscedasticity of dataset, which the variability between variables is dramatically reduce. Log 
[43,57,66,69,70,72,76,79] is the main transformation in BC metabolomics. However, cubic root 
[51,59] and quantile [48] transformations are also used.   
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Table 1. 2 - Chemometric methods applied to metabolomic studies. 
Biological sample Data Pre-treatment Pre-processing Processing Validation Post-processing References 
Diagnostic tool             
Human BC cell lines 
Scaling (Pareto scaled), 
Transformation (log 
transformed) 
PCA, HCA OPLS-DA LOOCV, ROC none [43] 
Centering (mean centered), 
Scaling (autoscaled) 
ANOVA, PCA, HCA, Pearson 
correlation 
PLS-DA LOOCV none [46] 
Experimental correction (sample 
weight corrected) 
PCA none none none [61] 
none none none none none [45] 
none ANOVA, PCA PLS, LDA K-CV none [44] 
Human blood 
none T-test PLS-DA, LRA ROC, Permutation test none [47] 




RF ROC, Bootstrapping none [58] 
Human Exhaled breath 
Transformation (quantile 
transformed)  






Correlation feature selection 
(CFS) 
LRA, SVM, RF K-CV, ROC 
Pathway-based metabolite 
sets analysis (pathifier) 
[65] 
Scaling (median value scaled), 
Transformation (log 
transformed)  
ANOVA, PCA none none none [66] 
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Biological sample Data Pre-treatment Pre-processing Processing Validation Post-processing References 
Human BC cell lines, 
plasma 
none KS-test, T-test, PCA none none none [50] 
Human saliva 
none none none none none [52] 
Scaling (Pareto and total 
intensity value scaled) 
T-test, PCA PLS-DA ROC, Permutation test none [53] 
none none LDA K-CV, ROC none [54] 
Scaling (autoscaled and median 
value scaled), Transformation 
(cubic root transformed) 





(internal standard corrected) 
MW-test, PCA PLS-DA, SVM, LRA K-CV, ROC none [105] 
Human tissues 
Scaling (Pareto scaled) PCA OPLS K-CV none [55] 
none PCA, HCA none none none [56] 
Scaling (median scaled), 
Transformation (log 
transformed) 
T-test none none none [57] 
Scaling (total intensity value 
scaled) 




Scaling (median scaled) PCA PLS-DA LOOCV none [75] 
Scaling (median scaled) T-test, PCA PLS-DA LOOCV none [78] 
Transformation (log 
transformed) 
T-test, Pearson correlation, 
HCA 
none none none [76] 
none T-test, Pearson correlation PLS-DA K-CV, ROC none [77] 
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Biological sample Data Pre-treatment Pre-processing Processing Validation Post-processing References 
Human serum 
Centering (mean centered), 
Scaling (total intensity value 
scaled) 
PCA PLS-DA, OPLS-DA K-CV, ROC none [67] 
Centering (mean centered), 
Scaling (total intensity value 
scaled) 






correction (internal standard 
corrected) 
ANOVA, PCA PLS-DA, LRA K-CV, ROC none [69] 
Human urine 
Scaling (autoscaled and median 
value scaled), Transformation 
(cubic root transformed) 





      
            




T-test, Pearson correlation none none none [70] 
BC tissues 
Centering (mean centered), 
Transformation (log transformed 
- only in univariate analysis)  
T-test, Pearson correlation, 
PCA 
PLS-DA K-CV, Permutation test none [79] 
Scaling (mean scaled - only in 
PCA) 
ANOVA, Spearman 





Scaling (total intensity value 
scaled) 
MW-test OPLS-DA LOOCV none [81] 
none Spearman correlation none none none [82] 
Serum 
Scaling (total intensity value 
scaled) 
T-test PLS, PLS-DA LOOCV, ROC none [71] 
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Biological sample Data Pre-treatment Pre-processing Processing Validation Post-processing References 





Scaling (total intensity value 
scaled) 
KS-test, L-test, SW-test, T-test, 
PCA 




none T-test, PCA PLS-DA K-CV none [84] 
Metabolic reprogramming 
     
          
Human BC cell lines, BC 
xenografts 
none ANOVA, PCA PLS-DA K-CV none [64] 
Mouse BC tissue Scaling (median scaled) ANOVA, PCA none none none [83] 
Endogenous factors     
 
      
            
Human plasma none 
T-test, Spearman correlation, 
PCA 




Pearson correlation, PCA LRA none none [72] 
ANOVA – Analysis of variance; ROC – Receiver operating characteristic; LOOCV – leave-one-out-cross validation; AUC – Area under the curve; BFS– Bootstrap feature selection; GGM –  Gaussian graphical 
modelling; HCA – Hierarchical cluster analysis; LDA – Linear discriminant analysis; MCCV – Monte Carlo cross validation; MWT – Mann Whitney U test; NRI – Net reclassification improvement; OPLS-DA – 
Orthogonal projections to latent structures discriminant analysis; LRA - logistic regression analysis; OSC-PLS – Orthogonal signal correction partial least squares; PC – Pearson correlation; PCA – Principal 
component analysis; PEA – Pathway enrichment analysis; PLS-DA – Partial least squares discriminant analysis; RF – Random Florest classifier; SCC – Spearman correlation coefficient; SVM – Support vector 
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Other normalization approaches based on experimental corrections are also used in metabolomics, 
such as internal standards [105,106] and sample weight [61]. Internal standards normalization 
assumes that the heteroscedasticity of all variables is systematic and can be corrected by variance of 
internal standards. Sample weight normalization is the direct correction of variables values by 
experimental sample measures (e.g., volume and weight). 
 
Pre-processing 
Pre-processing methods are performed to obtain an exploratory projection of dataset or an 
overview of variables importance prior to prediction models processing. Primarily, normality tests 
are used to determine if the data distribution is normal (parametric) or not normal (non-parametric). 
The most commonly used are Kolmogorov-Smirnov test (KS-test) [50,73], Shapiro-Wilk test (SW-
test) [73] and Lilliefors test (L-test) [73]. Two types of approaches are normally used in exploratory 
projections/variables importance ranking of BC metabolomics datasets: univariate and multivariate 
analysis. Univariate statistical methods are used to analyzed only one variable at a time, being useful 
to easily discover significant differences or measure correlations between samples groups. The 
differentiation is based on variance between groups by rejection of the null hypothesis or acceptation 
the alternate hypothesis [101,107,108]. The most common methods used when the data is parametric 
T-tests [31,47,68,70,71,74,76–79,84,48–50,53,57,59,62,63] and ANOVA 
[33,44,46,63,64,66,68,69,72,83]. T-tests, such as Student and Welch's tests, are recommended to 
analyze differences between two groups, and ANOVA-based methods, such as one-way ANOVA, 
two-way ANOVA, factorial ANOVA and MANOVA are used to evaluate more than two groups. 
Alternative univariate methods are implemented when the assumption of the normal distribution is 
non-parametric, such as Mann-Whitney test (MW-test) [51,81,105] and Wilcoxon test (W-test) [58]. 
In addition, univariate methods are also widely used to measure the correlations between continuous 
variables and response. The Pearson correlation [46,70,72,76,77,79] is the preferred option for linear 
relationships in populations with normal distribution. On the other hand, the Spearman correlation 
[31,80,82] is usually used in non-parametric datasets [109]. More complex correlation methods are 
also used in data analysis, such as Correlation Feature Selection (CFS) [65], where the appropriate 
correlation measure and a heuristic search strategy are performed by experiments on artificial and 
natural datasets based on algorithms. 
Similarly, the multivariate methods are also widely used for exploratory studies to obtain dataset 
patterns based on relationships between groups, being divided into two sub-groups, unsupervised and 
supervised methods. Unsupervised methods are the preferential option for exploratory studies, where 
the modeling process is based only on the explanatory variables, without external intervention of user 
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[100]. The most commons are principal component analysis (PCA) [31,33,63,64,66–
69,72,75,78,79,43,80,83,84,105,44,46,49,53,55,56,61] and hierarchical cluster analysis (HCA) 
[33,43,51,56,59,76]. PCA provides the projection of dataset into low dimensional based on 
orthogonal transformation, converting the variables variability from a set of observations into score 
vectors and loadings, called principal components [100,110]. HCA methods are used to form subsets 
of samples at ordered levels based on variables similarities/dissimilarities (such as distances or 
correlations), and can be performed in agglomerative mode (samples are aggregate into clusters) or 
divisive mode (complete dataset is divide into clusters). In both modes, the linkage criterion need to 
be selected, being that the most commonly used are single-linkage clustering (the minimum of 
distances) and complete linkage clustering (the maximum of distances) [111,112]. 
 
Processing methods 
After the explorative studies and variable selection, the next step is the processing of dataset in 
order to create a predictive response model to classification of new samples (ex. diagnostic tools), 
identification of valuable variables (ex. biomarkers) or exploring the mechanisms of metabolomic 
studies (ex. metabolic pathways). In this stage, the supervised methods are the preferential choice, 
where the response models are mainly based on two types, continuous (regression) and discrete 
(classification) [100,102]. The main methods for continuous response are based on multiple linear 
regression (MLR), sometimes called ordinary least squares (OLS). MLR is performed to predict the 
values of a dependent variable (response) based on a set of continuous explanatory variables, 
assuming a linear combination of the explanatory variables [110]. The most applied MLR-based 
method in metabolomics is partial least squares (PLS) [44,55,68,71]. Unlike PCA, which uses only 
the variables variation, PLS is a predictive and supervised method that use an informative response 
to maximize the covariance between the explanatory variables and the response, producing score 
vectors and loading vectors. The prediction model is based on interaction between the variables and 
response, ignoring the variables with irrelevant importance. The importance of each variable is 
defined according the PLS-based criteria, such as loading weights, variable importance on projection 
scores, regression coefficient, target projection and selectivity ratio [100,101,110]. However, when 
categorical variables are introduced, the discrete models should be used. Discrete models provide a 
predictive classification of response based on continuous and categorical variables, being classified 
into linear or non-linear. In linear methods, the classification is performed by highest probability 
based on linear relationships between explanatory variables, where exist a grouping variable 
(categorical). Linear discriminant analysis (LDA) [44,54] is the preferential method to classification 
models of discrete responses. LDA perform linear transformations of explanatory variables to create 
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discriminant functions that will maximize the separation between multiple classes of samples 
(groups) based on the information of the categorical variables (Liland, 2011). Among the various 
LDA-based methods, PLS-DA [33,46,74,75,77–79,84,105,113,47,51,53,59,63,64,67,69] is most 
widely used in metabolomics studies. PLS-DA is a successful combination of PLS and LDA that 
provides a visual low-dimensional pattern of samples discrimination based on the analysis of 
relationships between continuous and categorical variables [101,110]. Recently, some extensions of 
PLS-DA were used in BC metabolomics, namely the OPLS-DA [43,51,67,73,81]. OPLS-DA 
separates out response orthogonal variations in rotations of the original component [110]. 
On the other hand, non-linear methods are used when metabolomics dataset follow a non-linear 
response. The most applied non-linear methods are support vector machines (SVM) [48,59,65,105], 
random forests (RF) [33,48,58,59,65,80] and logistic regression analysis (LRA) 
[31,47,65,69,72,105]. SVM is a kernel-based model used for regression and classification of non-
linear datasets, transforming the non-linear data into more general spaces (linear) by algorithm based 
on kernels functions. SVM perform the mapping of dataset into a high-dimensional space through 
kernels functions for the separation of two groups of samples into distinctive regions. The separation 
is based on support vectors, which are points (samples) on the boundary or on the incorrect side of 
the margin supporting the separation. SVM is a versatile method that transforms non-linear complex 
datasets into a high-dimensional space where classes are linearly separable [100,101,110]. RF is a 
non-linear method for regression and classification of high-dimensional datasets, where a large 
number of classification and regression trees are created by bootstrapping (replacement) based on 
random selection of a training samples from the original dataset. Afterwards, bootstrapping is 
performed systematically to build a large group of simple trees that are used to estimate classification 
accuracy of the model [100,101]. Another non-linear predictive method widely used is LRA, which 
is similar to linear regression, but with a binomial response variable. LRA is used to explain the 
relationship between one dependent binary variable and one or more nominal, ordinal, interval or 
ratio-level independent variables [114]. 
 
Model validation 
The validation of predictive models is a key step in data analysis of metabolomics studies. 
Validation process analyzes the performance/ability of model to predict correctly the hypothesized 
relationships between variables and responses [101]. Several validation methods have been used in 
BC metabolomics. The coefficient of determination (R2) is the simplest method to evaluate the ability 
of predictive model, being used for continuous responses. The R2 is expressed as the ratio between 0 
and 1, where a value of 1 indicates the perfect prediction. However, this validation is recommended 
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for small datasets, due to fact that the R2 value tends to be increased when a predictor variable is 
added to the model [115]. However, in validation of predictive models used to high-dimensional and 
complex datasets, as the case of metabolomics studies, the cross validation (CV) methods are the 
preferential option. CV provides qualitative and quantitative analysis of the model ability to model’s 
ability to predict new independent samples without collecting additional data. During the CV, the 
available data are split into two sets, where one set is used to create a predictive model using the 
values of continuous and predictor variables (training set). The second set is used to test the 
performance of predictive model (validation set) [100]. The most applied CV procedure is k-fold (K-
CV) [33,44,73,77,79,80,84,105,54,55,63–65,67–69]. K-CV processing is based on random partition 
of original dataset into equal sized subsamples (k). A single k subsample is used as the validation set 
for testing the model, and the remaining k -1 subsamples are used as a training set. This process is 
then repeated k times (folds), with each of the k subsamples being used exactly one time as the 
validation set [106]. One special type of K-CV is the leave-one-out cross validation (LOOCV) 
[43,46,48,74,75,78,81], where the number of folds equals the number of k subsamples. LOOCV is 
considered an exhaustive CV, being recommend for small datasets [106,115]. Another type of CV is 
the Monte Carlo cross validation (MCCV) [51,59]. Although less used in metabolomics than 
LOOCV, MCCV is asymptotically consistent and showed better prediction ability. In MCCV 
proceeding, significant part of dataset is leaved out at a time during model validation, repeating 
systematically this procedure several times [116,117]. The Q2 value, which is the equivalent R2 value, 
is the preferential coefficient of determination for CV procedures.  
A visual and easy model validation method is the receiver operating characteristic (ROC) curve 
[31,33,65,67–69,71,73,74,77,105,43,47,48,53,54,58,59,63] which the prediction ability of a model is 
validated considering the specificity (ratio of the correctly predicted negatives) and sensitivity (ratio 
of correctly predicted positives). The ROC curve is given by plotting the sensitivity versus (1 - 
specificity) across a series of cutoff points. The area under curve (AUC) is a quantitative measure 
(between 0 and 1) of the ability of predictive model, where a AUC value close to 1 indicates a nearly 
perfect prediction response [100,115]. 
Random resampling-based methods are a robust alternative for model validation. The most used 
in BC metabolomics are bootstrapping [48,58,68,80] and permutation tests [47,51,53,79,80]. 
Bootstrapping is a model validation based on replacement of samples, which can be considered non-
parametric when the replacement is from the original dataset, or parametric when random noise is 
added from a recognized distribution to the dataset to estimate underlying sampling distribution or 
establish robust confidence intervals. Normally, in metabolomics studies the common approach is 
non-parametric bootstrapping [115,118]. Permutation tests provide the exact control of false positives 
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from a predictive model (linear or non-linear), under minimal assumptions, based on differences 
between the randomly permuted response variables model and the original model. Permutation tests 
are based on a repeatedly permuting (repetitive reordering) of the N entries in the response variable. 
Permuted vectors containing integers between 1 and N are produced in a random number generator, 
creating new scrambled response variables only by switching their internal positions. The scrambled 
vectors are modelled one by one, where for every test, the R2 and Q2 values are calculated and saved. 
After, these values are compared with the values calculated from the original data. The results of 
permutation tests are displayed as a percentage overlap between the real and permuted R2 and Q2 
values, where a 0% of overlap is the optimal result [110,119]. 
 
Post-processing 
The post-processing step consists in interpretation of metabolomic responses from original dataset. 
Normally, pathway analysis is the most used strategy to provide an overview of 
association/relationship between identified metabolites and metabolic pathways and other general 
biological networks. Pathifier [65] and metaboanalyst [33,59,63,73,74] are the most used software 
for this propose in metabolomics. 
 
Future directions 
The advances in analytical techniques and chemometric methods in metabolomics have been 
growing rapidly becoming possible the identification of potential biomarkers. Furthermore, the 
integration of analytical platforms increases the comprehensive analysis of metabolites in biological 
samples. In this context, metabolites became valuable identifications, regardless their hierarchical 
source, enabling the phenotypic properties in a biological system. Additionally, the identification of 
key metabolic pathways from which significant metabolites are linked, it is possible to reveal 
potential targets for cancer therapy.  
Also, standard procedures for sample collection, data analysis and shared in repositories have 
potential to be adopted by both researchers and medical communities. 
Since the metabolome instantly responds to environmental stimuli including therapeutic or surgical 
intervention, could be also used to monitor the metabolic status of the individual and indicate any 
possible toxic effects. Moreover, metabolomics may help in the detection of potential cancer 
biomarkers, being useful for example in the development of different devices, including biosensors, 
that can significantly improve the cancer diagnosis. These devices include a biorecognition element 
within a biosensor system. The biorecognition molecules interact with the target, which is then 
converted into a measurable signal by a transducer. Basically, these molecules, usually enzymes or 
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antibodies, can be immobilized on the transducer surface and interact with the target (biomarker) to 
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Although breast cancer (BC) research is directed towards the improvement of diagnostic/screening 
techniques in the last decades, new tools are needed for BC diagnosis due to the limited sensitivity 
and specificity of current screening methods, as well as the perceived discomfort of mammography 
and potentially hazardous exposure to radiation. In recent years a promising and attractive hypothesis 
is based on small molecular-weight volatile organic metabolites (VOMs), consumed or released by 
cancerous cells, is emerging as an attractive and non-invasive approach for cancer diagnostics. These 
molecules, which can be perceived as odors, have been shown to function as cancer ‘‘biosignatures”. 
In this context, the present thesis incompassed the study of the metabolomic profile of urine, cell lines 
and tissues from BC patients and CTLs with the aim of discover a set of metabolites able to be used 
as potential BC biomarkers. 
 
To achieve the main goal, the experimental design was followed being summarized in the flowchart: 
 
Figure 2. 1 - General diagram of the study performed in the thesis. 
The specific objectives of the thesis included: 
I. The application of a multivariate experimental design (central composite design) to 
optimize the SPME-influencing parameters as a mean to improve VOMs extraction 
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II. The establishment of the urinary metabolomic profile by 1H NMR from BC patients as 
well as from CTLs as a powerful tool to detect potential BC-specific metabolites; 
 
 
III. Study of VOMs released from human BC cell lines: MCF7, T47D and MDA-MB-231, 
and from normal breast cell lines, as primary mammary epithelial cells (HMEC); 
 
IV. To characterize the metabolomic fingerprint of BC tissues and compare to breast normal 
tissue; 
 
V. Combination of NMR- and GC-qMS-based method, multivariate statistics and metabolic 
correlation networks, in order to find a panel of biologically significant metabolites as 
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3.1| Implementing a Central Composite Design for the 
optimization of solid phase microextraction to establish the 
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Abstract 
BC is positioned as the second among all cancers remaining at the top of women´s diseases 
worldwide followed by colorectum, lung, cervix, and thyroid cancers. The main drawback of most 
the screening/diagnostic methods is their low sensitivity/specificity and in some cases the invasive 
procedure required to obtain the samples. On the present investigation, we report a statistical design 
was to evaluate by central composite design the influence towards the optimization of the most 
significant variables of solid-phase microextraction (SPME) procedure for the isolation of volatile 
organic metabolites (VOMs) from urine of BC patients (n=31) and healthy individuals (CTL; n=40). 
The establishment of the urinary volatomic composition, through gas chromatography-mass 
spectrometry (GC-MS) analysis, can boost the identification of volatile organic metabolites (VOMs) 
potential BC biomarkers useful to be used together or to complement the current BC diagnostics tools. 
Better early detection methods are needed to improve the outcomes of patients with colorectal cancer 
(CRC). Several combinations of experiments were considered with a Central Composite Design 
(CCD) of Response Surface Methodology (RSM) for the urinary volatomic pattern. Three-level three-
factor CCD was employed assessing the most important extraction-influencing variables - fiber 
coating, NaCl amount, extraction time and temperature. The optimal conditions were achieved using 
a carboxen/polydimethylsiloxane fiber with 15% (w/v) NaCl during 75 min at 50 ºC.  
A total of ten VOMs belonging to sulfur compounds, terpenoids and carbonyl compounds presented 
the highest contribution towards discrimination of BC patients from CTL (variable importance in 
projection (VIP) >1, p < 0.05). The discrimination efficiency and accuracy of urinary metabolites was 
ascertained by receiver operating characteristic (ROC) curve analysis that allowed the identification 
of some metabolites with highest sensitivity and specificity to discriminate the groups. The results 
obtained with this approach suggest the possibility to identify endogenous metabolites as a platform 
to discovery potential BC biomarkers and paves a way to explore the related metabolomic pathways 
in order to improve BC diagnostic tools. 
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Introduction 
BC remains as the most common invasive cancer in women worldwide , accounting for 24.2% of 
all cancer cases, followed by colorectum, lung, cervix, and thyroid cancers according to the 
International Agency for Research on Cancer (IARC) [3]. Being a disease caused by a combination 
of genetic and environmental factors, BC is often characterized by an absence of early symptoms, 
which results in a late detection of the disease. Detection at advanced stages of BC implies that the 
treatment is harder and uncertain. Appropriate screening methods have been conducted within 
organized preventive examinations and have made significant contributions to early BC detection 
[39,120,121]. Moreover, if the disease is detected at an early stage of development, the healing 
percentage will increase. In this sense, it is necessary to detect disease as earlier as possible [121]. 
Furthermore, there is still the need for the development of new methodologies to support or monitor 
the disease together with current diagnostic tools, namely with mammography, ultrasound imaging 
or tumor marker analysis. Moreover, before the initiation of a BC therapy, complex and time-
consuming analyzes are still required, being the most significant the determination of the histological 
type and grading, and the evaluation of ER, PR and HER-2, among others [122]. The main drawback 
of most of these screening/diagnostic methods is their low sensitivity and specificity and in some 
cases the invasive procedure required to obtain the samples [123]. Taking into account these aspects, 
the investigation is leading towards the research of new tools that can support the clinicians in BC 
treatment and monitoring of their recurrence [124]. In this sense, in recent years the -omic studies 
have emerged as a powerful tool to investigate the changes and/or metabolic responses of living 
systems to stimuli or genetic modifications [39]. The metabolome profile represents the quantitative 
and qualitative analysis of the complete set of metabolites present in cells, body fluids or tissues 
[125]. To date, based on the most used biological specimens (e.g., exhaled breath, urine, saliva, 
blood), the metabolome coverage in BC can be maximized by merging different technologies for 
metabolic profiling, namely with GC-MS. The results obtained can be useful to classify BC, helping 
to identify new prognostic and predictive markers and to discover new targets for future therapeutic 
interventions [126]. Many metabolomic studies have referenced the presence of glycolytic markers 
as an indication of the Warburg effect driven by malignancy, so that it remains a metabolic pathway 
of ongoing interest in cancer research [39]. Among them, the study of VOMs present in biological 
samples, namely in saliva, urine, exhaled breath and tissues can be useful for a cancer diagnosis, in 
particular for BC [107]. The principle is that disease and normal condition can be distinguished from 
each other by changes in their physiology and metabolic rates, which leads to the production of 
disease specific alterations in VOMs [30]. The most common procedure used in extraction of volatile 
compounds in biological samples is SPME, normally in headspace mode, being used in several 
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biological matrices [44,59,127,128]. In fact, SPME offers several advantages over conventional 
solvent extraction procedures: it is rapid, easy to use, solvent-free and does not require any 
concentration step before analysis [129]. Being a technique based on the equilibrium between sample 
matrix /headspace and between headspace/fiber coating, HS-SPME efficiency is dependent on several 
factors, namely the target compounds to be extracted, fiber coating, extraction temperature, extraction 
time and salting-out effect [127]. Taking into account that SPME is affected by several parameters 
and their optimization is a laborious and time-consuming process, the RSM can be a suitable tool for 
optimizing the process. This approach consists of a combination of statistical and mathematical 
techniques and has been highly used in optimization processes, since RSM reduces the number of 
experimental assays. Frequently, CCD is used as an experimental design to fit a second-order 
polynomial function by a least squares technique. An equation is used to define how test variables 
affect the response and determine the interrelationship among the variables [130,131]. Monteiro et 
al. [131] used CCD to optimize the SPME extraction parameters to discriminate patients with renal 
cell carcinoma, whereas Calejo et al. [132] used CCD to select the optimal conditions to extract 
carbonyl compounds to discriminate individuals with smoking habits using an in-solution 
derivatization with O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine hydrochloride (PFBHA) 
combined with SPME. As for example, GC-qMS was used to screen salivary volatiles for putative 
BC as an exploratory study involving geographically distant populations [51], also to establish the 
metabolomic signature of human BC cell lines [44] and to discriminate different types of cancer based 
on urinary volatomic biosignatures [59]. In the first study, up to 120 VOMs from distinct chemical 
families, with significant variations among the groups, were identified [51], whereas Silva et al. [44] 
and Porto-Figueira et al. [59] identified 60 and 130 VOMs in BC cell lines and urine, respectively. In 
turn, Dougan et al. [66] used GC-MS to evaluate the detectability, reliability, and distribution of 
metabolites measured in pre-diagnostic plasma samples of a pilot study from women listed in the 
Northern California site of the BC Family Registry. In this study, 661 VOMs were detected, 338 (51 
%) of them were found in all samples, and 490 (74 %) in more than 80 % of samples. 
In the current study, CCD was used for the optimization of experimental parameters, such as fiber 
coating, NaCl amount, extraction time and temperature as useful strategy to improve SPME extraction 
efficiency of VOMs from urine samples. The potential of SPME/GC-qMS data combined with 
chemometric tools was evaluated to discriminate the urinary volatomic biosignatures from BC 
patients and healthy controls (CTL), in order to identify a set of potential BC-specific biomarkers that 
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Materials and Methods 
Chemicals and materials 
Sodium chloride (NaCl), hydrochloric acid (HCl) and 4-methyl-2-pentanol were supplied by 
Panreac (Barcelona, Spain) and Sigma Aldrich (St. Louis, MO, USA), respectively. The digital 
stirring plate (Cimarec™) was supplied by Thermo Scientific (Waltham, MA, USA) while SPME 
holder for manual sampling, together with 65 µm polydimethylsiloxane/divinylbenzene 
(PDMS/DVB), 50/30 µm (DVB/CAR/PDMS) and 75 µm carboxen/polydimethylsiloxane 
(CAR/PDMS) fibers, were purchased from Supelco (Bellefonte, PA, USA). 
 
Urine samples collection and preparation 
Urine samples (first urine morning) from BC patients (n=30) were taken at the Haemato-Oncology 
Unit from Dr. Nélio Mendonça Hospital, while the urine collection from healthy individuals (n=40) 
(Table 3.1.1) was carried out in Blood Transfusion Medicine Service in the same Hospital at the same 
time. Participants were instructed to collect the first urine morning (after the rejection of the first urine 
stream) into a sterile bottle using a disposable collector that was provided to them. 
 
Table 3. 1. 1 - List of collected urine samples from breast cancer (BC) patients and healthy volunteers 
(CTL). 
Urine Samples BC CTL 
Number 30 40 
Age (range, median) (44-85, 65) (43-80, 64) 
 
The collected urine samples were aliquoted into 4 mL glass vials and stored at -80 °C until analysis. 
The analysis begun with the thawing of urine samples, after this they were centrifuged at 4000 rpm 
for 20 min at 4 °C. Then, the supernatant was collected and used for the extraction procedure. All the 
analyzes were performed in triplicate. 
The research was approved by the Ethics Committee of Funchal Central Hospital Dr. Nélio 
Mendonça and have been performed in accordance with the ethical standards as laid down in the 1964 
Declaration of Helsinki and its later amendments or comparable ethical standards. All the participants 






54 Catarina Silva (2019) 
HS-SPME optimization: CCD approach 
Three types of fiber coatings (Supelco, Bellefonte, PA, USA) were used to evaluate the extraction 
performance of VOMs from urine samples: PDMS/DVB, DVB/CAR/PDMS and CAR/PDMS. They 
were daily conditioned according to the manufacturer´s recommendations, in order to avoid carryover 
between sets of analyzes. For the HS-SPME optimization, a CCD model was applied for each fiber, 
in order to build a second order (quadratic) model for the response. This model was defined by the 
equation 2k + 2k + n, where k is the number of factors and n is the number of centre runs. In this case, 
k and n were set at 3 and 5, respectively, meaning that 45 experiments (each experiment was 
performed in triplicate) were ran with 15 experiments for each fiber in the centre of the design. The 
factors were salt addition (NaCl, g), extraction time (text, min) and extraction temperature (Text, ◦C). 
The CCD included five different levels (centre runs), k central points (mean value of each variable) 
and 2k star points (minimum and maximum level of the range). The axial distance (α) given by the 
equation, α = 2k/4, was calculated to satisfy the rotatable of the design and was considered α = ±2 
[133]. The 45 experiments (combinations) were run in randomised order to minimise the effects of 
variability in the response due to irrelevant factors (Table 3.1.2). 
 
Table 3. 1. 2 - Experimental conditions and values for the response (expressed in total areas) obtained 










40 30 10 35 1.89E+09 
2 40 30 20 44 2.05E+09 
3 40 60 10 49 4.98E+09 
4 40 60 20 39 3.66E+09 
5 60 30 10 56 5.75E+09 
6 60 30 20 62 6.93E+09 
7 60 60 10 72 1.18E+10 
8 60 60 20 79 1.11E+10 
9 30 45 15 45 2.43E+09 
10 70 45 15 108 1.27E+10 
11 50 15 15 42 1.28E+09 
12 50 75 15 108 1.96E+10 
13 50 45 5 84 5.54E+09 
14 50 45 25 83 4.97E+09 
15 50 45 15 91 5.34E+09 
16 
DVB/CAR/PDMS 
40 30 10 54 2.47E+09 
17 40 30 20 58 1.65E+09 
18 40 60 10 63 2.81E+09 
19 40 60 20 66 3.18E+09 
20 60 30 10 73 5.18E+09 
21 60 30 20 82 6.41E+09 
22 60 60 10 75 6.20E+09 
 
 








23 60 60 20 82 5.74E+09 
24 30 45 15 56 1.52E+09 
25 70 45 15 75 1.24E+10 
26 50 15 15 57 1.53E+09 
27 50 75 15 68 6.30E+09 
28 50 45 5 49 2.67E+09 
29 50 45 25 64 5.05E+09 
30 50 45 15 57 3.45E+09 
31 
PDMS/DVB 
40 30 10 43 1.11E+09 
32 40 30 20 45 2.21E+09 
33 40 60 10 40 1.74E+09 
34 40 60 20 48 2.13E+09 
35 60 30 10 51 3.37E+09 
36 60 30 20 61 4.68E+09 
37 60 60 10 66 6.01E+09 
38 60 60 20 61 7.20E+09 
39 30 45 15 50 1.69E+09 
40 70 45 15 67 7.59E+09 
41 50 15 15 57 1.38E+09 
42 50 75 15 57 4.65E+09 
43 50 45 5 49 3.82E+09 
44 50 45 25 52 3.73E+09 
45 50 45 15 49 4.65E+09 
a Text, extraction temperature, b text, extraction time 
 
Application to urine samples 
The optimal HS-SPME extraction conditions used to analyze urine samples from CTL and BC 
groups were obtained with CCD model as described in previous section. Briefly, urine samples were 
thawed and then 4 mL of urine was placed into 8 mL vials together with 17 % NaCl (w/v) and 100 
µL of the internal standard (IS, 4-methyl-2-pentanol, 1.6 mg/L). The pH was adjusted to 2 with small 
amounts of HCl 5M. Then, the vial was capped with a Teflon (PTFE) septum using a screw cap and 
the CAR/PDMS fiber was introduced and exposed into the headspace during 75 min at 50 °C at 800 
rpm (0.5 mm × 0.1 mm bar). After this period, the fiber was removed from the vial and inserted into 
the GC injection port and the extracted VOMs were desorbed for 10 min at 250 °C. Each sample was 
analyzed in triplicate and the blanks were performed before each analysis. 
 
Gas chromatography quadrupole mass-spectrometry (GC-qMS) conditions 
After the extraction procedure, the SPME fiber with the analytes was inserted into the injection 
port of an Agilent Technologies 6890N Network gas chromatograph system (Palo Alto, CA, USA) 
where the VOMs were desorbed at 250 °C for 10 min. The gas chromatograph was equipped with a 
60 m × 0.25 mm I.D.× 0.25 µm film thickness, BP-20 (SGE, Dortmund, Germany) fused silica 
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capillary column and interfaced with an Agilent 5975 quadrupole inert mass selective detector. The 
following oven temperature profile was set: (a) 5 min at 45 °C; (b) increase temperature until 150 °C, 
at a rate of 2 °C min−1 (hold for 10 min); (c) 150 °C for 10 min; (d) increase temperature until 220 
°C, at a rate of 7 °C min−1; and (e) 220 °C for 10 min for a total GC run time of 87.5 min. The column 
flow was constant at 1.3 mL min−1 using Helium (He, N60, Air Liquide, Portugal) as the carrier gas. 
The injection port was operated in the splitless mode and held at 250 °C. For the 5975 MS system, 
the operating temperatures of the transfer line, quadrupole and ionization source were 270, 150 and 
230 °C, respectively, while electron impact mass spectra were recorded at 70 eV ionization voltage 
and the ionization current was 10 µA. Data acquisition was performed in the scan mode (30–200 
m/z). Metabolites identification was accomplished through manual interpretation through single ion 
monitorization (SIM) of spectra and matching against the Agilent MS ChemStation Software, 
equipped with a NIST05 mass spectral library with a similarity threshold higher than 80 % and 
comparison with commercially available standard samples when available. The analyzes were 
performed in triplicate and the results expressed by mean ± standard deviation. 
 
Statistical Analysis 
The statistical analysis for the CCD design was performed using Statistica, Version 10.0 (Statsoft 
Inc., Tulsa, OK, USA) while the web server Metaboanalyst 4.0 [134] was used for the multivariate 
statistical analysis - namely, principal component analysis (PCA), partial least squares-discriminant 
analysis (PLS-DA) and orthogonal projections to latent structures discriminant analysis (OPLS-DA) 
applied on urine metabolomic profile dataset in order to provide insights into the separations among 
the groups under study. For the evaluation of the applicability of the developed CCD method, data 
analysis was based on a non-targeted volatile approach. Moreover, the metabolites with Variable 
Importance in Projection (VIP) scores higher than 1.0 were selected by the PLS-DA analysis and used 
for the pathway analysis. Additionally, hierarchical cluster analysis by K-means of the two groups in 
study was carried out and Pearson´s correlation was used to build the heat map with the aim of 
identifying clustering patterns. The receiver operating characteristic curves (ROC) were attained to 
verify which metabolites had the highest sensitivity/specificity for a potential BC diagnosis. Also, 
Random forest (RF) classification was performed to determine the ability of VOMs to accurately 
classify the study subjects into their corresponding groups. Finally, the selected metabolites were 
used for the metabolic pathway analysis to identify the most relevant metabolic pathways involved 
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Results and Discussion 
Optimization of HS-SPME methodology 
Regarding the optimisation of the ideal SPME extraction-influencing parameters- for VOMs 
extraction from urine samples, three different fiber coatings were used. In this case, the authors 
choose to use the fibers with two or more coatings in order to cover the maximum amount of chemical 
classes of metabolites, which is the most appropriate procedure in an untargeted metabolomic 
approach. Overall, the performance of each fiber was evaluated based on the number of identified 
VOMs, relative GC peak area, and reproducibility expressed as the relative standard deviation 
(RSD%). The performance obtained in terms of relative GC peak area for each tested fiber is shown 
in Figure 3.1.1. 
 
Figure 3. 1. 1 - Efficiency of fiber coatings in the extraction of VOMs from urine samples by HS-
SPME. The numbers refer to the number of identified VOMs. 
The CAR/PDMS fiber was the one that provided the uppermost extraction efficiency when 
compared with PDMS/DVB and DVB/CAR/PDMS fibers. In addition, the CAR/PDMS also 
presented the highest number of identified VOMs and the best reproducibility when compared with 
other tested fibers. Regarding the application of the CCD model, other factors that affected the SPME 
extraction efficiency were taken into account. This design was used as an experimental approach to 
assess the optimal value for each parameter with influence in SPME extraction efficiency and 
optimize the response of the process (Table 3.1.2). The particular value of a factor at which an 
experiment is run is called factor level. This approach allows the evaluation of the individual 
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and also the correlations among them. The other influencing parameters, such as the sample amount, 
pH and volume (4 mL of urine into a 8 mL glass vial), were fixed by the authors and based in previous 
studies with urine samples [127,128]. In the present case, 45 runs were performed randomly and the 
obtained response was based on the number of identified VOMs and sum of relative GC peak areas. 
The application of this type of statistical optimization procedure is useful over the univariate approach 
where the effect of possible interactions between important variables are not taken into account. 
Furthermore, this type of strategy enables the determination of the optimal conditions with fewer 
number of experiments when compared with full factorial design (FFD) [132,133]. The Pareto charts 
were built to illustrate the influence of each factor regarding the VOMs extraction performance as 
shown in Figure 3.1.2 (A and B).  
 
Figure 3. 1. 2 - Pareto charts of standardized effects of CCD factorial design for total GC peak area; 
(A) based on the extraction temperature and time, (B) extraction time and NaCl amount. The y axis 
of both graphs includes all variables considered in this study, their possible combinations and effects 
on the study. 1L-extraction temperature; 2L-extraction time; 3L-NaCl amount; Q-quadratic function; 
L-linear function. 
This type of chart contains a bar for each evaluated factor as well as their combinations, which are 
ordered from the most to the least significant. Also, the vertical line indicates the critical value for 
Student´s t–test which was considered 0.05, meaning that any factor that extended that line was 
considered significant for the analysis. Regarding the charts obtained, in the case of the number of 
compounds identified, the variable with the greatest influence for the extraction of VOMs from urine 
samples was the extraction temperature (Figure 3.1.2 A) while, in terms of the total GC areas, was 
the extraction time and NaCl amount, as observed in Figure 3.1.2 B. Considering the combination of 
p = 0.05
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variables, none of the evaluated combinations had a significant contribution for the analysis. In Figure 
3.1.3 (A-F) the surface response graphs obtained for the CCD model are represented.  
 
Figure 3. 1. 3 - Surface response obtained by central composite design (CCD) in the optimization of 
the SPME conditions and respective combinations. For number of identified compounds; (A) 
extraction time and temperature, (B) NaCl amount and extraction temperature and (C) NaCl amount 
and extraction time. Regarding the total peak areas, (D) extraction time and temperature, (E) NaCl 
amount and extraction temperature and (F) NaCl amount and extraction time. 
Regarding the results, it was expected that for higher temperatures, the number of extracted VOMs 
increased, but also high temperatures are responsible for sample degradation and decrease the fiber 
lifetime. The first parameter that was taken into account was the number of identified VOMs (Figure 
3.1.3 A-C) and as temperature, extraction time and NaCl amount increased (responsible for the 
“salting-out” effect), the extraction efficiency also increased, but when comparing with the total areas 
(Figure 3.1.3 D-F), the surface graphs indicated that the ideal extraction temperature was 70 °C. In 
this case, as mentioned before, this temperature was considered too high once there is the potential 
risk of metabolite degradation as reported in previous studies [127,128]. In this sense, 50 °C as 
extraction temperature and 75 min as extraction time were selected as optimal conditions. In sum, 
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and CTL groups using 75 min as extraction time, 50 °C as extraction temperature and an addition of 
15 % (w/v) of NaCl. 
 
Urine volatomic pattern based on GC-qMS 
A total of 116 VOMs were identified in BC and CTL urine samples which were classified in 
several chemical families, namely sulphur compounds, furanic compounds, phenols, terpenoids, 
carbonyl compounds, norisoprenoids, acids, alcohols and miscellaneous (Figure 3.1.4). 
 
Figure 3. 1. 4 - Major chemical families identified in BC and CTL urine samples. Legend: SC-sulfur 
compounds; FC-furanic compounds; CC-carbonyl compounds; Alc-alcohols; Terp-terpenoids; 
Norisop-norisoprenoids; Misc-miscellaneous. 
The data obtained was processed using an appropriate software (NIST, 2005; Mass Spectral Search 
Program V.2.0d) which provides quality matching using advanced spectral matching algorithms 
background subtraction. Regarding the chemical families, for the CTL group, all chemical families 
had a higher impact when compared with the BC group, with exception of alcohols. The highest 
contribution for the volatile profile was obtained for phenols in the CTL group, whereas in the BC 
group was alcohols. The main VOMs identified in these families were phenol, 4-methyl-phenol and 
2-ethyl-1-hexanol, respectively. These metabolites were already reported in literature in biological 
matrices such as urine [127,128], cancer cell lines [44,135], saliva [51], and exhaled breath [135,136]. 
Table 3.1.3 presents the identification of VOMs in urine samples, as well as their minimum and 
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Table 3. 1. 3 - Identification of metabolites of urine samples from BC patients and healthy volunteers (CTL) through GC-qMS, minimum (Min) and 
maximum (Max) relative peak areas, variation of relative peak areas regarding to BC group and frequency of occurrence FO (in %) of VOMs from BC 







Relative GC Peak Areas 
Variation FO % BC CTL 
Min Max Min Max 
A1 47 4.72 methanethiol 2.00 78.56 2.20 97.14 ↓ 100 
A2 68 5.03 furan 1.75 108.12 3.48 121.92 ↓ 100 
A3 43,58 5.24 acetone 1.70 77.42 1.01 107.71 ↓ 100 
A4 82 6.09 2-methyl-furan 1.02 69.71 1.44 354.65 ↓ 96 
A5 43 6.40 ethyl acetate 0.23 1.72 1.59 1.71 ↑ 18 
A6 43, 72 6.69 2-butanone 0.30 8.98 0.55 49.61 ↓ 100 
A7 96 8.07 2,5-dimethyl-furan 0.39 60.24 1.15 178.30 ↓ 77 
A8 43, 86 8.79 2-pentanone 3.54 192.37 1.32 99.72 ↑ 96 
A9 95, 110 10.94 1-(2-furanyl)-ethanone 0.07 103.73 0.38 102.50 ↑ 99 
A10 91 11.22 toluene 1.18 65.82 0.32 122.29 ↓ 100 
A11 41, 55 11.37 3,7-dimethyl-1,6-octadiene 0.12 21.71 0.15 19.71 ↑ 83 
A12 43, 57 11.71 3-hexanone 0.21 17.13 0.27 17.39 ↓ 99 
A13 94 12.70 dimethyl disulfide 16.26 693.52 11.84 726.00 ↓ 100 
A14 44, 56 13.13 hexanal 0.42 20.98 0.18 12.96 ↑ 99 
A15 97, 113 13.48 3-methyl-tiophene 0.19 17.45 0.08 6.50 ↑ 69 
A16 43, 71 15.49 4-heptanone 12.03 380.27 17.71 133.36 ↑ 99 
A17 121, 93 17.81 α-terpinene 0.03 18.19 0.07 128.23 ↓ 93 
A18 111 18.12 1,4-cineole 0.03 4.03 0.15 43.21 ↓ 92 
A19 43, 58 18.57 2-heptanone 0.13 8.44 0.56 46.99 ↓ 100 
A20 68, 93 18.73 D-limonene 0.03 2.49 0.05 4.49 ↓ 86 
A21 91 19.36 propyl-benzene - - 0.02 2.28 - 37 
A22 43, 72 19.63 3-methyl-2-heptanone 0.12 1.80 0.09 14.56 ↓ 82 
A23 43 19.76 eucalyptol 0.13 2.86 0.11 4.62 ↓ 59 
A24 105 20.10 1,2,4-trimethylbenzene 0.02 6.51 0.06 17.76 ↓ 93 
A25 81 20.62 2-pentylfuran 0.08 31.71 0.19 92.69 ↓ 94 
A26 41, 55 20.84 2-hexenal 0.09 1.83 0.05 5.46 ↓ 11 
A27 93 21.20 γ-terpinolene 0.01 23.50 0.09 120.92 ↓ 79 
 
 







Relative GC Peak Areas 
Variation FO % BC CTL 
Min Max Min Max 
A28 79 22.19 3,8-p-menthadiene 0.16 6.96 0.16 8.61 ↓ 58 
A29 119 22.69 p-cymene 0.15 350.42 13.54 483.82 ↓ 100 
A30 93, 121 23.16 α-terpinolene 0.11 2.87 0.05 75.80 ↓ 65 
A31 105 23.31 1-ethyl-2-methylbenzene 0.07 20.50 0.05 9.36 ↑ 76 
A32 117, 132 24.11 2-methyl-1-propenylbenzene 0.05 67.38 0.03 45.29 ↑ 75 
A33 119 24.49 1-methyl-2-isopropylbenzene 0.04 69.76 0.11 2.09 ↑ 46 
A34 43,58 24.71 2-octanone 0.08 3.15 0.12 5.22 ↓ 85 
A35 114 25.84 2-methoxythiophene 0.06 19.56 0.30 11.53 ↑ 100 
A36 105 26.86 1,2,3-trimethylbenzene 0.30 104.18 0.80 65.63 ↑ 96 
A37 159 26.96 α-ionene 0.02 12.64 0.12 52.61 ↓ 86 
A38 83, 55 27.73 3-ethylcyclopentanone 0.17 1.26 0.07 7.68 ↓ 70 
A39 128, 113 28.05 2-methyl-5-(methylthio)-furan 0.25 47.44 0.25 27.96 ↑ 97 
A40 45, 55 28.33 2-heptanol 1.95 1.95 0.38 0.40 ↑ 4 
A41 72 28.72 3,4-dimethyl-2-hexanone 0.07 2.43 0.18 3.34 ↓ 65 
A42 99 29.10 allyl Isothiocyanate 0.04 420.94 0.01 27.32 ↑ 48 
A43 159 29.26 1,2,3,4-tetrahydro-1,6,8-trimethylnaphthalene 0.09 12.66 0.03 57.10 ↓ 56 
A44 121 29.47 2,6-dimethyl-2,4,6-octatriene 0.22 0.22 0.03 0.47 ↓ 7 
A45 126 29.83 trimethyl trisulfide 0.56 227.20 6.79 704.86 ↓ 99 
A46 113, 128 30.46 2-methoxy-5-methyl-tiophene 0.11 116.90 0.47 61.27 ↑ 99 
A47 121 30.86 3,4-dimethyl-2,4,6-octatriene 0.07 1.99 0.07 0.97 ↓ 18 
A48 133 31.07 1,3-diethyl-5-methyl-benzene 0.02 7.46 0.05 10.98 ↓ 25 
A49 58, 43 31.21 2-nonanone 0.04 9.61 0.16 4.44 ↑ 90 
A50 82 32.03 2-cyclohexen-1-one 0.52 16.77 0.22 22.70 ↓ 94 
A51 57 32.39 nonanal 0.07 8.52 0.13 5.53 ↑ 45 
A52 159 32.43 1,2,3,4-tetrahydro-1,5,8-trimethylnaphthalene 0.03 24.07 0.34 170.12 ↓ 94 
A53 132 33.19 1-ethenyl-3,5-dimethyl-benzene 0.12 182.80 0.06 150.56 ↑ 37 
A54 105 33.55 (1-methylbutyl)-benzene 0.09 0.77 0.11 1.47 ↓ 14 
A55 132 33.79 1-methyl-4-(1-methylethenyl)-benzene 0.17 62.11 0.48 367.81 ↓ 90 
A56 159 34.04 1,2,3,4-Tetrahydro-1,4,6-trimethyl naphthalene 0.77 100.00 0.38 264.72 ↓ 92 
A57 73 34.84 3,7-dimethyl-3-octanol 0.19 37.82 0.16 23.66 ↑ 80 
A58 117, 132 35.41 1-ethenyl-4-ethyl-benzene 0.05 249.39 0.20 414.60 ↓ 58 
A59 57 35.98 1-octen-3-ol 0.03 2.38 0.09 1.76 ↑ 56 
A60 96 36.77 furfural 1.19 48.59 0.27 148.62 ↓ 83 
 
 







Relative GC Peak Areas 
Variation FO % BC CTL 
Min Max Min Max 
A61 119 36.92 prehnitene 1.59 60.02 0.97 399.65 ↓ 90 
A62 59 37.20 2,6-dimethyl-7-octen-2-ol 0.15 331.07 0.57 184.17 ↑ 93 
A63 43,60 37.33 acetic acid 1.90 93.59 3.45 291.59 ↓ 97 
A64 57 38.49 2-ethyl-1-hexanol 2.97 125.41 1.12 58.98 ↑ 99 
A66 192 39.69 vitispirane I 1.53 317.57 0.95 328.65 ↓ 99 
A67 192 39.85 vitispirane II 0.61 131.23 0.41 119.19 ↑ 99 
A68 105 40.02 benzaldehyde 0.28 7.88 0.21 9.71 ↓ 82 
A69 130 40.10 2-(methylthio)-tiophene 0.30 14.62 0.22 13.52 ↑ 66 
A70 56 42.58 1-octanol 0.09 25.62 0.15 4.66 ↑ 94 
A71 110 43.23 5-methyl-2-furancarboxaldehyde 0.62 30.63 0.27 122.84 ↓ 99 
A72 81 43.54 1-terpinenol 0.19 2.53 0.13 46.41 ↓ 39 
A73 131 43.88 2-methyl-benzofuran 0.03 26.22 0.07 5.24 ↑ 82 
A74 58 44.55 2-undecanone 0.02 3.76 0.17 2.54 ↑ 58 
A75 71 44.62 menthol 0.23 183.84 0.44 123.43 ↑ 73 
A76 84 44.90 4-terpineol 0.03 3.48 0.12 15.35 ↓ 48 
A77 111 46.26 isomaltol 0.11 4.53 0.27 36.11 ↓ 73 
A78 71, 81 47.22 menthomenthol 1.08 550.81 0.41 340.85 ↑ 76 
A79 105, 77 47.54 acetophenone 0.14 8.59 0.27 56.57 ↓ 83 
A80 93 48.16 2,6-dimethyl-5,7-octadien-2-ol 0.06 14.21 0.09 40.14 ↓ 52 
A81 59 48.26 4-methyl-1,4-hexadiene n.d. n.d. 0.14 3.29 - 3 
A82 56 48.55 1-nonanol 0.40 1.43 0.41 0.65 ↑ 6 
A83 134 48.88 1-ethenyl-4-methoxy-benzene 0.09 1.77 0.14 3.08 ↓ 14 
A84 111 49.95 3-thiophenecarboxaldehyde 0.25 15.77 0.60 16.73 ↓ 94 
A85 145 50.31 2-methyl-3-phenyl-2-propenal 0.14 27.65 0.49 123.30 ↓ 99 
A86 59 50.48 α-terpinol 0.70 2.06 0.10 5.54 ↓ 20 
A87 109 51.12 phellandranal 0.03 4.73 0.09 100.55 ↓ 66 
A88 82 52.06 D-carvone 0.55 372.76 0.28 142.95 ↑ 85 
A89 157 52.57 1,2-dihydro-1,1,6-trimethylnaphthalene 2.04 500.14 6.89 629.74 ↓ 97 
A90 120 54.31 methyl salicylate 0.25 25.81 0.55 99.17 ↓ 82 
A91 133 54.63 p-isopropylbenzaldehyde 0.06 8.30 0.27 87.43 ↓ 89 
A92 132 55.30 1-Isopropenyl-4-methylbenzene 0.09 2.48 0.33 356.82 ↓ 48 
A93 121 55.69 4-hydroxy-acetophenone 0.02 3.78 0.13 81.92 ↓ 68 
A94 69 57.00 β-damascenone 0.25 63.23 2.06 51.48 ↑ 99 
 
 







Relative GC Peak Areas 
Variation FO % BC CTL 
Min Max Min Max 
A95 135 58.81 p-cymen-8-ol 0.09 1.60 0.30 7.71 ↓ 21 
A96 60, 73 59.09 hexanoic acid 0.18 3.49 0.28 7.29 ↓ 97 
A97 109, 124 59.38 2-methoxy-phenol 0.60 233.16 1.89 216.04 ↑ 97 
A98 123, 138 59.90 4-methoxy-3-methyl-phenol 0.01 6.78 0.19 1.80 ↑ 18 
A99 123, 138 65.73 2-methoxy-5-methylphenol 0.05 22.64 0.14 83.85 ↓ 68 
A100 73, 88 66.07 2-ethyl-hexanoic acid 0.14 0.17 0.44 5.96 ↓ 10 
A101 60, 73 66.27 heptanoic acid 0.11 25.48 0.23 26.03 ↓ 96 
A102 175 68.94 1-ethyl-3,5-diisopropyl-benzene 0.14 299.80 0.24 91.62 ↑ 99 
A103 94 69.82 phenol 16.94 637.24 8.40 427.47 ↑ 99 
A104 60,73 72.54 octanoic acid 0.29 35.90 0.44 95.05 ↓ 99 
A105 119,169 73.01 1-methyl-7-isopropylnaphthalene 2.07 2.07 0.60 13.57 ↓ 13 
A106 107 73.18 4-methyl-phenol 3.32 254.95 9.60 281.82 ↓ 100 
A107 60,73 75.84 nonanoic acid 0.90 43.87 0.42 61.49 ↓ 96 
A108 107 75.99 4-ethyl-phenol 0.14 20.30 0.11 99.24 ↓ 28 
A109 135,150 76.95 thymol 0.10 177.78 0.41 81.58 ↑ 96 
A110 132 77.26 4-(2,3,6-Trimethylphenyl)-2-butanone 0.24 6.95 0.12 9.10 ↓ 65 
A111 60,73 78.28 decanoic acid 0.27 15.20 0.20 16.64 ↓ 97 
A112 135 78.62 p-tert-butyl-phenol 9.49 177.87 6.11 160.77 ↑ 97 
A113 173 78.74 3,3,5,6-Tetramethyl-1-indanone 0.10 121.92 0.69 120.24 ↑ 86 
A114 105 81.90 benzenecarboxylic acid 0.04 168.85 0.34 87.80 ↑ 92 
A115 117 82.31 indole 0.02 24.02 0.06 7.43 ↑ 85 
A116 105 83.26 benzophenone 0.08 4.55 0.15 3.17 ↑ 76 
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It can be observed that most of metabolites were identified in all samples with a FO higher than 
90 %, where the maximum relative area was obtained for dimethyl disulfide both in CTL and BC 
groups, followed by phenol in the CTL group and 1,2-dihydro-1,1,6-trimethylnaphthalene in the BC 
group. Regarding the relative area values obtained for the BC group, most VOMs were down-
regulated with exception of 2-pentanone, 1-(2-furanyl)-ethanone, hexanal, 4-heptanone, 2-
methoxythiophene, 1,2,3-trimethylbenzene, 2-methyl-5-(methylthio)-furan, among others, as shown 
in Table 4.1.3. Some of these have been already reported in literature, namely ethylbenzene and acetic 
acid were found as discriminant when associated with CTL in a study conducted by Ahmed et al. 
[137] where the authors investigated the possibility of faecal VOMs as potential diagnostic 
biomarkers for inflammatory bowel disease. Silva et al. [127,128] also reported phenols as the major 
chemical family identified in urine from the oncologic group. Furthermore, Raman et al. [138] studied 
faecal VOMs in obese humans and identified also acetic acid and phenol as major metabolites. On 
the other hand, Priscilla et al. [59] also identified p-xylene, o-xylene, acetic acid, phenol and p-tert-
butyl-phenol in urine from cancer patients, some of them having higher values in cancer patients. 
 
Multivariate statistical analysis of urine metabolomic profile 
The statistical analysis was performed using the Metaboanalyst 4.0 [134] web server as described 
in the experimental section. Only the VOMs with FO higher than 90% were considered for the 
statistical analysis, in a total of 53 VOMs as presented in Table 3.1.3. Initially, data was transformed 
by log transformation and mean centering approaches, before being subjected to multivariate 
statistical analysis. Partial least square-discriminant analysis (PLS-DA) was used as a supervised 
clustering method to verify the existence of an altered metabolite pattern. Additionally, this type of 
statistical analysis takes into account the variance/covariance between samples of groups where the 
samples are classified into different groups. Regarding the results obtained, a good discrimination 
was achieved (54.3%, total variance) between BC and CTL urine samples suggesting the occurrence 
of metabolic alterations in the groups under study (Figure 3.1.5 A). Then, the top ten metabolites (p-
cymene, 1-methyl-4-(1-methylethenyl)-benzene, 4-heptanone, trimethyl trisulfide, acetic acid, 
dimethyl disulfide, 2-pentylfuran, 1,2-dihydro-1,1,6-trimethylnaphthalene, α-terpinene and 2-
methyl-3-phenyl-2-propenal) with the highest contribution to group discrimination were selected with 
variable importance in projection (VIP >1) (Figure 3.1.5 B). 
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Figure 3. 1. 5 - (A) Score plots of partial least square discriminant analysis (PLS-DA) and (B) VIP 
scores selected by the PLS-DA analysis. For identification please see Table 3.1.3. 
Furthermore, the orthogonal partial least squares-discriminant (OPLS-DA) analysis was applied 
on urine metabolomic profile dataset in order to maximize the separation of BC and CTL groups. 
Significant group separation was observed in OPLS-DA score plot between BC and CTL groups 
indicating intrinsic metabolic alterations in each group (Figure 3.1.6 A). To attest the robustness of 
the model, a random permutation test with 1000 permutations was performed with OPLS-DA (Figure 
3.1.6 B). The permutation test yielded an R2 (represents goodness of fit) as 0.833 and a Q2 (represents 
predictive ability) of 0.742 indicating that the model is not over fitted and have a relative good 
predictive ability to distinguish between study groups. Additionally, the OPLS-DA uses class 
information allowing to show which variables are responsible for class discrimination using the 
predictive information of the first component. The main advantage of OPLS-DA when compared to 
PLS-DA is that a single component is used as a predictor for the class, while the other components 
describe the variation orthogonal to the first predictive component [139]. To further evaluate the 
VOMs predictive value to discriminate between BC patients and CTL, a ROC curve analysis was 
generated using the top ten metabolites identified by VIP values (Fig. 3.1.6 C and D). This type of 
analysis is used for the classification of true positives and false positives and the predictive ability is 
measured using the area under the curve (AUC) [140,141]. Xia et al. [108] reported that a value of 
AUC between 0.9 - 1.0 is excellent, between 0.8 – 0.9 is good, and comparing the results obtained, 
these were very good (AUC = 0.842). The AUC can be interpreted as the probability that a randomly 
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subject [108]. The greater AUC value gives us indication of the effectiveness to separate the control 
(CTL) group from the BC group. 
 
Figure 3. 1. 6 - (A) Loading score plots of orthogonal projection to OPLS-DA analysis, (B) model 
validation by permutation test based on 1000 permutations of VOMs obtained by GC-qMS of urine 
samples from the 2 groups under study, (C) ROC curves for the predictive model with a combination 
of metabolites calculated from the logistic regression analysis using the ten metabolites selected by 
the VIP (> 1.0) values, and (D) ROC curve for the top 4 metabolites with the highest ability to 
discriminate BC patients against CTLs. 
Furthermore, random forest (RF) was carried out to determine the ability of metabolites to 
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Figure 3. 1. 7 - (A) RF classification of urine metabolites from BC and CTL groups which indicates and overall error of 0.0 for BC and 0.03 for CTL, 
(B) Features ranked by their contributions to classification accuracy (Mean Decrease Accuracy) and (C) Heat map visualization and hierarchical 
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It uses an ensemble of classification trees (in this case 1000), each of which is grown by random 
feature selection from a bootstrap sample at each branch. RF classified BC and CTL groups with an 
accuracy of 100 and 90 % respectively, with an out of bag (OOB) classification error rate of 0.0211 
(Figure 3.1.7 A-C) where the major contribution of VOMs for classification are shown in Figure 3.1.7 
B. The OOB error rate is a measure of the prediction error of machine learning models such as RF. 
OOB is calculated by bootstrapping data, training data on one part and calculating error on the 
remaining. Since its calculation is for 1000s of trees, variances of error estimate are reduced. Tests 
have shown that OOB error is a reliable as a cross validation method [142]. 
Additionally, the heat map was constructed with the ten selected VOMs by VIP > 1, using 
Pearson´s correlation, providing intuitive visualization of the data set and was used to identify 
samples or features that are unusually high or low (Figure 3.1.7 C). Here, it could be observed that, 
for the majority of VOMs from the CTL group, the levels were higher than in the BC group. 
Finally, the metabolic pathway analysis was performed using the metabolites with VIP values 
higher than 1, in order to explore which pathways were altered in the groups under study. In tis type 
of analysis, the matched nodes show varied heat map colors and is based on p value while the node 
radius is determined based on the pathway impact values. Then, the pathway name is shown as mouse-
over tooltip. If we click the corresponding node it will launch the corresponding pathway view, 
showing which metabolites allowed the matching. Figure 3.1.8 A and B show the pathway impact for 
BC and CTL groups, respectively. It can be observed that the pathways with the highest impact were 
the pyruvate and sulfur metabolism due to acetic acid that was found lower in BC group when 
compared with CTL group. 
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Figure 3. 1. 8 - (A) The metabolome view map of significant altered metabolic pathways observed in 
urine samples from BC and CTL groups and (B) the pyruvate metabolism. The map was generated 
using reference map by KEGG. C00033 represents acetic acid. 
This metabolite according to the human metabolome database, is normally found in most tissues 
(liver, kidney, among others) and in several biofluids, namely saliva [51] and urine [127]. It results 
from several reactions namely from pyruvate metabolism, ethanol degradation and aspartate 
metabolism.  
Based on the results obtained, a successful discrimination of tissue samples was achieved, 
according to the group showing that the volatomic tissue profile can be a useful approach to identify 
potential BC biomarkers. Also, these results suggested the possibility to identify endogenous 
metabolites as a platform to discover- potential BC biomarkers and paves a way to investigate the 
related metabolomic pathways to improve the BC diagnostic tools. 
 
Conclusions 
This work described the development and optimization of and HS-SPME with GC-qMS 
methodology tandem with chemometric tools to analyze the VOMs of urine samples from BC and 
CTL groups. The CCD model was used in order to optimize the HS-SPME conditions and the results 
showed that the extraction temperature and extraction time were the factors that affected the analytical 
response. The best extraction conditions were reached by adding 15% (w/v) of NaCl to urine samples, 
and then extracting the VOMs using a CAR/PDMS fiber coating for 75 min at 50 °C. The developed 
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showing promising results that are essential to be explored. From the GC-qMS analysis, 116 VOMs 
were identified and multivariate statistical analysis revealed some metabolites significantly altered in 
BC patients. Of the metabolites identified, 3-methyl-thiophene, 4-heptanone, α-terpinene, 2-
pentylfuran, p-cymene, trimethyl trisulfide, 1-methyl-4-(1-methylethenyl)-benzene, acetic acid, 2-
methyl-3-phenyl-2-propenal and 1,2-dihydro-1,1,6-trimethylnaphthalene showed the utmost 
sensitivity and specificity to discriminate BC patients from healthy controls. The analysis of the plots 
leads to a metabolomic pattern comprising an array of several biochemical pathways altered in BC 
patients. The metabolic pathway analysis indicated that the discriminatory metabolites could be 
originated from several dysregulated pathways in BC such as pyruvate and sulfur metabolism. These 
results suggested the possibility to identify endogenous metabolites as a platform to discovery 
potential BC biomarkers and paves a way to investigate the related metabolomic pathways to improve 
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Abstract 
BC remains the second leading cause of death among women worldwide. An emerging approach 
based on the identification of endogenous metabolites (EMs) and the establishment of the 
metabolomic fingerprint of biological fluids constitutes a new frontier in medical diagnostics and a 
promising strategy to differentiate cancer patients from healthy individuals. 
In this work we aimed to establish the urinary metabolomic patterns from 40 BC patients and 38 
CTLs using 1H-NMR, as a powerful approach to identify a set of BC-specific metabolites which 
might be employed in the diagnostic of BC. OPLS-DA analysis was applied to 1H-NMR processed 
data matrix. Metabolomic patterns distinguished BC from CTL urine samples suggesting unique 
metabolite profiles for each investigated group. A total of 10 metabolites exhibited the highest 
contribution towards discriminating BC patients from CTLs (VIP >1, p < 0.05). The discrimination 
efficiency and accuracy of the urinary EMs were ascertained by ROC curve analysis that allowed the 
identification of some metabolites with the highest sensitivities and specificities to discriminate BC 
patients from healthy controls. The metabolomic pathway analysis indicated several metabolism 
pathways disruptions including amino acids and carbohydrates metabolism, in BC patients. The 
obtained results support the high throughput potential of NMR-based urinary metabolomics patterns 
in discrimination BC patients from CTL. Further investigations could unravel novel mechanistic 
insights into disease pathophysiology, monitor disease recurrence and predict patient response 
towards therapy. 
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Introduction 
The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million 
deaths in 2018 [143], being the second leading cause of death after cardiovascular diseases. This 
increasing trend is due to several factors, including ageing, population growth as well as the changing 
prevalence of certain causes of cancer linked to social and economic development [143]. Cancers of 
the lung and female breast are the leading types worldwide in terms of the number of new cases; for 
each of these types, approximately 2.1 million diagnoses were diagnosed in 2018, contributing about 
11.6 % of the total cancer incidence [143]. BC is also the leading cause of cancer death in women 
(15.0 %), followed by lung cancer (13.8 %) and colorectal cancer (9.5 %), which are also the second 
and third most common types of cancer, respectively [143]. Early stage BC patients have higher 5-
year survival rates than those diagnosed at later stages. Improved early BC detection methods could 
reduce patient mortality and improve therapeutic responses and prognosis [123]. Common methods 
of routine surveillance for BC include periodic mammography, self- or physician performed 
examination, and blood tests of tumor markers, including cancer antigens (CA 15.3, CA 27.29), 
carcinoembryonic antigen (CEA), tissue polypeptide specific-antigen, and human epidermal growth 
factor receptor 2 (the shed form). CA 15.3 and CEA represent the most widely used tumor markers 
[122]. An additional factor that contributes to the poor prognosis of patients diagnosed with BC is the 
fact that the diagnosis is often delayed due to limitations in screening tests [144]. A recent approach 
is metabolomics that studies a subset of small molecules derived from the global or targeted analysis 
of metabolic profiles from biological samples, such as blood, urine [145–148], cells, or tissue 
[135,149–152] representing a valuable tool in the detection of several diseases, including cancer. 
Several reports have already demonstrated the importance of studying the metabolome as a mean to 
discover a set of metabolites to be used as cancer biomarkers [127,128,153]. The study of specific 
metabolites to identify cancer fingerprints or signatures can aid in cancer detection and prognosis as 
well as the assessment of pharmacodynamic effects of therapy [149]. The most common approaches 
in metabolomics involve GC-MS [146], LC-MS [154] or NMR [67,123,127,128]. 
MS includes a separation stage using LC or GC and can discriminate between compounds based 
on mass-to-charge (m/z) ratio in charged particles. Although compared with NMR, MS exhibits a 
greater sensitivity, sample preparation is laborious and dependent on metabolite chemical properties 
[155]. In addition, MS lacks accuracy and precision producing an enhanced resolution profile with 
numerous peaks. However, only approximately 5% of these peaks are associated with known 
components [156]. Recently, non-invasive sampling strategies, including exhaled breath, urine and 
saliva, have emerged as attractive and useful approaches when coupled to high-throughput techniques 
such as NMR (1H NMR) [150,157,158]. NMR spectroscopy is a particularly appealing platform based 
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on the energy absorption and re-emission of the nuclei due to the magnetic field, where the selected 
isotopes having a momentum in an external magnetic field will give a signal. The most targeted 
isotope in samples with a biological origin is hydrogen (via 1H NMR) given its abundance in 
biological samples. Furthermore, other isotopes that are less abundant, such as carbon (via 13C NMR) 
or phosphorous (via 31P NMR) can also be used to provide additional information regarding specific 
metabolites[27]. The result is an NMR spectrum, and each separate resonance presented in the 
spectrum corresponds to a part of the spectral pattern of a unique metabolite and provides structural 
information that can simplify the identification of an unknown metabolite. The spectral peak areas 
generated by each molecule are used as an indirect measure of the amount of the metabolite present 
in the sample, not only allowing the quantification of the concentration of a metabolite but also 
providing information regarding its chemical structure. This technique presents several advantages, 
such as being a rapid, robust, cost-effective, highly reproducible, non-destructive, and fully 
quantitative. In addition, it requires no prior compound separation or derivatization generating spectra 
from a biological sample within few minutes being useful for conducting metabolomic studies on 
biofluids [27,159,160]. Zhang et al. [120] reviewed the most common methods for NMR 
spectroscopy based metabolite profiling, data processing and analysis. Bingol et al. [161] recently 
overview some advances in metabolomics field and contribution to targeted and untargeted 
approaches. A variety of studies have been conducted by NMR in disease research using urine 
[123,150], saliva [158,162], serum [163], plasma [164,165], tissue [166–169], and in cell culture 
[170–172].  
The aim of this study was to evaluate the ability of 1H NMR spectroscopy combined with 
multivariate statistical tools to differentiate and discriminate the urinary metabolomic patterns from 
BC patients and CTLs as a powerful approach to identify a set of BC-specific metabolites which 
might be employed in the diagnostic of BC. 
 
Materials and Methods 
Reagents 
3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) and deuterium oxide (D2O) were 
supplied by Acros Organics (Geel, Belgium).Potassium dihydrogen phosphate (KH2PO4), sodium 
azide (NaN3) and potassium deuteroxide solution (KOD) were purchased from Panreac (Barcelona, 
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Urine collection 
To investigate the urinary NMR profile, 40 urine samples from female patients with BC (n=40, 
age range 40-74 years, average 59 ± 10 years) and 38 urine samples from healthy female volunteers 
without any known pathology (n=38, age range 40-72 years, average 53 ± 8 years; control group - 
CTL) were obtained from the Haemato-Oncology Unit of Hospital Dr. Nélio Mendonça (Funchal, 
Portugal) and Blood Donors Bank of the same Hospital, respectively (Table 3.2.1), were randomly 
selected among the volunteers. Patients did not receive any neoadjuvant chemotherapy or radiation 
therapy prior to sample collection. Healthy controls were age- and gender-matched patients, and had 
no declared history of cancer or gastrointestinal symptoms. Exclusion criteria included pregnancy, 
inflammatory conditions, mental disorders, gastrointestinal tract disorders, hypertension, 
uncontrolled bacterial, viral, or fungal infection and diabetes mellitus. 
 
Table 3. 2. 1 - List of collected urine samples from BC patients and CTLs. SD: standard deviation. 
Sample group N. subjects Age range/years Mean Age ± SD 
Breast Cancer(BC) n = 40 40-74 59 ± 10 
Control (CTL) n = 38 40-72 53 ± 8 
 
The study was approved by the Ethic Committee of Hospital Dr. Nélio Mendonça (Approval no. 
S.1708625/2017). Written informed consent for the study was obtained from all participants. Each 
individual (either patient or healthy volunteer) provided a sample of morning urine (after overnight 
fasting) in a 20 mL sterile container. The samples were aliquoted into 4 mL glass vials and frozen at 
-80ºC until use in the experiments. 
Urine samples were thawed and centrifuged (8000 rpm for 5 min) to remove any suspended cells 
and other precipitated material. Then, 540 µL of urine was mixed with 60 µL of a buffer solution 
(KH2PO4, 1.5 M in D2O) containing 0.1% of TSP-d4 (used as chemical shift reference) and sodium 
azide (NaN3, 2 mM). The pH was adjusted to 7.00 ± 0.02 by adding small amounts of KOD. 
 
NMR measurements 
NMR spectral acquisition was performed using a Bruker Advance II Plus NMR spectrometer 
equipped with a 400 MHz magnet UltraShield™ 400 Plus at 300K. All NMR spectra acquisition and 
pre-processing were performed under the control of a workstation with TopSpin 3.5pl7 (Bruker 
BioSpin). For each sample, a standard 1D nuclear overhauser enhancement spectroscopy (NOESY) 
pulse sequence (noesypr1d) was used and solvent signal suppression was achieved by presaturation 
during relaxation and mixing time (SW 4807.692 Hz, TD 64 K data points, relaxation delay 5 s, 128 
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scans). The shimming was calibrated automatically. Also, all spectra were processed using a line 
broadening (1.0 Hz) and baseline automatically corrected. The NMR spectrum of each sample was 
aligned with reference to the TSP signal at δ 0.00 ppm. Spectral regions within the range of 0.94 to 
10 ppm were analyzed after excluding the sub-region δ 4.55-6.05 to remove variability arising from 
water suppression and possible cross-relaxation effect on the urea signal via solvent exchanging 
protons. As already known, the TSP signal may be affected by proteins or other macromolecules 
present in samples [173] and for that reason in the preparation of urine samples before NMR analysis, 
the step of centrifugation was taken into account and the rotations per minute (rpm) was used in order 
to remove any proteins present in samples. 
The analysis of NMR spectral data was performed using the Chenomx NMR Suite 8.2 (Chenomx 
Inc., Alberta, Canada) and relative concentrations (in mM) of metabolites were determined using the 
400MHz library from Chenomx NMR Suite 8.2, which compares the integral of a known reference 
signal (TSP) with signals derived from a library of compounds containing chemical shifts and peak 
multiplicities. 
In addition, the identication of selected metabolites was also cross checked from the Human 
Metabolome Database (HMDB) [174] and literature [175]. Regarding the metabolites that were not 
available in the library, identification was accomplished by running a standard solution and the 
relative concentration was calculated manually. This software not only allows the identification of 
compounds but also access their quantification based on advanced algorithms turning into a very 
straightforward tool to analyze NMR spectra. 
 
Statistical analysis 
Statistical analyses were performed using the web server Metaboanalyst 3.0 [134] where sample 
specific normalization allowed the manual adjustment of relative concentrations based on biological 
inputs (i.e., volume, mass), and row-wise normalization allowed the general-purpose adjustment for 
differences among samples. Regarding data transformation and scaling were accomplished using two 
different approaches to make features more comparable, raw data were scaled using mean-centring 
and cubic root transformation, with sample normalization by the sum. 
Then, multivariate statistical analyzes namely, PCA, PLS-DA and OPLS-DA were applied to the 
urinary metabolomic profile dataset to provide insights into the separations between the groups. 
Furthermore, hierarchical cluster analysis by K-means of the 2 groups in this study was performed 
and Pearson´s correlation was used to generate the heat map using the 32 metabolites to identify 
clustering patterns. RF classification was performed to determine the ability of the metabolites to 
accurately classify the study subjects into their corresponding groups. Moreover, the ROCs were 
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attained to verify which metabolites had the highest sensitivity/specificity for a BC diagnosis. Finally, 
the metabolites were used for the metabolic pathway analysis to identify the most relevant metabolic 
pathways involved in the BC and CTL groups. 
 
Results and Discussion 
Urinary metabolomic pattern based on 1H NMR 
1H NMR analysis was performed according to the procedure described in the Methods section. A 
representative first dimension urine 1H NMR spectrum, referenced to TSP (0. 0 ppm), from a BC 
patient is shown in Figure 3.2.1, and metabolites are indicated based on their chemical shifts. Table 
2 represents the identification of metabolites as well as their minimum and maximum relative 
concentrations (mM) for each group and the respective percentage of occurrence (FO). Each sample 
analysis was performed in triplicate and the relative standard deviation (RSD) was lower than 2 %. 
For most metabolites, the FO was greater than 90 % with the following exceptions: valine, 
glutamine, carnitine, trigonelline, 4-cresol sulphate and hypoxanthine for the BC group; α-
hydroxyisobutyrate, trimethylamine N-oxide, hypoxanthine and glycine for the CTL group. 
Regarding relative concentrations (mM), the highest level was obtained for creatinine followed by 
hippurate in the BC group and citrate in the CTL group. In addition, taurine and mannitol presented 
higher levels in BC group, respectively. It can also be highlighted that the majority of metabolites 
were down-regulated with regard to the BC group, except α-hydroxybutyrate, cis-aconitate, mannitol, 
hippurate and 3-methylhistidine, that were up-regulated, also identified by Carrola et al. [150]. As 
shown in Figure 3.2.1, 33 metabolites were identified and quantified. The main metabolites identified 
in urine mainly resulted from tricarboxylate (e.g., citrate, cis-aconitate), methane (e.g., 
dimethylamine, trimethylamine N-oxide) and amino acid metabolism (e.g., hippurate, glycine). The 
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Figure 3. 2. 1 - Typical 400 MHz representative urine 1H NMR spectrum from a BC patient, 
referenced to TSP (δ 0. 0 ppm). For peak identification see Table 3.2.2. 
These metabolites were already identified in several studies that use urine cancer sample 
[150,169,176]. Trimethylamine N-oxide is produced in the liver by intestinal bacteria from dietary 
quaternary amines, such as choline and carnitine trough trimethylamine (TMA) via flavin-containing 
monooxygenase (FMO3), and the levels in urine or plasma are used to determine FMO3 deficiency 
[177–181]. Creatinine is subsequently produced via a biological system involving creatine, 
phosphocreatine, and adenosine triphosphate (ATP), whereas hippurate and citrate are derived from 
phenylalanine metabolism and the citrate cycle [182]. The concentration of creatinine is age and sex 
dependent, decreasing with age and varying throughout the day. Normally, the concentration of 
creatinine is increased in males when compared with females given the increased body mass index 
[183]. Creatinine production from the muscles is proportional to the total muscle mass and muscle 
catabolism. In individuals with a relatively low muscle mass, including children, women, and cancer 
patients,  serum creatinine levels are reduced for a given glomerular filtration rate (GFR), which is 
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Table 3. 2. 2 - Metabolites identified in urine samples from BC patients and CTL through 1H NMR spectroscopy, relative concentrations (mM), variation 
of relative concentration regarding to BC group, K-S values for BC and CTL groups and frequency of occurrence (FO in %) of metabolites for each 
group. 
Peak n. Metabolite 
δ (ppm) 
Relative concentrations (mM) 
K-S values p-value 
(˂ 0.05) 
 Variation  
FO (%) 
BC CTL 
Multiplicity Min Max Average Min Max Average BC CTL BC CTL 
1 valine 1.030 (d) 0.10 1.24 0.67 0.26 1.63 0.95 0.166 0.180 4.127 e-04 ↓ 68 95 
2 α-hydroxybutyrate 1.188 (d) 0.35 4.89 2.62 0.47 2.06 1.26 0.186 0.175 9.201 e-06 ↑ 95 100 
3 β-hydroxyisovalerate 1.256 (s), 2.352 (s) 0.08 1.91 0.99 0.57 2.89 1.73 0.153 0.984 5.048 e-05 ↓ 100 98 
4 lactate 1.319 (d) 0.54 5.39 2.97 1.57 10.31 5.94 0.107 0.069 1.780 e-06 ↓ 100 98 
5 threonine 1.317 (d) 0.61 5.53 3.07 1.60 8.81 5.21 0.098 0.076 1.599 e-05 ↓ 93 98 
6 α-hydroxyisobutyrate 1.346 (s) 0.07 1.77 0.92 1.13 6.64 3.89 0.149 0.092 2.221 e-03 ↓ 100 78 
7 alanine 1.470 (d) 0.24 5.58 2.91 0.62 8.51 4.57 0.098 0.097 3.421 e-04 ↓ 100 100 
8 acetate 1.901 (s) 0.28 4.31 2.3 1.10 6.23 3.66 0.178 0.141 8.737 e-03 ↓ 96 95 
9 glutamine 2.105 (t) 0.34 11.00 5.67 1.47 20.67 11.07 0.193 0.098 5.407 e-03 ↓ 67 93 
10 acetone 2.221 (s) 0.07 4.10 2.08 0.49 4.84 2.66 0.164 0.084 3.367 e-02 ↓ 92 100 
11 carnitine 2.407 (s), 2.447 (s), 3.213 (s) 0.09 1.94 1.01 0.38 6.25 3.32 0.164 0.104 9.002 e-05 ↓ 80 100 
12 4-cresol sulphate 2.350 (s), 7.200 (d) 0.49 7.09 3.79 1.22 11.91 6.57 0.156 0.097 4.315 e-07 ↓ 84 100 
13 pyruvate 2.362 (s) 0.14 4.75 2.44 1.90 7.36 4.63 0.173 0.174 8.880 e-06 ↓ 100 100 
14 succinate 2.390 (s) 0.07 2.58 1.33 0.55 4.85 2.70 0.122 0.188 1.020 e-02 ↓ 96 100 
15 citrate 2.526 (d), 2.688 (d) 3.17 80.34 41.76 9.14 113.56 61.35 0.157 0.146 6.825 e-07 ↓ 100 100 
16 dimethylamine 2.715 (s) 0.19 11.97 6.08 4.49 15.73 10.11 0.199 0.132 2.488 e-04 ↓ 100 95 
17 α-oxoglutarate 2.996 (t) 0.52 12.35 6.43 1.79 15.55 8.67 0.107 0.144 1.172 e-08 ↓ 92 95 
18 creatinine 3.033 (s), 4.047 (s) 3.29 216.36 109.82 104.24 381.60 242.92 0.129 0.175 1.705 e-04 ↓ 100 100 
19 cis-aconitate 3.114 (d) 0.15 22.15 11.15 1.91 16.44 9.18 0.148 0.149 4.671 e-07 ↑ 100 95 
20 choline 3.189 (s) 0.11 2.93 1.52 0.77 3.85 2.31 0.167 0.164 8.094 e-03 ↓ 96 100 
21 betaine 3.252 (s) 0.08 4.13 2.11 0.46 4.61 2.53 0.152 0.154 8.105 e-03 ↓ 100 93 
22 trimethylamine N-oxide 3.254 (s) 0.52 18.04 9.28 1.70 33.81 17.76 0.146 0.082 1.418 e-02 ↓ 92 85 
23 taurine 3.251 (t) 1.05 21.79 11.42 2.59 18.66 10.63 0.200 0.166 n.s. ↑ 92 98 
24 4-hydroxyphenylacetate 3.438 (s) 0.14 4.63 2.38 0.38 5.95 3.17 0.188 0.087 3.503 e-04 ↓ 88 90 
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Peak n. Metabolite 
δ (ppm) 
Relative concentrations (mM) 
K-S values p-value 
(˂ 0.05) 
 Variation  
FO (%) 
BC CTL 
Multiplicity Min Max Average Min Max Average BC CTL BC CTL 
25 glycine 3.553 (s) 1.81 33.87 17.84 1.93 45.26 23.59 0.153 0.168 1.401 e-02 ↓ 100 88 
26 mannitol 3.671 (m) 2.07 78.45 40.26 13.85 63.76 38.81 0.143 0.153 n.s. ↑ 92 100 
27 guanidoacetate 3.786 (s) 1.71 21.30 11.51 7.10 29.50 18.30 0.122 0.118 4.738 e-03 ↓ 92 100 
28 serine 3.840 (q) 1.71 40.85 21.29 15.00 71.74 43.37 0.104 0.190 9.040 e-05 ↓ 92 95 
29 creatine 3.920 (s) 1.15 28.13 14.64 4.20 46.93 25.56 0.222 0.141 n.s. ↓ 92 98 
30 hippurate 3.957 (d), 7.538 (t), 7.628 (t), 7.823 (d) 2.10 130.18 66.14 5.56 70.01 37.79 0.229 0.163 3.085 e-04 ↑ 96 93 
31 trigonelline 4.428 (s), 8.073 (m), 8.834 (m) 0.10 6.2 3.15 0.44 17.79 9.12 0.136 0.104 1.296 e-03 ↓ 88 100 
32 3-methylhistidine 8.081 (s) 0.32 16.91 8.62 0.56 12.51 6.64 0.220 0.141 n.s. ↑ 100 93 
33 hypoxanthine 8.203 (s) 0.23 2.56 1.4 0.28 2.77 1.53 0.228 0.151 n.s. ↓ 64 80 
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Multivariate statistical analysis of urinary metabolomic profile 
The first step before performing multivariate statistical analysis was to verify the normal 
distribution of the urinary metabolomic profile dataset using the Kolmogorov-Smirnov test (Table 
3.2.2). All samples under analysis exhibited a normal distribution within each assigned group (p > 
0.05). 
To obtain a reliable dataset to apply multivariate analysis, the dataset was evaluated to exclude the 
metabolites that had an FO < 90 %. The dataset used to perform the statistical analysis also excluded 
creatinine as mentioned above as its concentration is dependent on age, gender and disease status, 
decreasing with age and varying throughout the day. Regarding creatinine relative concentration 
obtained in this study and the respective differences between groups under study, this metabolite 
might be considered a potential artefact given that creatinine values may be altered, as the generation 
of creatinine may not be simply a product of muscle mass but influenced by muscle function, muscle 
composition, activity, diet and health status [185]. Based on this, the dataset composed of 32 
metabolites and 70 samples (32 BC and 38 CTL) that fulfilled this condition was subject to principal 
component analysis (PCA). PCA is an unsupervised method performed to visualize the 
similarities/differences between urine samples profiles of groups in this study. In this step, the 
samples were analyzed individually, e.g., without classification according to the groups. PCA score 
plot from urine samples are presented in Figure 3.2.2. 
 
Figure 3. 2. 2 - Scores plot of PCA from urine samples based on 32 metabolites. For numbers 
identification see Table 3.2.2. 
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Although the projection of the variance between samples was performed without classification, it 
is possible to observe that the PCA of urine samples from BC patients and those from CTL presented 
a tendency for the formation of two clusters across the first principal component (PC1) that explains 
54.6 % of the total variance. Most of the metabolites exhibited enormous importance in the variance 
projection of samples. Then, the partial least square-discriminant analysis (PLS-DA) was used as a 
supervised clustering method to maximize the separation between the groups and demonstrated that 
the samples had a tendency to be grouped according with health condition of subject (BC and CTL) 
through its variance/covariance along the first component. Ten differently expressed metabolites that 
exhibited a variable importance in projection (VIP) score greater than 1 were identified: creatine, 
glycine, serine, dimethylamine, trimethylamine N-oxide, α-hydroxyisobutyrate, mannitol, glutamine, 
cis-aconitate and trigonelline (Figure 3.2.3 A-B). 
 
Figure 3. 2. 3 - Score plots of PLS-DA (A) and (B) VIP values of metabolites obtained by 1H NMR 
analysis of urine samples from the 2 groups in study. For number identification see Table 3.2.2. 
Many of these metabolites were already identified in various cancer types, including lung 
[150,186], breast, ovarian [123,144], bladder [187], and gastric cancers [188], in previous reports. 
Additionally, Zhou et al. [189] performed a metabonomics study using serum and urine from BC 
patients based on NMR where citrate, phenylacetylglycine and guanidoacetate exhibited significance 
in the discrimination of BC patients from CTLs. In addition, Slupsky et al. [123] accomplished a 
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Figure 3. 2. 4 - (A) Heat map visualization and hierarchical clustering analysis and was constructed using the 32 metabolites by Pearson distance 
analysis; (B) clustering analysis by K-means of the 2 groups; (C) RF classification of urine metabolites from BC and CTL groups which indicated and 
overall error of 0.19 for BC and 0.08 for CTL. 
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The authors found that certain intermediates of the tricarboxylic acid cycle and metabolites relating 
to energy metabolism, amino acids, and gut microbial metabolism were perturbed. With regards to 
aminoacids as raw materials of protein synthesis and catabolism products in vivo their changes 
whether in composition and concentration can reflect the metabolic status of patients [189]. 
Moreover, the heat map was constructed using Pearson´s correlation, providing intuitive visualization 
of the data set. The heat map contains the 32 metabolites and was used to identify samples or features 
that are unusually high or low (Figure 3.2.4 A). As noted in Figure 3.2.4, the higher relative 
concentrations for the majority of metabolites were found in the CTL group whereas the lowest 
relative concentrations were noted in the BC group. K-means clustering analysis was also performed 
as a non-hierarchical clustering technique. The method initially creates k random clusters (k is the 
number of groups in the study). The programme then calculates the mean of each cluster (indicated 
by the shaded line). If an observation is closer to the centroid of another cluster, then the observation 
is made by a member of that cluster. This process is repeated until none of the observations are 
reassigned to a different cluster (Figure 3.2.4 B). For this analysis, 8 BC and 25 CTL samples were 
included in cluster 1; 1 BC and 6 CTL samples were included in cluster 2; 23 BC and 7 CTL samples 
were included in cluster 3. 
RF analysis was performed to determine the ability of metabolites to accurately classify the study 
subjects into their corresponding group. The method uses an ensemble of classification trees (in this 
case 1000), and each of tree is grown by random feature selection from a bootstrap sample at each 
branch. Class prediction is based on the majority vote of the ensemble. These out-of-bag (OOB) data 
are then subsequently used as a test sample to obtain an unbiased estimate of the classification error 
(OOB error). The average value was 0.13, indicating that the accuracy of classification was lower 
(approximately 18 %) for the BC than for the CTL group at 8 % (Figure 3.2.4 C). 
Additionally, orthogonal partial least squares-discriminant (OPLS-DA) analysis was applied to the 
urinary metabolomic profile dataset to maximize the separation between the CTL and BC groups as 
presented in Figure 3.2.5 (A and B). OPLS-DA uses class information to demonstrate variables 
responsible for class discrimination using the predictive information of the first component. The main 
advantage of OPLS-DA when compared with PLS-DA is that a single component is used as a 
predictor for the class, whereas the other components describe the variation orthogonal to the first 
predictive component [139]. 
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Figure 3. 2. 5 – (A) Score plots of OPLS-DA analysis and (B) model validation by permutation tests 
based on prediction accuracy of metabolites obtained by 1H NMR analysis of urine samples from the 
2 groups in study. For number identification see Table 3.2.2. 
To attest the robustness of the model, a random permutation test with 1000 permutations was 
performed with OPLS-DA (Figure 3.2.5 C). The permutation test yielded R2 (represents goodness of 
fit) as 0.846 and Q2 (represents predictive ability) as 0.770 indicating that the model is not over fitted 
and have a relative good predictive ability to distinguish between study groups. Moreover, receiver 
operating characteristic curves (ROCs) was generated for the two groups (CTL-BC) using the 32 
identified metabolites and is presented in Figure 3.2.6. 
As noted in the Figure, as the number of metabolites increases the area under the curve (AUC) 
also increases. Thus, using only 2 metabolites, the AUC value obtained was 0.92 for the CTL-BC 
demonstrating the higher sensitivity/specificity to distinguish the groups. The metabolites with 
significance were creatine, glycine, serine, α-hydroxyisobutyrate and trimethylamine N-oxide. In 
addition, using all 32 metabolites it can be achieved the highest area under the curve. These results 
are in accordance with the literature, where Xia et al. [108], an AUC value between 0.9 and 1.0 is 
excellent, and a value between 0.8 and 0.9 is good, comparing the results, the values obtained were 
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Figure 3. 2. 6 - ROC curves for the predictive model. A combination metabolites model calculated 
from the logistic regression analysis using the 32 identified metabolites for distinguishing BC patients 
from CTL. 
The AUC can be interpreted as the probability that a randomly selected diseased subject is 
classified as diseased than a casually selected healthy subject [108]. 
Finally, the metabolic pathway analysis was performed to determine which pathways were altered 
in the groups under study.  
 
Figure 3. 2. 7 - The metabolome view map (A) of significant altered metabolic pathways observed in 
urine from BC and CTL groups and (B) metabolic pathways with highest impact that include the most 
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Figure 3. 2. 7 - The metabolome view map (A) of significant altered metabolic pathways observed in 
urine from BC and CTL groups and (B) metabolic pathways with highest impact that include the most 
promising potential BC biomarkers identified in this study. 
Figure 3.2.7 (A and B) presents the impacted pathways in the CTL-BC groups, respectively. The 
most impacted metabolic pathways were glycine metabolism, glutamate metabolism; butanoate 
metabolism; glycolysis, citrate cycle (TCA cycle), taurine metabolism and pyruvate metabolisms, 
indicated by the red and yellow colors. It can be highlighted that the pathway with highest impact 
was the glycine metabolism (Figure 3.2.7 B). Based on these results, a successful differentiation and 
discrimination of samples was achieved between CTL and BC group. The results indicate that the 1H 
NMR urinary profile represents a useful approach to identify potential BC biomarkers. 
 
Conclusions 
This study assessed the metabolomic urinary profile in BC patients in active and follow-up stages 
compared with that in healthy volunteers using 1H NMR combined with multivariate statistical tools 
(PCA, PLS-DA and OPLS-DA) were applied to two groups (BC and CTL). Thirty-three metabolites 
were identified and quantified using Chenomx software. Multivariate statistical analysis revealed 
some metabolites were significantly altered in BC patients. Of the metabolites detected, creatine, 
glycine, serine, dimethylamine, trimethylamine N-oxide, α-hydroxyisobutyrate, mannitol, glutamine, 
cis-aconitate and trigonelline exhibited the highest sensitivities and specificities to discriminate BC 
patients from healthy controls. Plot analysis revealed a metabolomic biosignature comprising an array 
of several biochemical pathways altered in BC patients. Metabolic pathway analysis indicated that 
the discriminatory metabolites potentially originated from several dysregulated pathways in BC: 
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cycle), taurine metabolism and pyruvate metabolism. These results suggested the possibility of 
identifying endogenous metabolites as a platform to discover potential BC biomarkers and paves a 
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Abstract 
BC remains the most prevalent oncologic pathology in women, causing huge psychological, 
economic and social impacts on our society. Currently, the available diagnostic tools have limited 
sensitivity and specificity. Metabolome analysis has emerged as a powerful tool for obtaining 
information about the biological processes that occur in organisms and is a useful platform for 
discovering new biomarkers or make disease diagnosis using different biological samples. VOMs 
from the headspace of cultured BC cells and normal human mammary epithelial cells, were collected 
by HS-SPME and analyzed by GC–MS, thus defining a volatile metabolomic signature. Sixty VOMs 
were identified in all cell lines, belonging to different chemical families. From these, 2-pentanone, 2-
heptanone, 3-methyl-3-buten-1-ol, ethyl acetate, ethyl propanoate and 2-methyl butanoate were 
detected only in the headspace of cultured cancer cell lines. Multivariate statistical methods were 
used to verify the volatile metabolomic differences between BC cell lines and normal cells to find 
related volatile metabolites that could be associated with BC, providing comprehensive insight into 
VOMs as potential cancer biomarkers. The establishment of the volatile fingerprint of BC cell lines 
presents an opportunity to identify endogenous VOMs to discover biomarkers of BC and the related 
metabolomic pathways, thereby improving the available BC diagnostic tools. 
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Introduction 
Although there has been a sustained decline in mortality rates over recent decades, BC continues 
to be the most prevalent malignancy among women worldwide and is a major cause of female deaths. 
A number of associated factors, including age, gender, ethnicity, lifestyle (tobacco, alcohol, diet, and 
lack of exercise) and genetics, such as mutations in the tumor suppressor genes BRCA1 (mutation on 
chromosome 17) and BRCA2 (mutation on chromosome 13), have been identified as the most 
common inherited causes of susceptibility to BC. The BRCA1 and BRCA2 genes encode very large 
proteins that are expressed in a wide variety of different tissues and are implicated in processes such 
as DNA repair and recombination, checkpoint control of the cell cycle, and transcription. Families 
with a high incidence of BC may carry mutations in one or both of these genes, or alternatively, 
members of these families may have similar lifestyle habits and may have been affected by similar 
environmental factors [190,191]. Furthermore, other important gene mutations related to BC 
development include mutations in ATM (ataxia-telangiectasia mutated), TP53 (tumor protein p53), 
and PTEN (phosphatase and tensin homolog deleted on chromosome ten) [192–194]. Most of these 
are rare and often do not increase the risk of BC as much as do mutations in the BRCA genes. 
Detection of BC at an early stage is extremely important to reduce the burden of disease because 
earlier detection leads to better patient outcomes, as  metastatic states are avoided [107,195]. 
Currently, there is no single screening test that is totally reliable, and a number of tests can be 
combined to help detect early stage BC. Current screening techniques include self-examination for 
lumps or nodes, mammography, ultrasound, magnetic resonance imaging and biopsy using a fine 
needle or similar instrument to aspirate or otherwise remove a sample of fluid or cells from any 
suspicious lump or node for microscopic examination [113]. These methods are generally invasive, 
time-consuming and require special medical skills. Therefore, there is a need for non-invasive, 
accurate and rapid screening tests for early detection. In this context, it is useful to identify VOMs 
that may prevent or predict the occurrence of metastasis before it manifests in the patient.  
Metabolomics has emerged as a powerful tool for understanding biological processes that occur 
in humans, and it has mostly been based on the analysis of biofluids, such as blood, saliva, or urine, 
to discover new cancer biomarkers or to  diagnose a disease [196]. The use of cell culture 
metabolomics enables both the discovery of novel biomarkers of pathological conditions and 
investigation of the related metabolomic pathways (Figure 3.3.1). Many of the metabolic processes 
in the body, such as lipid peroxidation, energy metabolism through glycolysis and amino acid 
catabolism are common to all living cells [196]. It is believed that some metabolic pathways might 
be up- or down-regulated in cancer cells and, therefore, metabolome analysis may reveal differences 
between biological samples based on metabolic profiles or fingerprints. Indeed, cancer cells have an 
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altered metabolism compared with normal cells that may lead to the production of specific 
compounds [197]. In recent years, several studies have reported the analysis of cancerous cell lines 
to find potential cancer biomarkers [198–201]. The most recent techniques include the use of 
nanomaterial-based sensors [198], electrochemical sensors [202], or thermal desorption coupled with 
gas chromatography mass spectrometry [152]. However, most of these techniques are expensive and 
time-consuming. In this work, HS-SPME which was developed by the Pawliszyn group [203] in the 
early 90´s and consists of a fiber coated with different polymers extracting a wide range of chemical 
compounds, was selected as an extraction technique. This technique is superior to other extraction 
techniques, in that it is rapid, easy to use, sensitive and does not require a concentration step before 
analysis. 
 
Figure 3. 3. 1 - Formation of some intermediate products of lipid peroxidation. Adapted from Li et 
al. [204]. 
In this study, a comparative analysis of the volatile metabolomic signature of BC cell lines (T-
47D, MDA-MB-231, MCF-7) and normal human mammary epithelial cells (HMEC) was carried out, 
in order to identify BC-specific VOMs and to identify a set of biomarkers that could hopefully be 
correlated with VOMs released in vivo by BC cells. This finding will improve the knowledge about 
the origin of VOMs and providing comprehensive information as potential BC biomarkers. This 
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multi-factorial disease. The GC–qMS analyzes allow specific identification of VOMs, while 
multivariate statistical analysis is able to differentiate and discriminate oncologic from normal cells 
providing proof-of-principle for the detection of different volatile metabolomic patterns in target 
cells.  
 
Materials and Methods 
Reagents and materials 
PBS was purchased from Sigma-Aldrich (St. Louis, MO, USA), sodium chloride was obtained 
from Panreac (Barcelona, Spain), the SPME holder for manual sampling of SPME fiber [50/30 µm 
divinylbenzene/carboxen/polydimethylsiloxane (DVB/CAR/PDMS)] and the glass vials were 
purchased from Supelco (Bellefonte, PA, USA). The SPME fiber was conditioned according to 
manufacturer’s instructions. Before each daily analysis, the fiber was conditioned for 10 min in the 
injector port to prevent carryover. T75 glass flasks were purchased from Ningbo (Ja-Hely 
Technology, China). 
 
Cell lines and cultivation conditions 
The human breast adenocarcinoma cell line MCF-7and human breast carcinoma cell lines T-47D 
and MDA-MB-231 were purchased from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany). MCF-7 was grown in 90% RPMI 1640 
(Life technologies, Gibco®) supplemented with 15% fetal bovine serum (FBS, Life technologies, 
Gibco®), 1% Antibiotic-Antimycotic solution (AA, Life technologies, Gibco®), 1% MEM Non-
Essential Amino Acids solution (Life technologies, Gibco®), 1 mM sodium pyruvate (Sigma-
Aldrich, St. Louis, MO, USA) and 10 µg/mL human insulin (Sigma-Aldrich, St. Louis, MO, USA); 
T-47D cell line was grown in 85% RPMI 1640 supplemented with 15% fetal bovine serum (FBS), 
1% Antibiotic-Antimycotic solution and 10 µg/mL human insulin, while the MDA-MB-231 cell line 
was grown in 85% RPMI 1640 supplemented with 15% fetal bovine serum (FBS) and 1% Antibiotic-
Antimycotic solution. Human mammary epithelial cells (HMEC) were purchased from Life 
technologies (Gibco®) and grown in HUMEC serum-free medium supplemented with 20 µg/mL of 
Antibiotic-Antimycotic solution (Life technologies, Gibco®). All cells were incubated in a 
humidified atmosphere containing 5% CO2 and 95% air at 37ºC. Culture media was changed every 2 
days and the cultures were passaged with 0.25% trypsin-EDTA (Life technologies, Gibco®) when 
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VOMs extraction from cell cultures  
To extract VOMs from cell cultures, glass flasks were treated with collagen to promote cell 
adherence. Briefly, the glass flasks were covered with a collagen solution (0.2 mg/mL) for 30 min 
and then washed with PBS (3 times). The cells were then cultured in the T75 flasks for 48 h. After 
this period, volatile metabolites were extracted using a DVB/CAR/PDMS SPME fiber exposed in the 
headspace of the flasks for 45 min at 37 ºC, followed by injection into the GC injection port for 10 
min to allow the desorption of VOMs from the fiber. After these extractions, cell-free aliquots were 
collected from the flasks holding 10 mL of the culture medium with growing cells. They were 
centrifuged to remove any suspended cells, and then 1 mL aliquots were adjusted to pH 2, 7 or10 
with 1M HCl  or 1M NaOH [205]. After the addition of 200 mg NaCl and subsequent stirring (0.5 
mm × 0.1 mm bar) at 800 rpm, the vials were capped with PTFE septa through which the SPME fiber 
was inserted in the headspace of the vial and placed in a thermostatic bath at 37 ºC for 45 min. After 
this, the fiber was withdrawn into the needle and injected in the GC port (250 ºC) over 10 min, when 
the analytes were thermally desorbed and transferred to the analytical column. Control headspace 
samples were also collected from flasks containing only empty media treated with the same 




VOMs in the headspace were analyzed using an Agilent Technologies 6890N Network gas 
chromatograph system (Palo Alto, CA, USA) equipped with a BP-20 fused silica column (60 m × 
0.25 mm I.D. × 0.25 µm film thickness, SGE, Dortmund, Germany) interfaced with an Agilent 5975 
quadrupole inert mass selective detector. The following oven temperature profile was set: (a) 5 min 
at 45 ºC; (b) increase temperature until 150 ºC, at a rate of 2 ºC min-1 (hold for 10 min); (c) 150 ºC 
for 10 min; (d) increase temperature until 220 ºC, at a rate of 7 ºC min-1; and (e) 220 ºC for 10 min. 
Column flow was constant at 1.0 mL/min using helium (He, N60, Air Liquide, Portugal) as the carrier 
gas. The injection port was maintained at 250ºC and operated in the splitless mode. Regarding MS 
analyzes, the operating temperatures of the transfer line, quadrupole and ionization source were 270, 
150 and 230ºC, respectively. The electron impact mass spectra were recorded at 70 eV and the 
ionization current was 10 µA, and data acquisition was performed in scan mode (30-200 m/z). The 
identification of metabolites was performed comparing mass spectra with the Agilent MS 
ChemStation Software (Palo Alto, CA, USA) equipped with the NIST05 mass spectral library with a 
similarity threshold higher than 80 %, or with commercially standards when available. All 
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Statistical tests were performed using the StatSoft STATISTICA 12.0 (2013) software (Tulsa, OK, 
USA). Differences in VOMs between groups were tested with one-way ANOVA, and p < 0.05 was 
considered as statistically significant. PCA, PLS and LDA were carried out on VOMs selected by 
ANOVA to evaluate differences among the studied groups. PCA was performed in order to obtain 
differentiation between samples under study without classification and PLS was used as a supervised 
linear pattern recognition algorithm for data classification of samples. PCA and PLS were performed 
through variables values scale by unit standard deviation with convergence criterion (0.0001) and 
leave-one-out cross validation for accuracy confirmation. For LDA analysis a backward selection 
method was used with a p < 0.05 through Wilks test. For cross validation a leave-one-out strategy 
was used.  
 
Results and discussion 
VOMs associated with normal breast cells (HMEC) and BC cell lines (T-47D, MDA-MB-231 and 
MCF-7 cells) were investigated. The cell lines for the present study were chosen based on their 
different molecular characteristics (Table 3.3.1): namely, the expression of the estrogen receptor 
(ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). It 
is well known that BC is heterogeneous and that its prognosis and treatment depends on the molecular 
subtype of the cancer cells. The VOMs arising from the cellular metabolism were studied using HS-
SPME/GC-MS: a) by direct analysis of the headspace of the culture flasks after cell growth (these 
results are hereinafter designated as “Cells”); and b) by analysis of the volatile metabolites from the 
culture media at different pH values. From the analysis of chromatograms, it was possible to identify 
60 VOMs belonging to distinct chemical groups, namely, alkanes, aldehydes, ketones, acids, alcohols 
and benzene derivatives. 
 
Table 3. 3. 1 - Characteristics of investigated breast cells. 
Cell line Molecular subtype 
Classification 
ER PgR HER2 
HMEC Epithelial Low Low Low 
MCF-7 Luminal A + + - 
T-47D Luminal A + + - 
MDA-MB-231 Triple negative - - - 
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor. 
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VOMs signature of BC cell lines and breast normal cells 
We identified twenty-six VOMs belonging to several chemical groups (Figure 3.3.2): namely, 
alkanes, aldehydes, ketones, acids, alcohols and benzene derivatives (Table 3.3.2). 
 
Table 3. 3. 2 - Identification of VOMs from investigated human mammary epithelial cells and human 





Abbreviation Ion Compound 
HMEC 
(× 105)  
T-47D 
(× 105)  
MDA-MB-231 
(× 105)  
MCF-7 
(× 105) 
2 4.356 HEXA 57 hexane 0.44  -  -  - 
4 5.127 M4HEPT 43, 70 4-methyl-heptane 4.83  -  -  - 
5 5.739 ACTONE 43, 58 acetone 9.24  501.87  10.82  22.00 
6 6.843 ETHATE 43, 61 ethyl acetate -  8.56  3.16  25.55 
8 8.716 ETHPPATE 57, 44 ethyl propanoate -  18.11  2.17  19.66 
9 9.337 PENTONE2 43, 86 2-pentanone -  -  -  22.74 
10 9.994 DECA 57, 44 decane 3.36  354.35  4.28  12.80 
12 12.341 M2BTATE 57 2-methyl butanoate -  12.83  -  13.88 
17 15.865 ETHBNZ 91, 106 ethylbenzene 12.1  4.02  2.38  10.23 
18 16.646 DMBNZ13 91, 106 1,3-dimethylbenzene 6.32  3.81  2.30  5.23 
19 17.395 BUTOL1 56, 41 1-butanol 1.21  2.84  2.88  5.94 
20 19.379 HPTONE2 43, 58 2-heptanone -  4.96  16.46  40.00 
22 20.157 DODEC 57, 43, 
71 
dodecane 14.19  21.29  19.93  54.42 
25 23.765 M33BUTOL1 41, 56 3-methyl-3-buten-1-ol -  -  -  3.93 
26 24.155 STYENE 104, 78 styrene 64.50  139.81  39.93  125.93 
27 25.511 TMBNZ124 105 1,2,4-trimethylbenzene 3.88  -  -  3.92 
29 26.207 CHEXONE 55, 42, 
98 
cyclohexanone 2.11  20.23  12.83  8.99 
32 33.450 TTDECANE 57 tetradecane 21.92  -  -  - 
33 33.598 CHEXOL 57, 82 cyclohexanol -  99.42  74.31  210.4 
34 35.176 B13DMEBNZ 175, 190 1,3-bis(1,1-
dimethylethyl)-benzene 
4.56  9.42  7.22  31.67 
36 39.305 E2HEXOL1 57, 43 2-ethyl-1-hexanol 28.32  950.78  184.81  1803.82 
38 41.341 BNZAL 106, 77 benzaldehyde 2.81  -  -  - 
45 48.761 ACTPONE 105, 77 acetophenone 4.44  -  -  - 
47 53.752 NPTENE 128 naphthalene 3.60  3.80  3.70  5.61 
54 70.775 PHOL 94 phenol 3.93  3.35  3.96  5.48 
60 79.610 DT24BPHOL 191 2,4-di-tert-butylphenol 51.57  73.53  71.04  160.00 
 
From these VOMs, 13 were found to be common in all studied breast cells (both normal and 
cancerous), 5 were present only in normal breast cells (HMEC), and 2 compounds were identified 
only in the MCF-7 breast cell line. As can be observed in Figure 3.3.2, the MCF-7 cell line 
demonstrated the most complex volatile metabolomic signature in terms of number of the identified 
VOMs and total GC peak areas compared with the other cell lines. Moreover, for all BC cell lines, 
the major chemical group identified was the higher alcohols, represented mainly by 2-ethyl-1-hexanol 
and cyclohexanol. These VOMs have already been reported in previous studies using BC cell lines 
[124,206] and in urine [127,128] from cancer patients. It is believed that their endogenous origin is  
as hydrocarbon metabolism byproducts [204,207]. The obtained data indicated that the levels of both 
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VOMs (2-ethyl–1-hexanol and cyclohexanol) were higher in all investigated BC cells than HMEC. 
This might be due to the production of lipid peroxidation biomarkers with hydroxylase that are 
mediated by cytochrome P450 [199,206]. 
 
Figure 3. 3. 2 - Distribution of VOMs identified in cultured breast cell lines. 
Similar results were reported by Peled and collaborators [208] when studying genetic mutations 
in lung cancer cells, and by Davies and collaborators [209], who compared the volatile  profile from 
the headspace of lung cancer cells with genetic mutations in TP53 and KRAS. Most of the identified 
VOCs were common to all BC cell lines and normal human mammary epithelial cells, but six of them, 
2-pentanone, 2-heptanone, 3-methyl-3-buten-1-ol, ethyl acetate, ethyl propanoate, and 2-methyl 
butanoate, were detected only in BC cell lines. This finding justifies a more detailed investigation to 
evaluate of these six VOMs as BC biomarkers. 
 
The influence of pH on the VOMs identified from culture media 
The pH is one of the parameters that influences the extraction efficiency of VOMs and therefore 
it is required an optimization step. This was accomplished by the assessment of volatiles from culture 
media at different pH. We evaluated the effect of pH on the volatile signature obtained from culture 
media. At pH 2, the MCF-7 cells had the highest total GC peak area with acids (hexanoic acid, 
octanoic acid and 2-ethyl-hexanoic acid) being the most dominant chemical group. Aldehydes 
(benzaldehyde and 3,4-dimethyl-benzaldehyde) were the most predominant chemical group in the T-
47D and MDA-MB-231 cells (Figure 3.3.2; Table 3.3.2). At pH 7, for MCF-7 cells, alkanes, ketones 
and alcohols were found the dominant chemical groups, which were represented by dodecane, 2-
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most representative chemical group. Finally, at pH 10 the main chemical group identified for MCF-
7 cells were alkanes, ketones and alcohols (2-ethoxy-2-methyl-propane, acetone and 2-ethyl-1-
hexanol). For T-47D and MDA-MB-231 cells, alcohols represented by cyclohexanol, presented the 
major contribution. As previously mentioned, it is believed that cancer cells have altered metabolisms 
leading to different volatile metabolomic patterns. This was observed in our study, where we 
identified some differences between BC cell lines and normal cells (Table 3.3.2). 
 
Figure 3. 3. 3 - Distribution by chemical families of VOMs identified in culture media at different pH 
conditions of breast cell lines. 
Several VOMs were found to be common in all breast cell lines for all conditions, including, 2-
ethoxy-2-methyl-propane, acetone, 2-methyl-2-propanol, cyclohexanol, 1,3-bis(1,1-dimethylethyl)-
benzene and 2-ethyl-1-hexanol which had higher levels in BC cells. Ethyl acetate was only present 
in the T-47D cell line (Table 3.3.2). Kwak and collaborators [205] described a similar study using 
melanoma cells and identified higher concentrations of acetone in cancer cells. The metabolomic 
origin of most VOMs is still unknown, as they rely on a variety of endogenous pathways and 
exogenous sources. Huang and collaborators [206] reported that cyclohexanol and 2-ethyl-1-hexanol 
had lower concentrations in BC cells and suggested that they were generated by endogenous 
hydrocarbon metabolism. Hydrocarbons can be metabolized to aldehydes or ketones in the body via 
alcohol dehydrogenase (ADH) and cytochrome P450 activities [199]. The higher activity of 
cytochrome P450 may explain why BC cell lines have less cyclohexanol than normal breast cells 
[206]. It can also induce a variety of biological responses, including the biotransformation of alkanes, 
alkenes and aromatic compounds [210]. Furthermore, Philips et al. suggested that breast diseases are 
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ethyl-1-hexanol was found at higher levels in BC cells than in to normal cells. According to the human 
metabolome database, 2-ethyl-1-hexanol is involved in cell signaling, membrane integrity/stability 
and energy storage and it was also detected in lung cancer cell lines [152] at increased levels when 
compared with the medium. At pH 10, the levels for most of the VOMs were higher in BC cells than 
in normal breast cells, including those of acetone, 2-pentanone, cyclohexanol, 2-ethyl-1-hexanol and 
acetophenone.  
 
PCA and PLS-DA analyzes of VOMs 
To verify the significance of the identified VOMs from the headspaces of the culture flasks and 
the cell culture media at different pH conditions, a one-way ANOVA test was applied to analyze the 
data matrix. From the identified VOMs, a total of 23 (from cultured flask headspace), 52 (from culture 
media at pH 2), 34 (from the culture media at pH 7) and 43 (from the culture media at pH 10) showed 
significant differences (p < 0.05) (Figure 3.3.4).  
Principal component analysis (PCA) was performed for each condition to identify variables to 
differentiate the VOMs pattern of the HMEC cells from those of the BC cell lines (MCF-7, T-47D 
and MDA-MB-231 cells), and from the VOMs patterns obtained from the culture media at different 
pH values (Figure 3.3.5). The differentiation between the above conditions was shown as the loading 
scores plot of the two principal components of the PCA. The PCA analysis is an unsupervised 
projection method used to visualize the dataset that displays the similarities and differences between 
groups and, in this case, demonstrated that the variables (scaled by standard deviation) used were 
sufficient to describe subsets with similar characteristics. These results demonstrated that the scores 
from the cancer cell lines and those from the normal breast cells exhibited separate trends in the plots. 
Figure 3.3.5 A shows the loading scatterplots of the PCA obtained from the analysis of the VOMs in 
the headspace of cultured flasks. It can be observed that 3 groups were formed, where HMEC cells 
was clearly differentiated from BC cell lines, which showed greater differentiation from MCF-7 cell 
lines across the PC1 and from T-47D and MDA-MB-231 across the PC2. Interestingly, BC cell lines 
formed two separated groups according molecular subtype (luminal A versus triple negative). 
However, no differentiation was achieved between T-47D and MDA-MB-231 cell lines, which 
formed a single group, perhaps this grouping of the two cell lines might be due to the fact that they 
have similar molecular characteristics. The variables that explain the differentiation between cell lines 
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Figure 3. 3. 5 - (A) Separation of breast cancer cell lines and normal cells based on PCA scores 
scatter plot and (B) Lineplot of principal component values obtained using selected compounds by 
significance of one-way ANOVA (p ˂ 0.05) obtained from the analysis of 4 types. 
The PCs values of MCF-7 cell lines were influenced by most of variables used in this test. On the 
other hand, PCs values of T-47D and MDA-MB-231 cell lines were highly influenced by 
cyclohexanone, 1,2,4-trimethylbenzene, ethylbenzene and 1,3-dimethylbenzene for PC1, and by 
cyclohexanone for PC2. The HMEC cells were influenced by 4-methyl-heptane, tetradecane, 
benzaldehyde and acetophenone for PC1 values, and by 1,2,4-trimethylbenzene, ethylbenzene, 1,3-
dimethylbenzene and phenol for PC2 values. 
Concerning the other tested conditions, the loading scatterplots of the PCA obtained from the 
analysis of VOMs from cell culture media at pH 2, pH 7 and pH 10, and respective influence of 
variables, are showed in Figure 4.3.6. Surprisingly, four groups were formed encompassing all breast 
cell lines in study under pH 2 and pH 7, where MCF-7 was differentiated from other cell lines mainly 
across PC1, while HMEC, T-47D and MDA-MB-231 were differentiated from each other through 
PC2. Under pH 10, the pattern of differentiation between cell lines is similar to obtained for 
headspace, in which 3 groups (HMEC, T-47D/MDA-MB-231 and MCF-7) were formed. The 
differentiation between cell lines obtained under pH 2 and pH 7 may be due to the alterations of 
molecular components released under more acidic conditions than those normally present in the 
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Figure 3. 3. 6 - (A) Loadings of variables on the PC1 × PC2 plane of culture media at different pH 
conditions and (B) Biplots of data obtained from different conditions using selected compounds by 
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However, for differentiation and discrimination between normal breast cell lines and oncological 
breast cell lines based on the VOMs emitted as close to reality as possible in human cell tissues, 
partial least squares analysis (PLS) and linear discriminant analysis (LDA) were performed only with 
data from headspace of cell cultures. The statistical data summary of PLS and LDA are described in 
Tables 3.3.3 and 3.3.4, respectively. 
 
Table 3. 3. 3 - Statistical data summary of Partial Least Square Analysis. 
PC R²X R²X(Cumul.) Eigenvalues R²Y R²Y(Cumul.) Q² Q²(Cumul.) Significance Interations 
1 0.561557 0.561557 14.60037 0.14286 0.14286 -0.03171 -0.03171 S 9 
2 0.306333 0.867891 7.96463 0.14286 0.28571 -0.05208 -0.08543 NS 7 
 
Table 3. 3. 4 - Statistical data summary of Linear Discriminant Analysis. 
Function Eigenvalue Canonical R Wilk's Lambda Chi-Sqr. df p-value 
1 111309.5 0.999996 1.34E-08 81.56097 4.000000 1.11E-16 
2 667.2 0.999251 1.50E-03 29.27062 1.000000 6.29E-08 
 
Sample classification by PLS showed that the differentiation between cell lines was explained 
through one single component. PLS loading lineplot are presented in Figure 3.3.7, which can be 
observed four centroids corresponding to each cell lines. 
 
Figure 3. 3. 7 - (A) Partial Least Square Analysis (PLS) scatter plot and (B) Lineplot of selected 
compounds by significance of one-way ANOVA (p ˂ 0.05) obtained from the analysis of 4 types of 
breast cell lines using cultured headspace analysis. 
Similar to obtained in the PCA, HMEC centroid was clearly differentiated from oncologic breast 
cell lines, and MCF-7 (triple negative type) was distinguished from two luminal A type cell lines. On 




















































































































































































































































110 Catarina Silva (2019) 
0.0588 and 0.0037, respectively. Regarding the influence of variables on PLS values of cell lines, 
HMEC was highly influenced by 4-methyl-heptane, tetradecane, benzaldehyde and acetophenone, T-
47D and MDA-MB-231 were influenced by cyclohexanone, 1,2,4-trimethylbenzene, ethylbenzene 
and 1,3-dimethylbenzene, and MCF-7 was influenced by the remaining VOMs. 
The linear discriminant analysis (LDA) was applied as a supervised pattern recognition method in 
order to discriminate statistically the cell lines under study, where samples were grouped according 
to molecular type as follows: N (HMEC), BL (T-47D and MDA-MB-231) and BTN (MCF-7). The 
LDA scatterplot of cell lines classification according to canonical functions were showed in Figure 
3.3.8.  
 
Figure 3. 3. 8 - (A) Linear discriminant analysis (LDA) scatter plot of cultured headspace from breast 
cell samples (B) Classification of breast cells according to the canonical discriminant functions. 
Legend: BL-breast luminal; N- normal; BTN- breast triple negative. 
The cell lines samples formed three clearly defined groups with a classification rate of 100%. 
Recognition ability, calculated as the percentage of members of the data set that were correctly 
classified, and prediction ability, calculated as the percentage of members that were correctly 
classified, were 100% in all cases. After applying LDA with backward removal (p ˂ 0.05) of 
variables, only two VOMs proved to be significant for discrimination between three defined 
previously, namely 1,2,4-trimethylbenzene and benzaldehyde. These compounds have been already 
identified in cancer cell studies by Brunner et al. [212] using PTR-MS, by Filipiak et al. [152] in lung 
cancer cells and Mochalski et al. [213] with human hepatocellular carcinoma cells where it was 
observed an increase in the release of this compound. Moreover, these two VOMs appear to be 
promise biomarkers due to fact that achieve a successful discriminant classification of samples 
according to molecular type of breast cell lines, demonstrating that volatile metabolomic signature of 
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Conclusions 
This study demonstrated that HS-SPME/GC-MS is a simple, rapid, sensitive and solvent-free 
method that can be used to establish the volatile metabolomic patterns of normal and cancer breast 
cells. In addition, this study showed the potential of screening the in vitro VOMs associated with BC 
to identify potential volatile biomarkers to be used in early diagnosis. The headspace of culture media 
of normal and cancer cell lines was analyzed at different pH conditions. Sixty VOMs were identified 
as belonging to several chemical groups: namely, alkanes, aldehydes, ketones, acids, alcohols and 
benzene derivatives. Most of the identified VOMs are common to all BC cell lines and normal human 
mammary epithelial cells, but six of them, 2-pentanone, 2-heptanone, 3-methyl-3-buten-1-ol, ethyl 
acetate, ethyl propanoate, and 2-methyl butanoate, were detected only in the headspace of cancer cell 
lines. Multivariate statistical data obtained in this study revealed that combining in vitro assays with 
HS-SPME/GC-MS is a useful strategy to differentiate and discriminate the volatile metabolomic 
signature of normal cells and BC cell lines according to molecular type, thus contributing to the 
discovery of novel biomarkers of BC and investigations of the related metabolomic pathways, and 
thereby improving the diagnostic tools for BC. 
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3.4| Volatomic pattern of breast cancer and cancer-free 
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Abstract 
BC is ranked as the fifth amongst all cancers, remains at the top of women’s cancers worldwide 
followed by colorectal, lung, cervix, and stomach cancers. The main handicap of most of the 
screening/diagnostic methods is based on their low sensitivity and specificity and the invasive 
behavior of most sampling procedures. The aim of this study was to establish the volatomic pattern 
of BC and cancer-free (CF) tissues (n = 30) from the same patients, as a powerful tool to identify a 
set of volatile organic metabolite (VOM) potential BC biomarkers which might be used together or 
complement with the traditional BC diagnostics strategies, through the integration of 
chromatographic data, obtained by solid-phase microextraction followed by gas chromatography-
mass spectrometry (SPME/GC-qMS), with chemometric tools. A total of four metabolites: limonene, 
decanoic acid, acetic acid and furfural presented the highest contribution towards discrimination of 
BC and CF tissues (VIP > 1, p < 0.05). The discrimination efficiency and accuracy of BC tissue 
metabolites was ascertained by ROC curve analysis that allowed the identification of some 
metabolites with high sensitivity and specificity. The results obtained with this approach suggest the 
possibility of identifying endogenous metabolites as a platform to find potential BC biomarkers and 
pave the way to investigate the related metabolomic pathways in order to improve BC diagnostic 
tools. Moreover, deeper investigations could unravel novel mechanistic insights into the disease 
pathophysiology. 
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Introduction 
BC is ranked as the fifth amongst all cancers remaining at the top of women´s cancers worldwide 
followed by colorectal, lung, cervix, and stomach cancers according to IARC, contributing with more 
than 11.6 % of all cancers [3]. Although BC is a multifactorial disease, with highly variable clinical 
behavior and response to therapy, it can be curable in early stages. Furthermore, there is still the need 
for the development of new methodologies to aid or monitor the disease together with the current 
diagnostic tools, namely mammography, ultrasound or tumor markers. Moreover, before BC 
treatment, a complex and time-consuming analysis is required that uses many different assays, such 
as the determination of histological type and grading, evaluation of estrogen receptor (ER), 
progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER-2), among others 
[122]. The main handicap of most of these screening/diagnostic methods is their low sensitivity and 
specificity and the invasive procedure required to obtain the samples [123]. Taking into account these 
aspects, research is being directed towards the use of new tools that can support the clinicians in BC 
treatment and follow-up [124]. In this sense, in recent years, metabolomic studies have emerged as a 
powerful tool to investigate the changes and/or metabolic responses of living systems to stimuli or 
genetic modifications [39]. The metabolome profile represents the unbiased quantitative and 
qualitative analysis of the complete set of metabolites present in cells, body fluids and/or tissues 
[125]. To date, beyond the most used biological specimens (e.g., urine, saliva, blood), BC tissues 
have been used in metabolomics with the aim of discriminating cancer from normal tissues suggesting 
that metabolomic profiles differ within molecular subtypes of BC [66,214]. The metabolome 
coverage in BC tissues can be maximized by combining different technologies for metabolic 
profiling, namely gas chromatography mass-spectrometry (GC-qMS), and the results can be used to 
classify BC helping to identify new prognostic and predictive markers and to discover new targets 
for future therapeutic interventions [126]. Among them, the study of volatile organic metabolites 
(VOMs) present in biological samples, namely in saliva, urine, breath and tissues can be useful for 
cancer diagnosis, in particular for BC. The most common procedure used in extraction of volatile 
compounds in biological samples is solid-phase microextraction (SPME), normally in headspace 
mode (HS-SPME) being used in several biologic matrices [44,59,127,128]. GC-qMS was used to 
screen salivary volatiles for putative BC as an exploratory study involving geographically distant 
populations [51], also to establish the metabolomic signature of human BC cell lines [44] and to 
discriminate different types of cancer based on urinary volatomic biosignatures [59]. In the first study, 
up to 120 VOMs from distinct chemical families, with significant variations among the groups, were 
identified [51], whereas Silva et al. [44] and Porto-Figueira et al. [59] identified 60 and 130 VOMs 
in BC cell lines and urine, respectively. On the other hand, Budczies et al. [77,82] used gas 
 
 
118 Catarina Silva (2019) 
chromatography time of flight mass spectrometry (GC-TOFMS) framework to evaluate the glutamate 
enrichment as a new diagnostic opportunity in BC and to accomplish  comparative metabolomics of 
estrogen receptor positive (ER+) and estrogen receptor negative (ER-) samples. Budczies et al. [82] 
identified 19 VOMs and the GC–TOFMS based analysis of metabolites present in BC tissues revealed 
significantly differences in central metabolism in the more aggressive ER− compared to the ER+ type. 
The detected changes included the metabolism of glutamine with a decrease in concentration of 
glutamine and an increase in concentration of glutamate and 2-hydroxyglutaric acid [82]. In turn, 
Dougan et al. [66] used GC-MS to evaluate the detectability, reliability, and distribution of 
metabolites measured in pre-diagnostic plasma samples in a pilot study of women listed in the 
Northern California site of the BC Family Registry. In this study, 661 VOMs were detected, 338 (51 
%) of them were found in all samples, and 490 (74 %) in more than 80 % of samples. The aim of this 
study was to establish the volatomic pattern of BC tissue and CF tissue samples collected after 
surgery, from the same patient (to minimize the interference of epigenetic and external factors) in 
order to find a set of volatile metabolites to be used as potential BC biomarkers, using HS-SPME/GC-
qMS combined with multivariate statistical tools. This high-throughput strategy might have the 
potential to be applied in a clinical environment as a diagnostic approach or as a complementary way 
with the current diagnostic methods to improve the diagnostic decision. 
 
Materials and Reagents 
Reagents and materials 
Sodium chloride (NaCl), hydrochloric acid (HCl) and 4-methyl-2-pentanol were supplied by 
Panreac (Barcelona, Spain) and Sigma Aldrich (St. Louis, MO, USA), respectively. Phosphate buffer 
saline (PBS) was also purchased from Sigma-Aldrich (St. Louis, MO, USA). The C8-C20 alkanes 
solution (concentration of 40 mg/L in n-hexane) was purchased from Fluka (Buchs, Switzerland). 
The digital stirring plate (Cimarec™) was supplied by Thermo Scientific (Waltham, MA, USA) while 
SPME holder for manual sampling and 75 µm carboxen/polydimethylsiloxane fiber (CAR/PDMS) 
were purchased from Supelco (Bellefonte, PA, USA). 
 
Subjects and tissue collection 
To investigate the BC tissue metabolomic profile, 30 samples from patients with breast cancer 
(BC, n=30, age range 44-85, average 67), and 30 samples from cancer-free tissue (CF, n=30, age 
range 44-85, average 67) without malignant infiltration were resected from each patient. The resected 
samples were divided into the active carcinoma and cancer-free tissue outside the tumor margin and 
were immediately frozen in liquid nitrogen, in a total set of 60 samples. The tissues were stored at -
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80°C until extraction. These samples were obtained at the Pathologic Anatomy Unit of Hospital Dr. 
Nélio Mendonça (Funchal, Portugal) according to Table 3.4.1. 
 
Table 3. 4. 1 - List of collected tissue samples from breast cancer patients and CF individuals. 
Samples BC tissue Cancer-free 
Number 30 30 
Age (range, median) (44-85, 65) (44-85, 65) 










All experiments were performed in accordance with the standard Guidelines from Declaration of 
Helsinki and approved by the institutional ethics committee of Hospital Dr Nélio Mendonça and 
University of Madeira. All the participants of this study were informed about the investigation and a 
signed informed consent was obtained from all human participants prior to sample collection. Using 
the TNM (tumor, node, and metastasis) staging approach, the examined BC cases included five of 
stage IA, ten of stage IIA, one of stage IIIA B, seven of stage IIB, five of stage IIIB and two of stage 
IIIC. 
 
Extraction of metabolites from breast tissues 
The HS-SPME extraction conditions were based on a developed method previously established in 
our laboratory [127,128]. Briefly, tissue samples were thawed and then portions of 100 mg were 
weighted into 20 mL vials together with 17 % NaCl (w/v), 1000 µL of ultrapure water and 100 µL of 
the internal standard (IS, 4-methyl-2-pentanol, 1.6 mg/L). The pH was adjusted to 2 with small 
amounts of HCl 5M. Then, the vial was capped with a Teflon (PTFE) septum using a screw cap and 
the SPME fiber was introduced and exposed into the headspace during 75 min at 50 °C at 800 rpm 
(0.5 mm × 0.1 mm bar). After this period, the fiber was removed from the vial and inserted into the 
GC injection port and VOMs extracted were desorbed for 10 min at 250 °C. Each sample was 
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Gas chromatography quadrupole mass-spectrometry (GC-qMS) conditions 
After the extraction procedure, the SPME fiber with the analytes was inserted into the injection 
port of an Agilent Technologies 6890N Network gas chromatograph system (Palo Alto, CA, USA) 
where the VOMs were desorbed at 250 °C for 10 min. The gas chromatograph was equipped with a 
60 m × 0.25 mm I.D.× 0.25 µm film thickness, BP-20 (SGE, Dortmund, Germany) fused silica 
capillary column and interfaced with an Agilent 5975 quadrupole inert mass selective detector. The 
following oven temperature profile was set: (a) 5 min at 45 °C; (b) increase temperature until 150 °C, 
at a rate of 2 °C min−1 (hold for 10 min); (c) 150 °C for 10 min; (d) increase temperature until 220 
°C, at a rate of 7 °C min−1; and (e) 220 °C for 10 min for a total GC run time of 87.5 min. The column 
flow was constant at 1.3 mL min−1 using Helium (He, N60, Air Liquide, Portugal) as carrier gas. The 
injection port was operated in the splitless mode and held at 250 °C. For the 5975 MS system, the 
operating temperatures of the transfer line, quadrupole and ionization source were 270, 150 and 230 
°C, respectively, while electron impact mass spectra were recorded at 70 eV ionization voltage and 
the ionization current was 10 µA. Data acquisition was performed in the scan mode (30–200 m/z). 
The electron multiplier was set to the auto tune procedure. Metabolites identification was 
accomplished by manual interpretation through single ion monitorization (SIM) of spectra and 
matching against the Agilent MS ChemStation Software, equipped with a NIST05 mass spectral 
library with a similarity threshold higher than 80% and comparison with commercially available 
standard samples when available. A series of C8–C20 n-alkanes were analyzed using the same 
extraction procedure to establish the kovat indices (KI), and to confirm the identity of the VOMs by 
comparison with the literature. The analyzes were performed in triplicate and the results expressed 
by mean ± standard deviation.  
 
Statistical Analysis 
Statistical analysis was performed using the web server Metaboanalyst 4.0 [134]. The multivariate 
statistical analysis, namely the principal component analysis (PCA), the partial least squares-
discriminant analysis (PLS-DA) and the orthogonal projections to latent structures discriminant 
analysis (OPLS-DA) were applied on tissue metabolomic profile dataset to provide insights into the 
groups under study. The metabolites with VIP scores higher than 1.0 were selected by the PLS-DA 
analysis as well as for the pathway analysis. Furthermore, hierarchical cluster analysis by K-means 
of the two groups in study was carried out and Pearson´s correlation was used to build the heat map 
with the aim of identifying BC clustering patterns. Moreover, Random forest (RF) classification was 
carried out to determine the ability of VOMs to accurately classify the study subjects into their 
corresponding groups. The receiver operating characteristic curves (ROC) were attained to verify 
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which metabolites had the highest sensitivity/specificity for a potential BC diagnosis. Finally, the 
selected metabolites were used for the metabolic pathway analysis to identify the most relevant 
metabolic pathways involved in BC. 
 
Results and Discussion 
Tissue metabolomic pattern based on GC-qMS 
A total of twenty-nine VOMs were identified in BC tissue and CF tissue samples which were 
classified in several chemical families, namely phenols, benzene derivates, carbonyl compounds, 
acids, alcohols and furanic compounds as presented in Figure 3.4.1. 
 
Figure 3. 4. 1 - Major chemical families identified in BC and CF tissue samples. Legend: BD-benzene 
derivates; CC-carbonyl compounds; Alc-alcohols; FC-furanic compounds. 
Data was processed using software (NIST, 2005; Mass Spectral Search Program V.2.0d) which 
provides quality matching using advanced spectral matching algorithms background subtraction and 
KI comparison. The KI were determined through the injection of a C8-C20 alkane solution in order to 
confirm the identity of the VOMs by comparison with the literature (e.g., pherobase). It can be 
observed in Table 3.4.2 that the KI of the identified VOMs, when compared to the ones found in 
literature for a similar column (BP-20), are closer to one another, ensuring that a good identification 
was achieved. The highest contribution for the volatile profile was from phenols in the BC group, 
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families were phenol, toluene and acetic acid, respectively. These metabolites were already identified 
in several reports in literature in biological matrices such as urine [127,128], cancer cell lines 
[44,135], saliva [51], and exhaled breath [135,136]. In Table 3.4.2 is represented the identification of 
VOMs, as well as the minimum and maximum relative GC peak areas for each metabolite and group. 
It can be observed that most metabolites were identified in all samples with a frequency of 
occurrence (FO) higher than 90 %, where the maximum relative area was obtained for p-tert-butyl-
phenol in the CF group and phenol for the BC group. For the CF group, the major VOMs identified 
include acetic acid, phenol and p-tert-butyl-phenol. 
Some of these have been already reported in literature, namely acetic acid was found as 
discriminant when associated with CTL in a study conducted by Ahmed et al. [137] that investigated 
the possibility of faecal VOMs as potential diagnostic biomarkers for inflammatory bowel disease. 
Mochalski et al. [206] investigated the emission of volatile compounds from gastric cancer tissues 
and non-cancerous tissues with the aim of identifying characteristic chemical patterns associated with 
gastric cancer. 
Furthermore, Silva et al. [127,128] also reported phenols as the major chemical family identified 
in urine from the oncologic group. Furthermore, Raman et al. [138] studied faecal VOMs in obese 
humans and identified also acetic acid and phenol as major metabolites. On the other hand, Priscilla 
et al. [59] also identified p-xylene, o-xylene, acetic acid, phenol and p-tert-butyl-phenol in urine from 
cancer patients, with some of them presenting higher values in cancer patients. Regarding the relative 
area values obtained for the BC group, most VOMs were down-regulated with exception of acetic 
acid, toluene, octanal and nonanal.  
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Table 3. 4. 2 - Identified metabolites in tissue samples from BC patients and cancer-free (CF) through GC-qMS, minimum (Min) and maximum (Max), 
variation of relative peak areas (relative to internal standard, RSD<10%)regarding to BC group and their frequency of occurrence FO (in %). 
Identification mode and the Kóvats index for each identified VOM and the literature values for a similar GC column. 
Peak n. IECa 
RT 
(min)b 
IDc KIcald KIlite VOMf 
Relative GC Peak Areas 
Variation FO (%) CF BC 
Min Max Min Max 
A1 41, 69 9.77 MS 990 983 methyl isobutyrate 0.03 1.81 0.02 1.66 ↓ 71 
A2 91 11.24 Std, MS 1029 1042 toluene 0.03 7.62 0.01 17.17 ↑ 100 
A3 44, 56 13.12 Std, MS 1073 1075 hexanal 0.03 6.82 0.04 2.09 ↓ 99 
A7 41, 70 18.48 Std, MS 1172 1168 heptanal 0.04 0.17 0.05 0.19 ↑ 13 
A8 68, 93 18.73 Std, MS 1176 1198 limonene 0.01 4.46 0.01 1.03 ↓ 92 
A10 43, 33 19.84 Std, MS 1187 - 2-methyl-1-propanol 0.01 1.44 0.01 0.51 ↓ 79 
A11 81 20.69 MS 1197 1229 2-pentyl-furan 0.01 0.07 0.01 0.13 ↑ 77 
A12 105, 120 21.39 MS 1209 - trimethylbenzene 0.01 5.41 0.01 1.70 ↓ 64 
A13 119, 134 23.18 Std, MS 1237 1234 o-cymene 0.01 0.84 0.01 0.33 ↓ 24 
A14 42, 55 24.36 MS 1254 1255 1-pentanol 0.01 0.03 0.01 0.23 ↑ 50 
A15 43, 56 24.90 Std, MS 1262 1280 octanal 0.01 0.24 0.01 9.19 ↑ 34 
A16 56 30.20 Std, MS 1338 1360 1-hexanol 0.01 0.05 0.01 1.17 ↑ 27 
A17 41, 57 31.89 Std, MS 1362 1385 nonanal 0.02 0.48 0.17 2.36 ↑ 52 
A18 117, 132 34.45 MS 1396 - p-cymenene 0.01 0.76 0.01 0.15 ↓ 100 
A19 43, 60 36.42 Std, MS 1428 1450 acetic acid 0.62 42.75 0.10 12.28 ↓ 100 
A20 96 36.61 Std, MS 1431 1455 furfural 0.01 5.87 0.04 18.03 ↑ 100 
A21 57 38.53 Std, MS 1461 1487 2-ethyl-1-hexanol 0.01 0.50 0.01 3.20 ↑ 2 
A22 43, 57 38.77 Std, MS 1465 1484 decanal n.d.g n.d. 0.14 0.15 - 72 
A23 77, 106 39.81 Std, MS 1480 1495 benzaldehyde 0.01 0.36 0.01 0.33 ↓ 54 
A24 41, 56 42.63 MS 1525 1553 1-octanol 0.01 0.17 0.01 1.57 ↑ 74 
A25 77, 105 47.36 MS 1602 1607 acetophenone 0.01 0.19 0.01 0.42 ↑ 79 
A26 60, 73 58.70 Std, MS 1802 1829 hexanoic acid 0.01 1.25 0.02 5.77 ↑ 100 
A27 94 69.54 Std, MS 1968 1965 phenol 0.51 23.32 0.45 44.08 ↑ 39 
A28 60, 73 72.22 Std, MS 2004 2013 octanoic acid 0.01 0.25 0.01 6.51 ↑ 76 
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Peak n. IECa 
RT 
(min)b 
IDc KIcald KIlite VOMf 
Relative GC Peak Areas 
Variation FO (%) CF BC 
Min Max Min Max 
A29 107 73.00 MS 2009 2017 4-methyl-phenol 0.01 1.08 0.01 3.72 ↑ 45 
A30 60, 73 75.65 Std, MS 2027 - nonanoic acid 0.01 0.18 0.01 0.64 ↑ 29 
A31 155, 170 75.71 MS 2027 - 1,6,7-trimethyl-naphthalene 0.02 0.41 0.01 0.37 ↓ 39 
A32 60, 73 78.15 Std, MS 2043 - decanoic acid 0.01 0.11 0.02 0.52 ↑ 100 
A33 135, 150 78.49 Std, MS 2045 - p-tert-butyl-phenol 0.02 53.76 0.03 20.71 ↓ 100 
a IEC - ion extraction chromatogram; b Retention time (min); c metabolite identification using a standard compound (St) or mass spectra of the NIST library search (MS); d Kovat index relative n-
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Multivariate statistical analysis of tissue metabolomic profile 
The statistical analysis was performed using the Metaboanalyst 4.0 [134] web server as described 
in the experimental section. Only the VOMs with FO higher than 90 % were considered for the 
statistical analysis, in a total of 8 VOMs (toluene, hexanal, limonene, p-cymenene, acetic acid, 
furfural, hexanoic acid and decanoic acid). Initially, data were transformed by log transformation and 
mean centering approaches, before being subjected to multivariate statistical analysis. Partial least 
square-discriminant analysis (PLS-DA) was used as a supervised clustering method to verify the 
existence of an altered metabolite pattern. Additionally, this type of statistical analysis takes into 
account the variance/covariance between samples of groups where the samples are classified into 
different groups. Regarding the results obtained, a good discrimination was achieved (80.5 %, total 
variance) between BC and CF tissue samples suggesting the occurrence of characteristic metabolic 
alterations in the groups under study (Figure 3.4.2 A). Then, the top four metabolites (limonene, 
decanoic acid, acetic acid and furfural) with the highest contribution for group discrimination were 
selected with variable importance in projection (VIP > 1) (Figure 3.4.2 B). 
 
Figure 3. 4. 2 - (A) Loading score plots of PLS-DA and (B) VIP scores of tissue samples from BC and 
CF subjects. For identification please see Table 3.4.2. 
Moreover, orthogonal partial least squares-discriminant (OPLS-DA) analysis was applied on 
tissue metabolomic profile dataset to maximize the separation of BC and CF groups. Significant group 
separation was observed in OPLS-DA score plot between BC patients and CF group indicating 
intrinsic metabolic alterations in each group (Figure 3.4.3 A). To attest the robustness of the model, 
a random permutation test with 1000 permutations was performed with OPLS-DA (Figure 3.4.3 B). 
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ability) as 0.691 indicating that the model is not over fitted and have a relative good predictive ability 
to distinguish between study groups.  
Although in literature there are no reports regarding the volatile profile of human tissues, many of 
these metabolites were already identified in previous reports, namely in lung [150,186], breast, 
ovarian [123,144], bladder [187], and gastric cancers [188]. The OPLS-DA uses class information 
allowing to show which variables are responsible for class discrimination using the predictive 
information of the first component. The main advantage of OPLS-DA when compared to PLS-DA is 
that a single component is used as a predictor for the class, while the other components describe the 
variation orthogonal to the first predictive component [139]. 
 
 
Figure 3. 4. 3 - (A) Loading score plots of OPLS-DA and (B) model validation by permutation test 
based on 1000 permutations of VOMs obtained by GC-qMS of tissue samples from the 2 groups under 
study. 
To further evaluate the predictive value of the metabolites to discriminate between BC patients 
and CF, a receiver operating characteristic curve (ROC) analysis was generated using the top four 
metabolites identified by VIP values (Figure 3.4.4 A and B). This type of analysis is used for the 
classification of true positives and false positives and the predictive ability is measured using the area 
under the curve (AUC) [140,141]. According to Xia et al. [108], an AUC between 0.9 - 1.0 is excellent 
and between 0.8 – 0.9 is good. Based on this classification, the results obtained were, thus, very good 
(AUC = 0.966). 
ROC curves were generated by Monte-Carlo cross validation (MCCV) using balanced sub-
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importance. The top 3 important features were then used to build classification models which were 
then validated on 1/3 of the samples that were left out. This procedure was repeated multiple times to 
calculate the performance and confidence interval of each model. The AUC can be interpreted as the 
probability that a randomly selected diseased subject is ranked as more probable to be diseased than 
a randomly selected healthy subject [108]. A greater AUC value indicates the effectiveness to separate 
the CF group from the cancer group (BC). 
 
Figure 3. 4. 4 - ROC curves for the predictive model. (A) A combination metabolites model calculated 
from the logistic regression analysis using the 4 metabolites selected by the VIP (> 1.0) values, (B) 
ROC curve for the top 4 metabolites (limonene, decanoic acid, acetic acid and furfural) with highest 
ability to discriminate BC patients against the CF. 
Additionally, a 10-fold cross validation was used to generate a logistic regression model and the 
performance was calculated according to the equation: 
 
log it (P) = log (P/(1 – P)) = – 0.077 + 0.966 limonene – 0.752 acetic acid – 0.076 furfural – 
decanoic acid 
 
where P is Pr(y = 1|x). The threshold (or cut-off) for the predicted P was 0.61. Figure 3.4.5 A and 
B show the results obtained for the predicted probabilities using the OPLS-DA model and the average 
of the predictive accuracy for the same model, where it can be observed that the model allowed a 
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Figure 3. 4. 5 - (A) Plot of the predicted class probabilities for all samples using the OPLS-DA 
biomarker model based on AUC and (B) box plot of the predictive accuracy (with an average of 
0.908) of the biomarker model based on 100 cross validations. 
Moreover, 20 samples without known labels were processed together with the ones with known 
labels in order to obtain the probability of class labels. Most of the cases were classified in their 
respective groups with the exception of O10, O5 and O18 with a probability score ranging from 0.982 
to 0.595. 
Also, the heat map was constructed with selected VOMs by VIP > 1, using Pearson’s correlation, 




Figure 3. 4. 6 - Heat map visualization and hierarchical clustering analysis using the four metabolites 
with significance (p < 0.05) by Pearson’s distance analysis (A8 – limonene; A19 – acetic acid; A32 
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Finally, the metabolic pathway analysis (Figure 3.4.7 A) was performed in order to explore which 
pathways changed in BC. In Figure 3.4.7 B, we can observe the utmost important metabolomics 
routes producing the most significant volatile metabolites in BC (indicated by KEGG accession 
number). It can be observed that the pathway with highest impact was the pyruvate and sulfur 
metabolism due to acetic acid. This metabolite according to human metabolome database is normally 
found in most tissues (liver, kidney, among others) and in several biofluids, namely saliva [51] and 
urine [127]. Moreover, limonene was also included as a significant metabolite belonging to the class 
of monoterpenoids involved in monooxygenase activity through cytochrome P450 and the 
mevalonate pathway [215,216].  
 
Figure 3. 4. 7 - (A) The metabolome view map of significant altered metabolic pathways observed in 
tissue samples from BC and CF groups and (B) the pyruvate metabolism. The map was generated 
using reference map by KEGG; C00033 represent acetic acid. 
Based on the results obtained, a successful discrimination of tissue samples was achieved, 
according to the group showing that the volatomic tissue profile can be a useful approach to identify 
potential BC biomarkers. 
 
Conclusions 
This study has enabled the untargeted assessment of the metabolomic tissue profile from BC 
patients when compared with CF tissues using GC-qMS combined with multivariate statistical tools 
(PLS-DA and OPLS-DA). Twenty-nine metabolites were identified and multivariate statistical 
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analysis revealed some metabolites significantly altered in BC patients. Of the metabolites identified, 
limonene, decanoic acid, acetic acid and furfural showed the highest sensitivity and specificity to 
discriminate BC patients. Also, the analysis of the plots leads to a metabolomic pattern comprising 
an array of some biochemical pathways altered in BC patients. The metabolic pathway analysis 
indicated that the discriminatory metabolites could originate from several dysregulated pathways in 
BC such as those involved in pyruvate and sulphur metabolism, and limonene degradation. 
In addition, the analysis of cancer and non-cancer tissue from the same subject can also aid to 
balance the effect of external interferents, such as diet or environmental exposure and help to identify 
potential biomarkers. These results suggest a possibility of identifying endogenous metabolites as a 
platform to discover potential BC biomarkers and paves a way to investigate the related metabolomic 
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3.5| Integrated metabolomics based on GC-MS and NMR 
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Abstract 
BC is leading at the top of women´s diseases, and as a multifactorial disease, there is the need for 
the development of new approaches to aid clinicians on monitoring BC treatments. In this sense, 
metabolomic studies have become an essential tool allowing the establishment of interdependency 
among metabolites in biological samples. The goal is to capture the main changes and the overall 
physiological status in biochemical pathways to enlighten sites of perturbations in diseases, such as 
cancer. In this study, we used the combination of NMR and GC-qMS based metabolomic analyzes of 
urine and breast tissue samples from BC patients and cancer-free individuals. The data was processed 
using multivariate statistical tools to obtain a panel of metabolites (and their metabolic profiles) that 
can discriminate malignant from healthy status assisting in the diagnostic field. 
Tissue and urine samples were collected from BC patients (urine: n=31; tissue n=30) and cancer-
free (CF) subjects (urine n=40 tissue n=30) and analyzed by NMR and GC-qMS methodologies. The 
OPLS-DA model showed a clear separation between BC patients and controls for both class of 
samples. Namely, for urine samples, the goodness of fit was R2Y = 0.946 and predictive ability was 
Q2 = 0.910 while for tissue the R2Y = 0.888; Q2 = 0.813 had a good predictable accuracy. The 
discrimination efficiency and accuracy of BC tissue and urine metabolites was ascertained by ROC 
curve analysis that allowed the identification of some metabolites with high sensitivity and 
specificity. The metabolomic pathway analysis identified several dysregulated pathways in BC 
patients, including those related with pyruvate and glutamine metabolism. Moreover, possible 
correlations between urine and tissue metabolites were investigated and five metabolites were found 
significant using a dual platform approach. Overall, this study suggests that an improved metabolic 
profile combining NMR and GC-qMS may be useful to achieve more insights regarding the 
mechanisms underlying cancer. 
 








Catarina Silva (2019) 135 
Introduction 
Up to date, BC is leading at the top of women´s diseases, accounting with around 2.1 million cases 
diagnosed in 2018 and expected to increase 1.1 million by 2040, according to IARC [3]. Being a 
multifactorial disease, with highly variable clinical behavior and response to therapy, it can be curable 
when detected in early stages. Although the extensive investigation on new therapy targets and 
diagnosis, there is the need for the development of new approaches to aid clinicians to monitor BC 
treatments and follow-up together with the current diagnostic tools, namely mammography, 
ultrasound or tumor markers [124]. Nowadays, the available diagnostic tools have supported in BC 
early detection leading to the improved of survival rates. In this regard, metabolomics (metabolomic 
profiling) studies along with the related area of metabonomics emerged as powerful approaches to 
study the metabolic changes in several diseases including cancer [67,217] involving a comprehensive 
analysis of all metabolites present in biological systems (metabolome) [107,218,219]. Indeed, 
metabonomics refers to the “quantitative measurement of the multiparametric metabolic responses of 
living systems to patho-physiological stimuli or genetic modifications” [220] and represents a subset 
of metabolomics. So, whereas metabolomics is the analysis of the biochemical profile of an organism 
under normal conditions, metabonomics is focused on the analysis of the changes in that biochemical 
profile under diseased conditions or genetic modifications. Moreover, metabolomics plays an 
important role in disease profiling being a promising approach for the pursuit of new biomarkers in 
biological matrices, such as cell extracts, tissues or biological fluids. As a fast growing field that focus 
on the investigation of metabolites present in biological systems, it reflects the altered metabolism 
and the physiological status [125]. Normally these studies are combined with analytical techniques 
being the most popular NMR spectroscopy and MS that have gained attention in this field as strong 
tools for the identification of potential biomarkers in a variety of clinical fields [161,217]. Usually, 
MS includes a separation stage LC or GC and can discriminate between compounds based on mass-
to-charge (m/z) ratio in charged particles. Regarding NMR, it is an appealing technique that allows 
the investigation of metabolism due to its advantages as non-destructive, non-invasive, highly 
reproducible, giving information about biological samples environment offering both qualitative and 
quantitative measure. When compared with NMR, MS exhibits a greater sensitivity, although sample 
preparation is laborious and dependent on metabolite chemical properties [155]. On the other hand, 
MS lacks accuracy and precision producing an enhanced resolution profile with several peaks. In 
addition, these platforms can be used together, often applied to complex samples and coupled with 
advanced chemometric tools integrating the datasets obtained by the analytical techniques. If used in 
combination, these techniques enable the identification of a more comprehensive panel of metabolites 
involved in metabolic alterations and help unraveling the possible correlations and the underlying 
 
 
136 Catarina Silva (2019) 
mechanisms induced by a disease [217,221,222]. A variety of studies have been conducted by NMR 
and DART-MS using this approach to find serum biomarkers for BC [67]. Another study was 
developed by Chen et al. [217] that used the dual platform of NMR and MS methods to establish the 
urinary metabolomic profile of bipolar disorder (BD) subjects with a diagnosis purpose. Marshall et 
al. [223] combined direct infusion electrospray ionization mass spectrometry (DI-ESI-MS) and NMR 
to analyze the impact of neurotoxins involvement in dopaminergic cell death which is relevant to 
Parkinson´s disease. Wei et al. [71] used NMR, LC–MS and statistical analysis to predict the response 
to chemotherapy in the neoadjuvant setting using serum samples from 28 patients with breast cancer. 
In turn, Falegan et al. [224] used urine and serum samples from renal cell carcinoma (RCC) patients 
with the aim of distinguishing between stages of the disease and also to make a distinction between 
benign renal tumors and RCC. In summary, multiplatform approaches are useful tools to achieve a 
comprehensive analysis of the broad variety of metabolic alterations in cancer progression and 
development. 
The current work describes the combination of NMR and GC-qMS based metabolomic analyzes 
of urine and breast tissue samples from BC patients and cancer-free individuals combined with 
multivariate statistical tools in order to obtain a panel of metabolites (and their metabolic profiles) 
that can discriminate malignant from healthy status, thus assisting in the diagnostic field.  
 
Materials and Methods 
Reagents and materials 
All solvents and chemicals used in the experimental work were analytical grade. 
For the NMR analysis, 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) and deuterium 
oxide (D2O) were supplied by Acros Organics (Geel, Belgium) while potassium dihydrogen 
phosphate (KH2PO4), sodium azide (NaN3), phosphate buffer solution (PBS), potassium deuteroxide 
solution (KOD) were purchased from Panreac (Barcelona, Spain) and Sigma Aldrich (St. Louis, MO, 
USA), respectively. Methanol (MeOH) and chloroform (CHCl3) were purchased from Thermo Fisher 
Scientific (Waltham, Massachusetts, USA). 
For the GC-qMS analysis, sodium chloride (NaCl), hydrochloric acid (HCl) and 4-methyl-2-
pentanol (internal standard, IS) were supplied by Panreac (Barcelona, Spain) and Sigma Aldrich (St. 
Louis, MO, USA), respectively. The SPME holder for manual sampling together with 75 µm 
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Subjects and sample collection 
Urine samples 
Urine samples (first urine morning) from BC patients (n=30) were collected at the Haemato-
Oncology Unit from Dr. Nélio Mendonça Hospital, while the urine collection from CTLs (n=40) 
(Table 3.5.1) was carried out in Blood Transfusion Medicine Service in the same Hospital. 
 
Table 3. 5. 1 - List of collected urine samples from breast cancer BC patients and CTLs. 
Sample group N. subjects Age range/years  Mean Age  
Breast Cancer (BC) n = 30 44-85 67 
Control (CTL) n = 40 43-80 64 
 
Participants were instructed to collect the first urine morning (after the rejection of the first urine 
stream) into a sterile cup. The collected urine from either patients or healthy volunteer were aliquoted 
into 4 mL glass vials and stored at -80 °C for further analysis by GC-MS and NMR. Prior to analysis, 
all urine samples were centrifuged at 4000 rpm for 20 min at 4 °C, and the supernatant used for the 
analysis. All the analyzes were performed in triplicate. The research was approved by the Ethics 
Committee of Funchal Central Hospital Dr. Nélio Mendonça (Approval no. S.1708625/2017), and 
have been performed in accordance with the ethical standards as laid down in the 1964 Declaration 
of Helsinki and its later amendments or comparable ethical standards. All the participants were fully 
informed of the objectives of the study and signed the informed consent. 
 
Tissue samples 
Regarding the tissue samples, 30 samples from patients with breast cancer (BC, n=30, age range 
44-85, average 67), and 30 samples from cancer-free tissue (CF, n=30, age range 44-85, average 67) 
without malignant infiltration were resected from each patient. The resected samples were divided 
into the active carcinoma and cancer-free tissue outside the tumor margin and were immediately 
frozen in liquid nitrogen, in a total set of 60 samples. The tissues were stored at -80 °C until extraction. 
With regard to tissue, the analysis of cancer and non-cancer tissue from the same subject can also aid 
to balance the effect of external interferents, such as diet or environmental exposure. These samples 
were obtained at the Pathologic Anatomy Unit of Hospital Dr. Nélio Mendonça (Funchal, Portugal) 
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Table 3. 5. 2 - List of collected tissue samples from BC patients and CF individuals. 
Samples  BC tissue Cancer-free 
Number 30 30 
Age (range, median) (44-85, 65) (44-85, 65) 
Histological grade 
(number of samples) 
IA (5)  
IIA (10)  
IIIA (1)  
IIB (7) Not applicable 
IIIB (5)  
IIIC (2)  
 
The resected BC tissues were classified using the TNM (tumor, node, and metastasis) staging 
approach which included five cases of stage IA, ten cases of stage IIA, one case of stage IIIA B, seven 
cases of stage IIB, five cases of stage IIIB and two of stage IIIC. The research was approved by the 
Ethics Committee of Funchal Central Hospital Dr. Nélio Mendonça (Approval no. S.1708625/2017), 
and have been performed in accordance with the ethical standards as laid down in the 1964 
Declaration of Helsinki and its later amendments or comparable ethical standards. All the participants 
were fully informed of the objectives of the study and signed the informed consent.  
 
Sample preparation 
Urine samples by HS-SPME/GC-qMS 
Prior to HS-SPME, urine samples were thawed and then 4 mL of urine was placed into 8 mL vials 
together with 17 % NaCl (w/v) and 100 µL of the, 4-methyl-2-pentanol (IS = 1.6 mg/L). The pH was 
adjusted to 2 with small amounts of HCl 5M. Then, the vial was capped with a Teflon (PTFE) septum 
using a screw cap and the CAR/PDMS fiber was introduced and exposed into the headspace during 
75 min at 50 °C at 800 rpm (0.5 mm × 0.1 mm bar). After this period, the fiber was removed from 
the vial and inserted into the GC injection port and the extracted VOMs were desorbed for 10 min at 
250 °C. Each sample was analyzed in triplicate and blanks were performed before each analysis. 
 
Urine samples by NMR 
Before NMR analysis, urine samples were thawed and centrifuged (8000 rpm for 5 min) to remove 
any suspended cells and other precipitated material. Then, 540 µL of urine was mixed with 60 µL of 
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a buffer solution (KH2PO4, 1.5 M in D2O) containing 0.1 % of TSP-d4 (used as chemical shift 
reference) and 2 mM NaN3. The pH was adjusted to 7.00 ± 0.02 by adding small amounts of KOD. 
 
Tissue samples by HS-SPME/GC-qMS 
Tissue samples were thawed and then portions of 100 mg were weighted into 20 mL vials together 
with 17 % NaCl (w/v), 1000 µL of ultrapure water and 100 µL of the 4-methyl-2-pentanol (IS = 1.6 
mg/L). The pH was adjusted to 2 with small amounts of HCl 5M. Then, the vial was capped with a 
Teflon (PTFE) septum using a screw cap and the SPME fiber was introduced and exposed into the 
headspace during 75 min at 50 °C at 800 rpm (0.5 mm × 0.1 mm bar). After this period, the fiber was 
removed from the vial and inserted into the GC injection port and VOMs extracted were desorbed for 
10 min at 250 °C. Each sample was analyzed in duplicate and blanks were performed before each 
analysis. 
 
Tissue samples by NMR 
The intact frozen tissues were weighed and portions of 100 mg were transferred into a glass vial. 
Then, 5 mL of a PBS was added to remove any blood residues from the samples. After this, 5 mL of 
cooled MeOH and CHCl3 were added prior to homogenization and vortex. The vials were placed at -
20 °C and the vials were vortexed three times every 10 min. After this procedure, the vials were 
centrifuged at 4000g for 15 min at 4 °C. The upper phase (methanol) containing the polar metabolites 
was placed into another vial and the MeOH was removed under a nitrogen stream before 
lyophilisation. At the time of the NMR analysis, 540 µL of D2O was added to the obtained extract 
and mixed with 60 µL of a buffer solution (KH2PO4, 1.5 M in D2O) containing 0.1 % of TSP-d4 (used 
as chemical shift reference) and 2mM NaN3. The pH was adjusted to 7.00 ± 0.02 by adding small 
amounts of KOD. 
 
GC-qMS conditions 
After the extraction procedure, the SPME fiber with the analytes was inserted into the injection 
port of an Agilent Technologies 6890N Network gas chromatograph system (Palo Alto, CA, USA) 
where the VOMs were desorbed at 250 °C for 10 min. The gas chromatograph was equipped with a 
60 m × 0.25 mm I.D.× 0.25 µm film thickness, BP-20 (SGE, Dortmund, Germany) fused silica 
capillary column and interfaced with an Agilent 5975 quadrupole inert mass selective detector. The 
following oven temperature profile was set: (a) 5 min at 45 °C; (b) increase temperature until 150 °C, 
at a rate of 2 °C min−1 (hold for 10 min); (c) 150 °C for 10 min; (d) increase temperature until 220 
°C, at a rate of 7 °C min−1; and (e) 220 °C for 10 min for a total GC run time of 87.5 min. The column 
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flow was constant at 1.3 mL min−1 using Helium (He, N60, Air Liquide, Portugal) as carrier gas. The 
injection port was operated in the splitless mode and held at 250 °C. For the 5975 MS system, the 
operating temperatures of the transfer line, quadrupole and ionization source were 270, 150 and 230 
°C, respectively, while electron impact mass spectra were recorded at 70 eV ionization voltage and 
the ionization current was 10 µA. Data acquisition was performed in the scan mode (30–200 m/z). 
The electron multiplier was set to the auto tune procedure. Metabolites identification was 
accomplished by manual interpretation through single ion monitorization (SIM) of spectra and 
matching against the Agilent MS ChemStation Software, equipped with a NIST05 mass spectral 
library with a similarity threshold higher than 80% and comparison with commercially available 
standard samples when available. A series of C8–C20 n-alkanes were analyzed using the same 
extraction procedure to establish the kovat indices (KI), and to confirm the identity of the VOMs by 
comparison with the literature. The analyzes were performed in triplicate and the results expressed 
by mean ± standard deviation. 
 
NMR measurements 
NMR spectral acquisition was performed using a Bruker Advance II Plus NMR spectrometer 
equipped with a 400 MHz magnet UltraShield™ 400 Plus at 300K. All NMR spectra acquisition and 
pre-processing were performed under the control of a workstation with TopSpin 3.5pl7 (Bruker 
BioSpin). For each sample, a standard 1D 1H NMR spectrum was acquired using a “noesypr1d” 
(Bruker library) water suppression pulse sequence with water irradiation during relaxation delay and 
mixing time (SW 4807.692 Hz, TD 64 K data points, relaxation delay 5 s, 128 scans). The shimming 
was calibrated automatically. Also, all spectra were processed using a line broadening (1.0 Hz) and 
baseline automatically corrected. The NMR spectrum of each sample was aligned with reference to 
the TSP signal at δ 0.00 ppm. Spectral regions within the range of 0.94 to 10 ppm were analyzed after 
excluding the sub-region δ 4.55-6.05 to remove variability arising from water suppression and 
possible cross-relaxation effect on the urea signal via solvent exchanging protons. Each sample 
analysis was performed in triplicate and the relative standard deviation (RSD) was lower than 2%. 
The analysis of NMR spectral data was performed using the Chenomx NMR Suite 8.2 (Chenomx 
Inc., Alberta, Canada) and relative concentrations were determined using the 400MHz library from 
Chenomx NMR Suite 8.2, which compares the integral of a known reference signal (TSP) with signals 
derived from a library of compounds containing chemical shifts and peak multiplicities. Regarding 
the metabolites that were not available in the library, identification was accomplished by running a 
standard solution and the relative concentration was calculated manually. This software not only 
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allows the identification of compounds but also access their quantification based on advanced 
algorithms turning into a very straightforward tool to analyze NMR spectra. 
 
Statistical Analysis 
Statistical analysis was performed using the web server Metaboanalyst 4.0 [134]. The multivariate 
statistical analysis, namely the orthogonal projections to latent structures discriminant analysis 
(OPLS-DA) were applied on tissue and urine metabolomic dataset to provide insights into the groups 
under study for each analytical platform. The metabolites with VIP scores higher than 1.0 were 
considered significant and used for further analysis. The receiver operating characteristic curves 
(ROC) were also attained to verify which metabolites had the highest sensitivity/specificity for a 
potential BC diagnosis. The selected metabolites were used for the metabolite set enrichment analysis 
(MSEA) to identify significant patterns of metabolite concentration changes. MSEA uses a collection 
of predefined metabolite pathways and disease states obtained from the HMDB. 
Furthermore, to inspect the correlations between urine and tissue metabolites, samples from the 
same individuals were matched and the correlation matrices obtained for the results for each 
analytical platform (GC-qMS and NMR) separately. The matrices were generated by calculating the 
Pearson´s correlation coefficient between each pair of variables from either NMR or GC-MS. The 
results were generated and plotted using MATLAB R2018b Academic version (MathWorks, Natick, 
MA, US). 
 
Results and Discussion 
Tissue and urine metabolomic pattern based on GC-qMS and 1H NMR spectroscopy 
The combined datasets of tissue and urine samples composed of 32 metabolites (GC-qMS) towards 
24 metabolites (NMR) in tissue samples and 52 metabolites (GC-qMS) towards 33 metabolites 
(NMR) in urine samples, were subjected to statistical analysis using the Metaboanalyst 4.0 [134] 
server in order to obtain a preliminary information about data projection. Prior to multivariate 
analysis, all datasets were scaled to unit variance to select which metabolites were used for further 
analysis (t-test, p < 0.05) and then the selected metabolites were autoscaled so that each variable had 
the same weight. OPLS-DA statistical analysis was generated to compare the metabolic profiles 
between BC patients and controls, maximizing the class discrimination. The quality of the model was 
evaluated by R2Y and Q2 values, which gave the variance explained and predicted for the model, 
respectively, thus confirming that the model was effective with a good predictable accuracy. 
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Figure 3. 5. 1 - Loading score plots of orthogonal projection to OPLS-DA analysis of tissue (A) and 
urine samples (B) model validation by permutation test based on 1000 permutations from the 2 groups 
under study. 
Figure 3.5.1 (A) and (B) show the results obtained for the multivariate analysis. (OPLS-DA) for 
tissue (R2Y = 0.888; Q2 = 0.813) and urine (R2Y = 0.946 and Q2 = 0.910) samples, respectively. As 
observed, the obtained OPLS-DA score plot showed a clear separation between BC patients and 
controls for both sort of samples. Additionally, the metabolites from each biological matrix with VIP 
values higher than 1.0 were used for the pathway analysis to verify which pathways were the relevant 
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Figure 3. 5. 2 - Top ten significant features from tissue (A) and urine (B) samples based on VIP value 
and ROC curves for tissue (C) and urine (D) samples using the selected metabolites by VIP values. 
Figure 3.5.2 A-B includes the top ten metabolites with the highest importance in the projection 
which comprised the majority of metabolites arising from the tissue analysis by NMR when compared 
with the VIP values from urine analysis that derived from the GC-qMS technique. Moreover, the 
ROC (Figure 3.5.2 C-D) curves for each type of biological sample (urine and tissue) were constructed 
using the metabolites with higher VIP values as described previously. Regarding the results obtained, 
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The values obtained for the AUC, namely 0.894 for tissue versus 0.902 for urine, were enough to 
provide a good sensitivity and specificity whereas for urine only three metabolites, namely glutamine, 
α-hydroxyisobutyrate and α-hydoxybutyrate were necessary (Figure 3.5.2 C-D). 
 
Figure 3. 5. 4 - The metabolome view map of significant altered metabolic pathways observed in 
tissue (A) and urine (B) samples from BC and CTL groups resulted from MESA. 
To go further, the metabolic pathway analysis using Metabolite Set Enrichment Analysis (MESA) 
was performed in order to identify which pathways were affected in both cases. This type of analysis 
is used as a mean to recognize biologically meaningful patterns that are enriched in metabolomic 
data. For the tissue analysis, the metabolic pathways mainly affected included those of pyruvate, 
alanine and glutamine whereas, for urine, only glutamine and alanine metabolisms had changes 
(Figure 3.5.3 A-B). The metabolites responsible for each pathway were lactate in the case of tissue 
samples and glutamine and glutamate for urine samples (Figure 3.5.4 A-B). In order to check the 
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matched and the correlation matrices obtained for the results for each analytical platform (GC-qMS 
and NMR) are presented in Figure 3.5.5. 
For this test, only the metabolites with correlation coefficient higher than 0.6 and p < 0.05 were 
used. Using this criterion, for example, there are no correlations for tissue vs urine in NMR or tissue 
NMR vs urine GC-qMS. By the Figure, we can observe that five metabolites were found significant 
as indicated in Table 3.5.3, being that the correlation level increases with the intensity of colour. 
 
Table 3. 5. 3 - Correlations obtained from tissue and urine samples by dual analytical platforms. 




acetone urine GC-MS 1-pentanol tissue GC-MS 0.858 3.37E-27 
3-hexanone urine GC-MS 1-pentanol tissue GC-MS 0.621 6.09E-11 
4-heptanone urine GC-MS 1-pentanol tissue GC-MS 0.645 6.85E-12 
2-methyl-5-(methylthio)-furan urine GC-MS decanal tissue GC-MS 0.906 1.32E-34 
acetate urine NMR 1,6,7-trimethyl-naphthalene tissue GC-MS 0.656 2.19E-12 
 
Regarding the possible origin of these metabolites, 4-heptanone was already identified in urine 
samples from cancer patients and healthy controls being hypothesized that it arises from in vivo β-
oxidation of 2-ethylhexanoic acid (EHA) from plasticizers, similar to formation of 3-heptanone from 
valproic acid [127,225]. Acetate is a common metabolite found in most tissues and was also identified 
in biological specimens such as urine, saliva or faeces. The main pathways where acetate is involved 
includes pyruvate, aminoacid and aspartate metabolisms [226]. Also, 2-methyl-5-(methylthio)-furan 
was identified in urine samples from cancer patients [127]. However, to the best of our knowledge 
the possible origin of this metabolite is not yet reported in literature. Regarding acetone, it was also 
identified in urine and tissue samples and the main pathways associated with it are the synthesis and 
degradation of ketone bodies and propanoate metabolism through acetyl-CoA in the liver [227]. The 
results obtained with this preliminary research suggest the possibility to identify endogenous 
metabolites using a dual platform to discover potential BC biomarkers and paves a way to investigate 
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Figure 3. 5. 5 - Correlation analysis of metabolites between tissue and urine samples. The matrices were generated by calculating the Pearson correlation 
coefficient between each pair of variables from either NMR or GC-qMS. 
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Conclusions 
This research allowed the combination of NMR and GC-MS based metabolomic analyzes of urine 
and breast tissue samples from BC patients and cancer-free individuals tandem with multivariate 
statistical tools in order to obtain a panel of metabolites (and their metabolic profiles) that can 
discriminate malignant from healthy status thus assisting in the diagnostic field. Additionally, using 
a dual platform approach (NMR and GC-qMS), we could enlarge the panel of identified metabolites 
showing a promising diagnostic tool for a BC diagnosis. Overall, this study suggests that an improved 
metabolic profile combining NMR and GC-qMS may be useful to achieve more insights regarding 
cancer mechanisms. Nevertheless, due to the challenge of identifying metabolites linked to BC, 
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The improvement of diagnostic/screening methods are important achievements in cancer research 
besides the intensive investigation undertaken on the discovery of new biomarkers. With the 
emergence of metabolomic studies in the last decade that successfully overcomed the knowlegde 
about pathological processes such as cancer, there is the hypothesis that metabolic alterations result 
in qualitative and quantitative alterations on metabolites. 
Although the sample size in a exploratory research is usually small, it is essential to analyze a 
larger number of sampels in order to verify and validate the results and to increase the statistical 
ability of the results. Moreover, the alterations on metabolites levels will be reflected in both genetic 
and environmental factors, leading to the increase of the susceptibility to cancer [217]. In the case of 
BC, numerous metabolomic studies have be conducted using biological samples, such as urine 
[63,189], serum [71,189] or tissues [228] by many analytical approaches, being the most commom 
the NMR and MS in single or in dual application [144]. 
Thus, the work described through this thesis represents a contribution on the study of BC 
metabolome, by analyzing urine, cell lines and breast tissue in order to gain a deeper understanding 
about the metabolic alterations occuring in BC and eventually find potential metabolites for BC 
diagnosis. The studies in this thesis were carried out using GC-qMS and NMR spectroscopy and their 
results are presented in Chapters 3.1 to 3.5. In general, the achieved results confirm that urine might 
be a source of valuable information for the search of BC biomarkers. 
In the first study, described in Sub-section 3.1, the main goal was the development of a statistical 
design (CCD) and the optimization of significant variables of SPME procedure for the isolation of 
VOMs from urine of BC patients (n=30) and CTL (n=40). This type of optimization takes into account 
the possible interations between the variables. The establishment of the urinary volatomic 
composition, through GC-qMS analysis, improved the identification of VOMs potential BC 
biomarkers useful to be used together or to complement the current BC diagnostics tools. For that 
purpose, several extraction influencing parameters (e.g., SPME coating, NaCl amount, extraction 
time and temperature) were tested. The developed HS-SPME method was applied to urine samples 
to discriminate between BC and CTL groups, showing promising results that are essential to be 
explored. Additionaly, from the GC-qMS analysis, 116 VOMs were identified and multivariate 
statistical analysis revealed some metabolites significantly altered in BC patients. Of the metabolites 
identified, 3-methyl-thiophene, 4-heptanone, α-terpinene, 2-pentylfuran, p-cymene, trimethyl 
trisulfide, 1-methyl-4-(1-methylethenyl)-benzene, acetic acid, 2-methyl-3-phenyl-2-propenal and 
1,2-dihydro-1,1,6-trimethylnaphthalene showed the utmost sensitivity and specificity to discriminate 
BC patients from CTL. Some of these metabolites have been already identified in urine from renal 
cell carcinoma (RCC) patients as being increased in RCC patients [229]. The metabolic pathway 
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analysis indicated that the discriminatory metabolites could be originated from several dysregulated 
pathways in BC such as pyruvate and sulfur metabolisms. These results suggested the possibility to 
identify endogenous metabolites as a platform to discovery potential BC biomarkers and paves a way 
to investigate the related metabolomic pathways to improve the diagnostic tools of BC. 
The second study (Sub-section 3.2) consisted of an extension of the abilities of urine on the field 
of BC biomarker discovery. For that purpose, the urinary metabolomic pattern was obtained from BC 
patients and CTL using 1H NMR spectroscopy, as a powerful approach to identify a set of BC-specific 
metabolites which might be employed in the BC diagnostic. OPLS-DA was applied to 1H-NMR 
processed data matrix. Metabolomic patterns distinguished BC from CTL urine samples suggesting 
unique metabolite profiles for each investigated group. The discrimination efficiency and accuracy 
of the urinary metabolites were ascertained by ROC curve analysis that allowed the identification of 
some metabolites with the highest sensitivity and specificity to discriminate BC patients from CTL. 
The metabolomic pathway analysis indicated several metabolism pathways disruptions including 
aminoacids and carbohydrates metabolism, in BC patients. The obtained results support the high 
throughput potential of NMR-based urinary metabolomics patterns in the discrimination BC patients 
from CTL. 
Moreover, the third study described in Sub-section 3.3 demonstrated that HS-SPME/GC-MS can 
be used to establish the in vitro volatile metabolomic patterns of normal and cancer breast cells. In 
addition, this study showed the potential of screening the in vitro VOMs associated with BC to 
identify potential volatile metabolites to be used in early diagnosis. VOMs from the headspace of 
cultured BC cells and normal human mammary epithelial cells, were collected by HS-SPME and 
analyzed by GC–qMS, thus defining the volatile metabolomic signature. Also, the headspace of 
cultured media of normal and cancer cell lines, containing the exometabolome with extracelular 
metabolites, was analyzed at different pH conditions. Most of the identified VOMs were common to 
all BC cell lines and normal human mammary epithelial cells, but 2-pentanone, 2-heptanone, 3-
methyl-3-buten-1-ol, ethyl acetate, ethyl propanoate, and 2-methyl butanoate, were detected only in 
the headspace of cancer cell lines. Multivariate statistical data obtained in this study revealed that 
combining in vitro assays with HS-SPME/GC-qMS is a promising strategy to discriminate the volatile 
metabolomic signature of normal cells and BC cell lines according to molecular type. 
The fourth study (Sub-section 3.4) consisted of the untargeted assessment of metabolomic tissue 
profile from BC patients when compared with CF tissues using GC-qMS tandem with multivariate 
statistical tools (PLS-DA and OPLS-DA). Twenty-nine metabolites were identified, and multivariate 
statistical analysis revealed some metabolites significantly altered in BC patients. Of the metabolites 
identified, limonene, decanoic acid, acetic acid and furfural showed the highest sensitivity and 
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specificity to discriminate BC patients. Also, the analysis of the plots leads to a metabolomic pattern 
comprising an array of some biochemical pathways altered in BC patients. The metabolic pathway 
analysis indicated that the discriminatory metabolites could be originated from several dysregulated 
pathways in BC such as those involved in pyruvate and sulphur metabolisms. 
In the last study (Sub-section 3.5) the combination of NMR and GC-qMS based metabolomic 
approach was applied using urine and breast tissue samples from BC patients and cancer-free 
individuals. The data obtained was processed using multivariate statistical tools in order to obtain a 
panel of metabolites (and their metabolic profiles) that could discriminate malignant from healthy 
status. Tissue and urine samples were collected from BC patients (urine: n=30; tissue n=30) and CF 
subjects (urine n=40; tissue n=30) and analyzed. The OPLS-DA model showed a clear separation 
between BC patients and controls for both classes of samples. The discrimination efficiency and 
accuracy of BC tissue and urine metabolites was ascertained by ROC curve. Regarding the 
metabolomic pathway analysis several dysregulated pathways including pyruvate and glutamine 
metabolisms, in BC patients were identified. Moreover, the correlations between urine and tissue 
metabolites were investigated being that five metabolites were found significant using a dual platform 
approach. Overall, this study suggests that an improved metabolic profile combining NMR and GC-
qMS may be useful to achieve more insights regarding cancer mechanisms. 
In summary, cancer is a complex disease where many metabolic pathways are dysregulated 
regardless on cancer type. This might be the major handicap of metabolomics studies when searching 
for specific biomarkers, since the results obtained can be the reflection of the commom carcinogenic 
processes and not from the type of cancer of interest. One of the important steps is the validation of 
the potential biomarkers, the requirement of a larger cohort and also the undertake of an external 
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The work described in this thesis emphasizes the potential of urine for the pursue of BC biomarkers 
for a non-invasive diagnosis, since it is the final step of metabolic pathways. Among the biofluids 
used in metabolomic studies, urine has been shown to contain a wealth of metabolic information that 
is believed to be changed in disease conditions, including cancer. Moreover, it is abundant, easily 
collected, stored and given its complexity, is particularly rich in potential disease biomarkers. This 
makes it an ideal biofluid for the detection or monitoring of disease evolution. However, to 
complement the data obtained from urine and to enhance a comphreensive analysis of BC 
metabolome, it is essential to use other biological samples, such as as tissue or cell lines once they 
can provide additional information regarding urine. 
 
The main conclusions of this thesis: 
 
✓ A CCD model was optimized and applied to urine samples from BC and CTL groups, using 
HS-SPME/GC-qMS in order to obtain the optimal extraction conditions for the VOMs 
extraction from the target samples. In this context, a CAR/PDMS fiber coating at 50 °C during 
75 min with the addition of 15 % NaCl were selected. All the assays to establish the volatomic 
composition of urine and BC tissue were carried out using the optimized conditions obtained 
by the CCD model; 
 
✓ The establisment of the metabolomic profile from urine samples based on volatile (GC-qMS) 
and non-volatile (1H NMR) fractions was performed and unveiled the ability to discriminate 
BC from CTL groups. The metabolites creatine, glycine, serine, dimethylamine, 
trimethylamine-N-oxide, α-hydroxyisobutyrate, manitol, glutamine, cis-aconitate and 
trigonelline exhibited the highest sensivitity in the discrimination of both groups by NMR 
studies, whereas 3-methyl-thiophene, 4-heptanone, α-terpinene, 2-pentylfuran, p-cymene, 
trimethyl trisulfide, 1-methyl-4-(1-methylethenyl)-benzene, acetic acid, 2-methyl-3-phenyl-
2-propenal and 1,2-dihydro-1,1,6-trimethylnaphthalene showed the utmost sensitivity and 
specificity to discriminate BC from CTLs using GC-qMS technique; 
 
✓ The establishment of the volatile metabolomic pattern by HS-SPME/GC-qMS of normal and 
cancer breast cells was obtained. The headspace of culture media of normal and cancer cell 
lines was analyzed at different pH conditions. Most of the identified VOMs were common to 
all BC cell lines and HMEC cells, with exception of 2-pentanone, 2-heptanone, 3-methyl-3-
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buten-1-ol, ethyl acetate, ethyl propanoate, and 2-methyl butanoate that were detected only in 
the headspace of cancer cell lines. Multivariate statistical analysis revealed that it was possible 
to differentiate the volatile metabolomic signature of normal cells and BC cell lines according 
to molecular type, thus contributing to the discovery of novel biomarkers and the related 
metabolomic pathways thus improving the diagnostic tools for BC; 
 
✓ The untargeted assessment of the metabolomic tissue profile from BC patients and compared 
with cancer-free (CF) tissues using GC-qMS tandem with multivariate statistical tools (PLS-
DA and OPLS-DA). From the identified metabolites, limonene, decanoic acid, acetic acid and 
furfural showed the highest sensitivity and specificity to discriminate BC patients from CTLs. 
The discriminatory metabolites could be originated from several dysregulated pathways in 
BC such as, those involved in pyruvate and sulphur metabolisms. Furthermore, the analysis 
of cancer and non-cancer tissue from the same subject can also aid to balance the effect of 
external interferents, such as diet or environmental exposure and help to identify potential 
biomarkers; 
 
✓ Urine and tissue samples from BC and CF subjects were analyzed by different analytical 
platforms (GC-qMS and NMR) in order to evaluate the correlations between urinary and 
tissue metabolites, where samples from the same individuals were matched through the 
integration of data, being that five metabolites (e.g., acetone, 3-hexanone, 4-heptanone, 2-
methyl-5-(methylthio)-furan and acetate) were found significant using a dual approach. 
Moreover, the integration of high-resolution analytical frameworks, namely MS and NMR, 
appeared as an outcome on metabolomics studies, providing a sensitive, reliable detection and 
the quantification of metabolites in biological samples and their related metabolic pathways; 
 
✓ Furthermore, the metabolic networks obtained by the correlation analysis will be also an 
attempt to analyze the complex interactions between metabolites as a complementary tool to 
statistical univariate and multivariate data analysis methods in order to reveal conections 
between pathways, identifying metabolite differences in physiological state. 
 
The future work challanges encompass: 
 
✓  To investigate the metabolic profile of cultured cells from breast tissue and urine samples 
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✓ To gain a better understanding of the causes of the dysregulation that occur in BC, by taking 
into account an external validation with larger cohorts of samples and using statistical tools 
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